



(51) International Patent Classification:

G06F 19/00 (2011.01) G01N 33/68 (2006.01)
G06F 19/24 (2011.01)

(21) International Application Number:

PCT/FI2016/050417

(22) International Filing Date:

10 June 2016 (10.06.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20155455 12 June 2015 (12.06.2015) FI
20155812 5 November 2015 (05.11.2015) FI

(71) Applicant: **TURUN YLIOPISTO** [FI/FI]; Yliopistonmäki, 20014 Turun yliopisto (FI).

(72) Inventors: **POUTANEN, Matti**; c/o Turun yliopisto, Turun Yliopisto, 20014 (FI). **SALONIEMI, Taija**; c/o Turun yliopisto, Turun Yliopisto, 20014 (FI). **HUHTINEN, Kaisa**; c/o Turun yliopisto, Turun Yliopisto (FI). **PERHEENTUPA, Antti**; c/o Varsinais-Suomen sairaanhoitopiirin kuntayhtymä, Kiinamyllynkatu 4-8, Turku, 20520 (FI). **SUVITIE, Pia**; c/o Varsinais-Suomen sairaanhoitopiirin kuntayhtymä, Kiinamyllynkatu 4-8, Turku, 20520 (FI). **AITTOKALLIO, Tero**; c/o Turun yliopisto, Turun Yliopisto, 20014 (FI). **SIITARI, Harri**; c/o Turun

yliopisto, Turun Yliopisto, 20014 (FI). **LAAJALA, Daniel**; c/o Turun yliopisto, Turun Yliopisto, 20014 (FI).


(74) Agent: **KOLSTER OY AB**; (Iso Roobertinkatu 23), P.O.Box 148, 00121 Helsinki (FI).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **DIAGNOSTIC BIOMARKERS, CLINICAL VARIABLES, AND TECHNIQUES FOR SELECTING AND USING THEM**



(57) Abstract: The present disclosure relates to the field of in vitro diagnostics. More specifically the present disclosure relates to non-invasive means and methods for determining a subject's diagnostic state. In particular, novel combinations of biomarkers and/or clinical variables, and processes for selecting or identifying them for determining a subject's diagnostic state are disclosed. The presently disclosed techniques for selecting and combining the biomarkers and clinical variables are applicable to determining a subject's diagnostic state of not only endometriosis but also other diseases particularly diseases associated with lower abdominal pain.



Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*

DIAGNOSTIC BIOMARKERS, CLINICAL VARIABLES, AND TECHNIQUES FOR SELECTING AND USING THEM

FIELD OF THE INVENTION

The present disclosure relates to the field of *in vitro* diagnostics.
5 More specifically the present disclosure relates to non-invasive means and methods for determining a subject's diagnostic state. In particular, novel combinations of biomarkers and/or clinical variables, and processes for selecting or identifying them for determining a subject's diagnostic state are disclosed. The presently disclosed techniques for selecting and combining the biomarkers and
10 clinical variables are applicable to determining a subject's diagnostic state of not only endometriosis but also other diseases particularly diseases associated with lower abdominal pain.

BACKGROUND OF THE INVENTION

Some specific use cases of the present disclosure relate to endo-
15 metriosis. Endometriosis is a chronic estrogen-dependent gynecological disorder characterized by the presence and growth of endometrial tissue outside of the uterus. Globally, the disease affects up to 10% of women (176 to 181 million worldwide). Patients with endometriosis commonly complain of progressive and debilitating dysmenorrhea that begins already before menstruation.
20 The pain may range from mild to severe, and is characteristically dull and aching. Dyspareunia, dysuria and painful defecation are also commonly associated with endometriosis. The experienced pain correlates poorly with the observed severity of the disease, although advanced endometriosis is strongly associated with infertility. The disease primarily affects women of reproductive
25 age, and the associated pain and infertility symptoms have a significant impact on physical and mental well-being. Consequently, the health burden and social cost associated with endometriosis are very high with a recent estimate of over 9000€ per woman per year in the EU due to loss of productivity and direct health care costs.

30 Patients with endometriosis have significant unmet needs due to the lack of non-invasive diagnostics and the lack of approved treatment options that could provide both continuous efficacy and a favorable long-term safety profile. Suspicion of endometriosis arises from the presenting symptoms. Despite typical symptoms and clinical findings the diagnostic delay is several
35 years. This delay is mostly a consequence of ineffective suspicion of endome-

triosis despite the presenting symptoms. A typical finding in endometriosis is the presence of painful nodules on the uterosacral ligaments. Limited mobility of the uterus is also common. When endometriosis is suspected, additional investigations are needed for definitive diagnosis. Laparoscopy is the gold standard, resulting in a correct diagnosis in ~90% of cases. It is also useful for the staging of disease. However, only 20–50% of women who undergo exploratory laparoscopy are found to have endometriosis. Currently, the most widely used staging system of the American Fertility Society relies on visualization and identification of endometriotic lesions. Even with the confirmed diagnosis there are currently no predictive tools to evaluate the response to medical treatment, rate of progression, risk of reoccurrence, risk of malignant transformation and effect on fertility.

Several serum markers have been studied for using in the diagnostics of endometriosis. Serum CA125 is elevated in the serum of ~60% of stage III and IV endometriosis patients. However, only 33% of stage I/II patients have elevated concentrations. Therefore, the assay is not considered to be sufficiently sensitive as a screening test. In addition, several other serum markers have also been studied, while none of the studies have been able to identify a set of serum markers clinically useful for identifying endometriosis. Thus, the diagnosis of endometriosis is currently mostly based on clinical signs and symptoms, physical examination and imaging techniques, such as ultrasound or MR imaging. However, as many of the clinical signs and symptoms of the disease, such as lower abdominal pain, are relatively unspecific and do not directly allow reliable diagnosis of endometriosis, incontrovertible proof of disease requires histological examination of specimens collected during laparoscopy. Due to the invasiveness of laparoscopic intervention, symptomatic women suspected of having endometriosis are often treated symptomatically with analgesics and hormonal medication prior to a definitive laparoscopic diagnosis.

Thus, there is an identified need for non-invasive and accurate methods for diagnosing and monitoring endometriosis. Furthermore, there is a need for enhanced computer-assisted processes for selecting effective biomarkers, clinical variables and/or combinations of these for a computer-implemented method for determining a subject's diagnostic state or condition.

BRIEF DESCRIPTION OF THE INVENTION

One aspect of the present disclosure is directed to a computer-implemented *in vitro* method of determining a subject's diagnostic state, as defined in claim 1. As used herein, determination of a subject's diagnostic state shall be interpreted in a slightly broader sense compared with unequivocal confirmation or exclusion of a disease. In the present disclosure, determination of the subject's diagnostic state shall also comprise processes whose outcome is a computed risk for the subject to have or develop a disease, although a conclusive diagnosis is not made. Other aspects of the present disclosure are directed to a processor specially adapted to carry out the method of claim 1, and to a tangible non-transitory memory, which comprises program code instructions as defined in the independent claim directed to the processor.

In a still further aspect, the present disclosure is directed to a method of determining a subject's endometriosis state, said method comprising:

a) assessing levels of biomarkers comprising human cancer antigen 125 (CA125), Midkine (MDK), and Elastin microfibril interfacier 1 (EMILIN1) in a sample obtained from said subject,

b) comparing the determined biomarker levels and corresponding control levels, and

c) responsive to the comparison, determining the subject's endometriosis state,

wherein increased levels of CA125 and MDK, and decreased level of EMILIN1 in said sample are indicative of endometriosis.

In some embodiments, said the biomarkers may further comprise at least one biomarker selected from the group consisting of Granulocyte-macrophage colony-stimulating factor (GM-CSF), phosphatidylcholine acyl-alkyl C38:1 (PC ae C38:1), phosphatidylcholine acyl-alkyl C38:2 (PC ae C38:2), and any combination thereof.

In some further embodiments, said biomarkers may additionally comprise at least one biomarker selected from the group consisting of epidermal growth factor (EGF), interleukin-1 receptor antagonist (IL-1Ra), interleukin-17 (IL-17), and any combination thereof.

In some still further embodiments, said biomarkers may further comprise human epididymal secretory protein E4 (HE4).

In some embodiments, the method further comprises assessing at least one clinical variable selected from the group consisting of the subject's

general information, surgical information, medical history, obstetric history, and pain symptoms. Preferably, the method comprises assessing at least one pain symptom selected from the group consisting of menstrual pain, intercourse pain, and defecation pain.

5 In some embodiments, determination of a subject's endometriosis state includes diagnosing, testing for, prognosing or monitoring endometriosis state, risk of endometriosis, response to treatment of endometriosis, recurrence or relapse of endometriosis, or risk of recurrence or relapse of endometriosis.

10 In some embodiments, the presence of endometriosis is determined on the basis of an increased level of said at least one biomarker as compared with a corresponding control level.

 In some embodiments, said determining the presence or absence of endometriosis in step c) includes determining or prognosing any possible relapse of the disease or response to treatment.

15 In some further embodiments, the method is used for excluding the presence or risk of a lower abdominal pain-associated disease other than endometriosis, such as disease selected from the group consisting of endometrial cancer, ovarian cancer, colon cancer, ulcerative colitis, irritable bowel disease, irritable bowel syndrome and Crohn's disease.

 In another aspect, the present disclosure provides an *in vitro* screening kit comprising reagents for determining a biological sample for the level of biomarkers comprising CA125, MDK, and EMILIN1.

 In some embodiments, the kit may further comprise reagents for determining the level of at least one biomarker selected from the group consisting of GM-CSF, PC ae C38:1, PC ae C38:2, and any combination thereof.

 In some further embodiments, the kit may additionally comprise reagents for determining the level of at least one biomarker selected from the group consisting of EGF, IL-1Ra, IL-17, and any combination thereof.

30 In some still further embodiments, the kit may additionally comprise one or more reagents for determining the level of HE4.

 In a further aspect, the present disclosure is directed to use of a biomarker combination comprising CA125, MDK, and EMILIN1 for determining a subject's endometriosis state.

35 In accordance with other aspects of the present disclosure, said use may further comprise use of at least one biomarker selected from the group

consisting of GM-CSF, PC ae C38:1, PC ae C38:2, and any combination thereof.

In some embodiments, said use may further comprise use of at least one biomarker selected from the group consisting of EGF, IL-1Ra, IL-17,
5 and any combination thereof.

In some further embodiments, said use may additionally comprise use of HE4.

Other objectives, aspects, embodiments, details and advantages of the present invention will become apparent from the following figures, detailed
10 description, examples, and dependent claims.

BRIEF DESCRIPTION OF THE DRAWINGS

In the following section, specific embodiments of the present disclosure will be described in greater detail in connection with illustrative but non-restrictive examples. Reference is made to the following drawings:

- 15 Figure 1 shows an overview of a feature selection and classification process in prediction of endometriosis;
Figure 2 generally illustrates the concept of a decision-making process in which a subject's diagnosis of endometriosis is either confirmed or excluded;
Figure 3 is a more detailed process flow chart;
20 Figures 4A and 4B depict sample screens (pages) of a tool view, which is used to obtain clinical variables concerning patients;
Figure 4C depicts a sample screen relating to risk assessment;
Figure 5 shows examples of decision trees with clinical variables and biomarkers; typically large numbers of such decision trees generated to fit the
25 patient information provided;
Figure 6A depicts ranking of the importance of features (clinical variables and biomarkers) used in the model;
Figure 6B depicts AUC (area under curve), sensitivity and specificity of the endometriosis diagnosis obtained by using the tool with the three most important
30 clinical variables and three most informative biomarkers included; and
Figure 7 depicts progress of AUC versus additional features, and maximum and minimum values obtained after 100 different repeats of the algorithm.

DETAILED DESCRIPTION OF SOME SPECIFIC EMBODIMENTS

As used herein, the term "biomarker" refers to a molecule whose measurement provides information regarding a disease state of a subject and is a distinctive indicator of a pathologic condition or its absence. The term "biomarker of endometriosis" refers to a biomarker selected from the set of biomarkers provided by the present invention and which is indicative of endometriosis. The terms "biomarker" and "marker" are used herein interchangeably and they include, but are not limited to, protein markers, nucleic acid biomarkers (e.g. mRNA or cDNA) corresponding to or encoding said protein markers, and lipid markers.

As used herein, the term "assessing a biomarker level", and any corresponding expressions, refer to quantifying a biomarker. The term "level" is interchangeable with the terms "amount" and "concentration", and can refer to an absolute or relative quantity. Assessing a biomarker may also include determining the absence or presence of the biomarker. Absolute or relative quantities of one or more biomarkers may also be referred to as "an expression profile" or "an expression pattern".

The level of a biomarker in a biological sample may be determined by a variety of techniques as is readily apparent to a skilled person. Non-limiting examples of suitable methods include mass spectrometry, immunoassays, spectrophotometry, enzymatic assays, ultraviolet assays, kinetic assays, electrochemical assays, colorimetric assays, turbidimetric assays, atomic absorption assays, flow cytometry, liquid chromatography such as high performance/pressure liquid chromatography (HPLC), gas chromatography, nuclear magnetic resonance spectrometry, and any combinations thereof.

As used herein, the term "sample" refers to a biological sample, typically a clinical sample which may be, for example, a tissue sample, such as a biopsy or a laparoscopy sample, or a sample of a bodily fluid, such as urine, blood, plasma, or serum, obtained from a subject. Generally, obtaining the sample to be analyzed from a subject is not part of the present method of determining a subject's state. Serum samples and plasma samples are the most preferred sample types to be used in the present method.

In some embodiments, biological samples may be obtained from the subject at various time points before, during, or after treatment. The expression levels of the present biomarker combinations in the biological sample are then determined and compared with those in a biological sample obtained from the

same subject at a different time point, or with a control level obtained, for example, from a reference sample derived from an individual whose endometriosis state is known and/or who has not been exposed to said treatment. In some embodiments, predetermined reference values obtained from a pool of
5 apparently healthy individuals may be used as control levels in said comparisons.

In some embodiments, clinical variables obtained from a subject may be used with or without biomarker data to determine the subject's diagnostic state. The clinical variables may be obtained at various time points before, during, or after treatment and compared with those obtained from the
10 same subject at a different time point.

As used herein, the term "clinical variable" includes various objective or subjective variables concerning a subject's health or general condition. For instance, the term includes, but is not limited to, general information such
15 as the subject's age, height, weight, menopausal status, and features of the menstrual cycle. The term also includes the subject's surgical history including status, reason, location, and number of previous abdominal surgery or surgeries, procedures used during previous abdominal surgery or surgeries, possible removal of the ovary and/or the Fallopian tube, and hysterectomy history. The
20 term also includes the subject's obstetric history including gravidity history and parity, ectopic pregnancies and treatments, history of miscarriage and medical abortions, history of infertility treatments, number of *in vitro* fertilizations (IVF, ICSI), history of insemination and ovulation induction, number of ovulation induction procedures, normality of partner's sperm, success of infertility treatments, and current desire for pregnancy (trying for more than a year without
25 success). Furthermore, the term includes other history information such as the subject's medication history (especially concerning hormonal medication), diagnostic history, and history of disorders associated with lower abdominal pain in close family member. The term also includes various pain-associated symptoms, such as menstrual pain (duration, frequency, and severity of menstrual
30 pain; type of medication required for alleviating menstrual pain); intercourse pain (description of pain, frequency and severity of pain, avoidance of intercourse because of pain), urinary pain i.e. pain associated with urinary bladder function (duration, frequency, and severity of pain, occasions of experienced
35 pain symptoms, association with menstrual cycle, and previously diagnosed bladder related diseases); chronic abdominal pain, i.e. history of recurrent pain

in the abdominal area lasting at least 6 months wherein the pain is other than menstrual pain, pain during intercourse, and defecation or urination associated pain (frequency of pain symptom, length of recurrent pain in the abdominal area, association with the menstrual period and severity of pain); and symptoms associated with the digestive tract, particularly defecation-related symptoms (duration, frequency and severity of defecation-associated pain, obstipation, diarrhea, association of the symptoms with menstruation, frequency of defecation previous diagnosis of haemorrhoid or anal fissure, previous diagnosis of a bowel related disease or symptoms, lactose intolerance, celiac disease. The severity of pain symptoms may be evaluated on a scale such as the one from 0 to 10, wherein 0 denotes no pain and 10 denotes the strongest imaginable pain. Typically, the clinical variables are obtained from the subject by a questionnaire comprising any number of relevant questions. As is evident to those skilled in the art, the clinical variables to be taken into account, and thus the questions to be comprised in the questionnaire, may vary and depend on the disease in question.

The herein-disclosed techniques and methods for determining a subject's diagnostic state may be applied to any diseases, disorders, or conditions. Some embodiments concern diseases associated with lower abdominal pain including, but not limited to urinary, disorders, such as bladder or kidney problems, bowel disorders, such as Crohn's disease, colon cancer, ulcerative colitis, irritable bowel disease (IBD) or irritable bowel syndrome (IBS), disorders of the reproductive system, such as endometriosis, endometrial cancer, ovarian cancer, or any other gynecological disease.

As used herein, the term "subject" refers to an animal, preferably to a mammal, more preferably to a human, and in connection with gynecological diseases, most preferably to a woman. Depending on an embodiment in question, said subject may suffer from endometriosis with or without diagnosis, be suspected to suffer from endometriosis, be at risk of endometriosis, or may have already been treated for endometriosis. Accordingly, said subject may also suffer from, be suspected to suffer from, be at risk of, or may have already been treated for a disease other than endometriosis, especially another disease associated with lower abdominal pain. Herein, the terms "human subject", "patient" and "individual" are interchangeable.

As used herein, the term "diagnostic state" refers any distinguishable manifestation of a disease, including non-disease. For example, the term

includes, without limitation, information regarding the presence or absence of the disease, the risk of the disease, the stage of the disease, progression or remission, relapse or recurrence of the disease over time, and the severity of the disease.

5 Accordingly and by way of example, the term “endometriosis state” refers any distinguishable manifestation of endometriosis, including non-disease. For example, the term includes, without limitation, information regarding the presence or absence of endometriosis, the risk of endometriosis, the stage of endometriosis, progression or remission, relapse or recurrence of endometriosis over time, and the severity of endometriosis. As is apparent to
10 those skilled in the art, corresponding terminology may be applied to any other disease, disorder, or condition as well, including but not limited to those associated with lower abdominal pain. As used herein, the term “determining a subject’s diagnostic state” refers, without limitation, to diagnosing, testing for,
15 prognosing or monitoring state of a disease, progression of said disease, risk of said disease, response to treatment, remission, relapse or recurrence of said disease, or a risk of remission, relapse of recurrence of said disease.

 Accordingly and by way of example, the term “determining a subject’s endometriosis state” refers, without limitation, to diagnosing, testing for,
20 prognosing or monitoring endometriosis state, progression of endometriosis, risk of endometriosis, response to treatment, remission, relapse or recurrence of endometriosis, or a risk of remission, relapse of recurrence of endometriosis. Again, corresponding terminology may be applied to any other disease, disorder, or condition including but not limited to those associated with lower
25 abdominal pain.

 As used herein, the term “diagnosing” refers, without limitation, to a process aimed at determining whether or not a subject is afflicted with a disease such as endometriosis or any other disease associated with lower abdominal pain. This is also meant to include instances where the presence or a
30 stage of said is not finally determined but that further diagnostic testing is warranted. In such embodiments, the method is not by itself determinative of the presence or absence of said disease, or the stage of said disease in the subject but can indicate that further diagnostic testing is needed or would be beneficial. Therefore, the present method may be combined with one or more other
35 diagnostic methods for the final determination of the presence or absence of said disease , or the stage of said disease in the subject. Such other diagnostic

methods are well known to a person skilled in the art, including but not limited to, laparoscopy.

In accordance with the above, the techniques disclosed herein may be used not only for diagnostic purposes but also for prognosis or predicting the outcome of or risk of a disease such as endometriosis or any other disease associated with lower abdominal pain, or monitoring the subject's disease state over time, any possible remission, recurrence or relapse of the disease, or response to treatment. Monitoring of a subject's disease state can be performed by continuously measuring certain parameters and/or performing a medical test repeatedly. In some embodiments of the present invention, a subject's disease state is monitored by obtaining bodily fluid samples repeatedly, assaying the samples using the method disclosed herein and comparing assay results with one another and with a reference value to identify any change in the subject's disease state.

Furthermore, the techniques disclosed herein may be used for differential diagnostics, i.e. for distinguishing of a particular disease, disorder, or condition from others that present similar clinical features. In some embodiments, the techniques are particularly suitable for differentiating various abdominal pain-associated diseases from each other.

As used herein, the term "indicative of a disease", when applied to a biomarker, refers to an expression pattern or profile which, using routine statistical methods setting confidence levels at a minimum of 95%, is diagnostic of said disease or a stage of said disease such that the expression pattern is found significantly more often in subjects with said disease or a stage of said disease than in subjects without said disease or another stage of said disease. Preferably, an expression pattern which is indicative of a disease is found in at least 80% of subjects who have the disease and is found in less than 10% of subjects who do not have the disease. More preferably, an expression pattern which is indicative of said disease is found in at least 90%, at least 95%, at least 98%, or more in subjects who have the disease and is found in less than 10%, less than 8%, less than 5%, less than 2.5%, or less than 1% of subjects who do not have the disease. In some embodiments, said disease is associated with lower abdominal pain. In some further embodiments, said disease is endometriosis.

For the sake of simplicity, as used herein, the terms "expression profile" and "expression pattern" refer not only to an expression level of a pro-

tein or nucleic acid biomarker or but also to a level of a lipid biomarker, although it is understood that lipids are not expressed through translation but synthesized in a series of defined steps in the cytoplasm.

To determine whether an expression profile of a biomarker is indicative of a disease, the expression profile of the biomarker in a relevant control has to be determined. Once the control levels are known, the determined marker levels can be compared therewith and the significance of the difference can be assessed using standard statistical methods. In some embodiments of the present disclosure, a statistically significant difference between the determined biomarker level and the control level is indicative of a disease such as endometriosis or any other disease associated with lower abdominal pain. In some further embodiments, before to be compared with the control, the biomarker levels are normalized using standard methods.

As used herein, the term "control" may refer to a control sample obtained from an apparently healthy individual or a pool of apparently healthy individuals, or it may refer to a predetermined threshold value which is indicative of the presence or absence of a disease in question. Statistical methods for determining appropriate threshold values will be readily apparent to those of ordinary skill in the art. The control or threshold values may have been determined, if necessary, from samples of subjects of the same age, demographic features, and/or disease status, etc. The threshold value may originate from a single individual not affected by a disease in question or be a value pooled from more than one such individual.

As used herein, the term "apparently healthy" refers to an individual or a pool of individuals who show no signs of a disease in question and thus are believed not to be affected by said disease in question and/or who are predicted not to develop said disease in question.

As used herein, the term "increased expression" refers to an increase in the amount of a biomarker in a sample as compared with a corresponding control sample. Said increase can be determined qualitatively and/or quantitatively according to standard methods known in the art. The expression is increased if the amount or level of the biomarker in the sample is, for instance, at least about 1.5 times, 1.75 times, 2 times, 3 times, 4 times, 5 times, 6 times, 8 times, 9 times, time times, 10 times, 20 times or 30 times the amount of the same biomarker in the control sample. In some embodiments, the term "increased expression" refers to a statistically significant increase in

the level or amount of the biomarker as compared with that of a relevant control.

As used herein, the term "decreased expression" refers to a decrease in the amount of a biomarker in a sample as compared with a corresponding control sample. Said decrease can be determined qualitatively and/or quantitatively according to standard methods known in the art. The expression is decreased if the amount of the biomarker in the sample is, for instance, at least about 1.5 times, 1.75 times, 2 times, 3 times, 4 times, 5 times, 6 times, 8 times, 9 times, 10 times, 20 times or 30 times lower than the amount of the same biomarker in the control sample. In some embodiments, the term "decreased expression" refers to a statistically significant decrease in the level or amount of the biomarker as compared with that of a relevant control.

As used herein, "sensitivity" is a measure of the ability of a marker to detect the disease. In other words, sensitivity represents the probability of a positive test result in subjects with the disease.

As used herein, "specificity" is a measure of the ability of a marker to detect the absence of the disease. In other words, specificity represents the probability of a negative test result in a subject without the disease.

As used herein, the term "false positive" (FP) refers to a test result which classifies an unaffected subject incorrectly as an affected subject, i.e. a subject having or predicted to develop a disease. Likewise, "false negative" (FN) refers to a test results which classifies a subject who has or will develop a disease incorrectly as an unaffected subject.

As used herein, the term "true positive" (TP) refers to a test result which classifies a subject who has or will develop a disease correctly as a subject having or predicted to develop a disease. Likewise, "true negative" (TN) refers to a test result which classifies an unaffected subject correctly as an unaffected.

In accordance with the above, the term "success rate" refers to the percentage-expressed proportion of affected individuals with a positive result, while the terms "false positive rate" and "false detection rate" (FDR) refer to the percentage-expressed proportion of unaffected individuals with a positive result.

As used herein, the term "accuracy", also called "diagnostic effectiveness", refers to a proportion of correctly classified subjects (TP+TN) among

all subjects (TP+TN+FP+FN).

Receiver Operation Characteristic (ROC) curves may be utilized to demonstrate the trade-off between the sensitivity and specificity of a marker, as is well known to skilled persons. The horizontal X-axis of the ROC curve represents 1-specificity, which increases with the rate of false positives. The vertical Y-axis of the curve represents sensitivity, which increases with the rate of true positives. Thus, for a particular cut-off (i.e. threshold) selected, the values of specificity and sensitivity may be determined. In other words, data points on the ROC curves represent the proportion of true-positive and false-positive classifications at various decision boundaries. Optimum results are obtained as the true-positive proportion approaches 1.0 and the false-positive proportion approaches 0.0. However, as the cut-off is changed to increase specificity, sensitivity usually is reduced and vice versa.

The area under the ROC curve, often referred to as the AUC, is a measure of the utility of a marker in the correct identification of disease subjects, i.e. subjects who are affected by a disease. Thus, the AUC values can be used to determine the effectiveness of the test. An area of 1.0 represents a perfect test; an area of 0.5 represents a worthless test. A traditional rough guide for classifying the accuracy of a diagnostic test is the following: AUC values 0.9 to 1.0 represent a test with excellent diagnostic power, AUC values 0.80 to 0.90 represent a test with good diagnostic power, AUC values 0.70 to 0.80 represent a test with fair diagnostic power, AUC values 0.60 to 0.70 represent a test with poor diagnostic power, and AUC values 0.50 to 0.60 represent a test with failed diagnostic power.

AN ALGORITHMIC APPROACH FOR DETERMINING A SUBJECT'S DIAGNOSTIC STATE

Figure 1 shows an overview of a feature selection and classification process in prediction of a subject's classification into one of diagnostic states, such as patient or control group. The following description and the associate drawings relate to an environment used for developing an algorithm for diagnosing endometriosis. Those skilled in the art will understand, however, that the algorithmic classification approach is applicable to other diseases or conditions for which the classification is based on combinations of clinical variables and biomarkers.

After combining clinical variables and biomarkers from patients, wrapper feature subset selection methodology (Kohavi, 1997) was used to select the best discriminating features (clinical variables and biomarkers) for the prediction problem, namely disease versus control classification. In this disclosure, “best” discriminating features means those that maximize the ratio of correct classifications to all classifications. In some implementations, sensitivity vs. (1-specificity) is plotted as a normalized curve, ie, a curve whose x- and y-axes are normalized to the range of {0, 1}, and the area under the curve (AuC) is used as the metrics. Sensitivity can be expressed as the ratio *true positives* / (*true positives* + *false negatives*) and specificity as the ratio *true negatives* / (*true negative* + *false positives*) of prediction.

The size of the search space for n features grows with 2^n , which means that exhaustive searches over typical clinical data sets are impractical or impossible. Instead, a heuristic function guides the search to find feature subsets with the highest-scoring evaluator functions. In “wrapper” selection methods the actual accuracy is not known, but an accuracy estimate is often used as both the heuristic function (which guides the search) and the evaluator function (which evaluates the goodness of a candidate subset). The inventors used repeated cross-validation as the evaluator function.

Each filtering approach emphasizes certain benefits. Wrapper feature subset selection methodology is one of several filtering approaches described by Kohavi et al. The inventors found wrapper feature subset selection attractive because it forces the accuracy estimation to execute cross-validation more times on small datasets than on large datasets. Because small datasets require less time to learn, the overall accuracy estimation time, which is the sum of the induction algorithm running time and the cross-validation time, does not grow too fast. This means that small datasets will be cross-validated many times to overcome the high variance resulting from small amounts of data. The inventors experimented with the wrapper subset selection strategy in a repeated cross-validation setting and assembled the results across different repeats of the cross-validation. In a feature selection phase, 200 repeats of cross-validation were performed. Special consideration was taken in encoding variables for clinical data because most of the variables were categorical. Finally, the results from the repeated cross-validations were assembled into a final list of features to be used for classification.

After the most discriminating features were selected, a similar repeated five-fold cross-validation was used to train the machine learning classifier for final classification as shown in Figure 1. As the machine-learning classifier, a version of bootstrap aggregation (“bagging”) with a random subset of features was used. A readily available software package is the Random forest package in R (Liaw, 2012). Some of the parameters used were also learned in the cross-validation setting (e.g. mtry parameter which is the number of variables randomly sampled as candidates at each split), while some others were default parameters of the Random forest package (e.g. ntree which determines the number of trees to grow). Repeated cross-validation was used to search for the best parameters of random forest and to quantify the predictive power of the machine learning model. The final results reported are averaged over all the repeats of the cross-validation. In final classification, 100 repeats of cross-validation were executed. Each repeat was randomly seeded at each iteration in both feature selection and final classification for variation in different random parameters (e.g. division of data into test and training set in cross-validation). The reported results are averages of different repeats.

Feature Selection

For the purposes of the present disclosure, the biomarker discovery can be formulated as:

Let $X = \{x_{(1)}, x_{(2)}, \dots, x_{(D)}\}$ be a set of predictors (features, i.e., biological measurements) and T be the target variable (i.e., the disease status we want to predict). The task of feature selection is to find a minimal subset $X' = \{x_{(1)}, x_{(2)}, \dots, x_{(d)}\}$ of X such that it achieves maximum classification performance of T (for a given classifier and a given classification metric) and $d \ll D$.

Classification: Bootstrap aggregation with random subset of features

Decision trees are excellent modelling tools which have found usage in many application domains. However, a major drawback of decision trees is that they are prone to overfitting to their training sets. Several techniques exist that address the overfitting problem. For instance, bootstrap aggregating of decision trees – abbreviated “tree bagging” – is a class of methods, in which the bagging algorithm repeatedly selects (B times) a random sample with replacement of the training set and fits trees to these samples.

Such algorithms improve the performance of the model by decreasing its variance without increasing bias.

The inventors have experimented with multiple different classification schemes and discovered that algorithms based on “Random forest” models are particularly effective for identifying effectively predictive biomarkers, at least for endometriosis. However, use of “Random forest” is registered as US trademark number 3185828, which is why the technically descriptive term “bootstrap aggregation with random subset of features” (or its shorter version “bagging with a random feature subset”) is preferred in this disclosure.

Bagging with a random feature subset is thus a technique which address the tendency of decision-tree-based decision algorithms to overfit to their training data sets. It uses a collection of decision trees, each of which is trained on different random permutations of the data as well as the predictive features. Finally, the results from these different decision trees are combined (typically, averaged) to get the final unbiased prediction, which ameliorates the disadvantages of a single decision tree and provides better and more robust generalization capabilities.

Bagging with a random feature subset

“Bagging” (bootstrap aggregation of) a decision tree with a random subset of features involves an ensemble of multiple decision trees that are useful for classification, regression, and also missing value imputation. In the presently disclosed application to endometriosis diagnosis, bagging is used to arrive at a classification setting which models a binary response (Patient or Control) as a function of predictor variables (biomarkers with or without clinical variables concerning patients). Generally, decision tree algorithms create a binary tree by repeatedly splitting the features in the dataset into two groups. At each branching point (a node in the tree), any feature can be divided into two groups (children) which results in the best separation between the categorical response. The splitting is performed until a criterion for stopping the splitting is completed. Typically the splitting is stopped when a minimum number of nodes n_{min} is reached of the tree needs no further splitting because its leaves contain observations of a single class

One of the major challenges in decision tree learning is how to determine the procedure to split the trees. A Gini impurity index (G) of the parents and its prospective child is often used as the splitting criterion. If the current

node consists of n observations in P classes, let n_p be the number of observations in the p^{th} class. We can now mathematically formulate the Gini impurity index as:

$$G = \sum_{p=1}^P \frac{n_p}{n} \left(1 - \frac{n_p}{n}\right) \quad - \text{eq. 1}$$

In the equation 1 (eq. 1) above, the value of G is at minimum ($=0$) when all the observations in a node are of the same class. Similarly, the Gini index G increases when observations from different classes are accumulated in the same node. Similar to the Gini index, other potential candidates for splitting criterion are: information gain, variance reduction, and other statistical tests.

The process of constructing of the tree is begun by computing the Gini index in the parent node. Then for all the predictors, different unique binary partitions are considered, first splitting between the first and second lowest values and continuing with the second and third lowest values and so on. At each split, samples with a value lower than or equal to the threshold of split is assigned to the one of the two children of the node (e.g. left child of the binary tree) and the samples with values larger than the threshold of split is assigned to the other child of the node (e.g. right child of the binary tree). We then compute the Gini index for each of the child node, and the final Gini index is the average of these two Gini index. Considering all the variables and value splits, we choose the split that leads to the largest reduction in the Gini index. We continuously split all the nodes until the Gini index is 0, i.e., all the samples in the child node are of the same class.

A simplified algorithm for bagging with a random feature subset can be described in the form of pseudocode as follows:

```

For a number of trees ( $b$ ) in 1 to  $B$ 
do
1. Use bootstrapping (bootstrap aggregating, or "bagging") to
draw a bootstrap sample  $Z^*$  of size  $N$  from the training data-
analysis;
2. Train a decision tree  $T_b$  to the bootstrapped data sample  $D^*$ 
recursively by:
a) Selecting  $I$  predictors at random from a total of  $p$  predic-
tors;
```

b) Picking the threshold to split the variable among all m variables (Gini index);

c) Splitting the node to two child nodes until the minimum number of nodes n_{min} is reached or the tree requires no further splits (e.g. Gini index is zero); and

3. Output ensemble of trees: $\{T_b\}_1^B$

Finally, to make a prediction at a new point x :

Let $\hat{C}_b(x)$ be the prediction from both decision tree in the set of bootstrap-aggregated decision trees with random feature subsets. Then the final prediction from the set of such trees is given by

$$\hat{C}_{rf}(x) = \text{majority vote} \{ \hat{C}_b(x) \}_1^B$$

The two-way arrows in Figure 1 indicate that feature selection and/or classification may be performed iteratively, to reduce the influence of random artefacts on final results.

Figure 2 generally illustrates the concept of an *in vitro* decision-making process in which a subject's risk of having or developing endometriosis is determined. As shown in Figure 2, features from one or two classes are obtained from the subject, namely biomarkers and/or clinical variables. Biomarkers, which are measurable indicators of some biological state or condition, can be obtained via well-known methods, which are beyond the scope of the present disclosure. It should be noted that the decision-making process described herein does not use physical samples obtained from subjects but data elements describing the physical samples.

Clinical variables are information elements which objectively and/or subjectively describe the subject. Examples of objective descriptors include the subject's age, weight, menopausal status, or the like. Examples of subjective descriptors include the subject's own evaluation of various pains. The features obtained from the subject are inputted to a computer-implemented model, which is based on the above-described machine-learning process. In that process, candidate sets of decisions trees are filtered to yield an optimized set of decisions trees, which is used to process the features obtained from the subject. The result of the *in vitro* decision-making process shown in Figure 2 may be a qualitative diagnosis (eg endometriosis or not) or a quantitative risk assessment (eg $x\%$ likelihood of having endometriosis, with $y\%$ confidence and $z\%$ accuracy).

Figure 3 is a more detailed flow chart of an overall process, which comprises model creation (shown as phase A) and diagnostic decision-making (shown as phase B). The model-creation phase comprises step 3-2, in which clinical variables describing large numbers of samples are obtained. In the
5 preset context, large numbers of samples means sample sizes large enough to draw scientifically solid conclusions, such as correlations between feature sets and diagnostic status.

In some embodiments the clinical variables are obtained via computerized user interfaces, which present one or more questionnaires. Each
10 questionnaire comprises multiple questions, whose answers will form the set of clinical variables concerning one sample. The set of clinical variables is optimized in the Feature selection phase described in connection with Figure 1. In this disclosure, we assume that biomarkers describing the same samples are also available, which is why the test 3-4 is answered positively and the flow
15 proceeds to step 3-6, in which the computer-implemented model (see Figure 2) is trained on both clinical variables and biomarkers obtained from the same samples. This model-training step 3-6 includes the feature-selection phase described in connection with Figure 1.

In phase B, the model trained in step 3-6 will be used in an *in vitro*
20 diagnostic phase (or risk-assessment phase) concerning an individual subject (prospective patient). Phase B begins in step 3-12, in which biomarkers and clinical variables of the subject are obtained. This step is analogous with steps 3-2 and 3-6 described above, apart from the fact that the steps of phase A were performed with respect to a large number of samples. In step 3-14 the
25 model trained in step 3-6 (namely the filtered sets of decision trees) is used to assess the subject's diagnostic status. In step 3-16 the result of step 3-12 are outputted from the computerized model. For instance, the results can be shown to a physician and/or the subject, but what the physician does with the results is beyond the scope of the present disclosure.

Figures 4A and 4B depict sample screens (pages) of a tool view,
30 which is used to obtain clinical variables concerning patients. By way of example, the screen shown in Figure 4A is used to obtain objective information, but similar screens can be used to obtain subjective information, such as the subject's own assessment of various pains. The screen shown in Figure 4B may
35 be used to combine biomarker data with clinical variables obtained by screens analogous with the one shown in Figure 4A.

Figure 4C depicts a sample screen relating to risk assessment. The exemplary screen indicates a 94.06% risk for a disease (eg endometriosis), and its inverse value, namely 5.94% likelihood of not having that disease. Instead of indicating a risk (or likelihood) for a subject to currently have a disease, a risk for having that disease in a future period of time may be calculated and shown. The two rightmost columns indicate an estimated confidence (97.30%) and estimated accuracy (87.78%).

Figure 5 shows examples of decision trees with clinical variables and biomarkers; typically large numbers of such decision trees generated to fit the patient information provided. Reference number 5-10 is one exemplary decision tree. The decision tree 5-10 has a root node 5-11, which is associated with a feature (clinical variable or biomarker) 5-12, herein menstrual pain strength, which may be entered via a user interface analogous with the one shown in Figure 4A. The feature 5-12 has a threshold value 5-13 (here: a value of 4 for subjective assessment of menstrual pain strength). Still further parameters may be associated with the feature 5-12, such as a confidence value 5-14. Use of the decision tree 5-10 begins at the root node 5-11. Its associated feature and threshold are used to retrieve the corresponding feature obtained from the subject, which is compared with the threshold. If, say, the feature obtained from the subject (menstrual pain) is less than or equivalent to the threshold, traversal of the decision tree 5-10 proceeds to intermediate node 5-15, which is associated with feature (biomarker) MDK and threshold 0.316. If the corresponding feature (level of MDK) obtained from the subject is less than or equivalent to the threshold 0.316, the threshold, traversal of the decision tree proceeds to 5-21, which is one of the leaf nodes 5-21 ... 5-25 of the decision tree 5-10. Leaf node 5-21 indicates an (approximately) 43% likelihood for classification as patient. Other decision trees, of which two exemplary ones are depicted by reference numbers 5-30 and 5-40 will be used to improve the confidence and accuracy of classification (prediction).

The nodes of decision trees, which are not leaf nodes, have associated features and threshold values, which the features are to be compared with. Several efficient features and feature sets will be given later in this disclosure, particularly for endometriosis. As regards determining the threshold values, the same threshold values that were used to create the decision trees in the machine-learning phase can also be used in the diagnostic or risk assessment phase. Figure 6A depicts ranking of the importance of features (clinical

variables and biomarkers) used in the model, while Figure 6B depicts AUC (area under curve), sensitivity and specificity of the endometriosis diagnosis obtained by using the tool with the three most important clinical variables and three most informative biomarkers included. Figure 7 depicts progress of AUC
5 versus additional features, and maximum and minimum values obtained after 100 different repeats of the algorithm. More information will be given in the Tables section at the end of this description.

CLINICAL VARIABLES

In some embodiments, any available clinical variables may be sub-
10 jected to the algorithm disclosed herein for determining a subject's diagnostic state. The number of the clinical variables to be utilized may vary from an embodiment to embodiment, and may include at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, etc. clinical variables selected independently from each other among
15 various variable categories such as the subject's general information, surgical information, medical history, obstetric history, and various pain symptoms including but not limited to, menstrual pain, intercourse pain, and pain associated with defecation or urination. In some embodiments, menstrual pain, intercourse pain, and defecation pain are the most relevant clinical variables for
20 determining a subject's endometriosis state.

BIOMARKERS

Serum concentrations of human cancer antigen 125 (CA125) are known to be elevated in patients with ovarian cancer, advanced endometriosis with peritoneal or deep lesions, or ovarian endometriomas. However, lack of
25 sensitivity and specificity of CA125 has significantly hampered its use as a diagnostic tool. Furthermore, the classical cut-off value of CA125 (35 U/ml) used for diagnostics of ovarian cancer is far too high for diagnosing endometriosis. Nevertheless, CA125 may be used as a biomarker for determining a subject's state of a disease associated with lower abdominal pain, especially endometri-
30 osis or ovarian cancer.

With reference to endometriosis and Example 1, determination of CA125 levels alone with a cut-off value of 35 U/ml provided a sensitivity value of 39.1, a specificity value of 100, and an accuracy value of 56.5. Reducing the cut-off value to 13 U/ml improved the sensitivity and accuracy values to 76.5
35 and 80.1, respectively, while lowered the specificity value to 89.1. At its high-

est, the accuracy value was 0.82 as shown in Table 1 below. Determination of CA125 levels alone provided an AUC value of 0.87.

Performance of the present method of determining a subject's endometriosis state was improved clearly when the levels of both CA125 and Midkine (MK or MDK), also known as neurite growth-promoting factor 2 (NEGF2), were assessed. With a CA125 cut-off value of 35 U/ml combined analysis of CA125 and MDK provided a sensitivity value of 76.3, a specificity value of 82.7, and an accuracy value of 78.2. Reducing the CA125 cut-off value to 13 U/ml improved the sensitivity, specificity, and accuracy values to 81.2 and 87, and 82.8, respectively. At its highest, the accuracy value was 0.861 as shown in Table 2 below. Overall, the combined analysis of CA125 and MDK provided an AUC value of 0.91 as shown in Table 7.

In some embodiments, performance of the present method was improved even further when the level of human epididymal secretory protein E4 (HE4, also known as WAP four-disulfide core domain protein 2) was assessed together with the levels of CA125 and MDK. Such a combined analysis provided an AUC value of 0.90 and, at its highest, an accuracy value of 0.886.

HE4 is a known biomarker whose expression is markedly increased in ovarian cancer, especially the stage I disease, and in endometrial cancer. Thus, another advantage associated with the use of HE4 in combination with CA125 and MDK is the differentiation of endometriosis from endometrial cancer and ovarian cancer.

In some embodiments, performance of the present method was improved further also when the level of any one of Elastin microfibril interfacer 1 (EMILIN1), Granulocyte-macrophage colony-stimulating factor (GM-CSF), and phosphatidylcholine acyl-alkyl C38:1 (lipid metabolite PC ae C38:1) or phosphatidylcholine acyl-alkyl C38:2 (lipid metabolite PC ae C38:2) were assessed together with the levels of CA125 and MDK. To be more specific, combined assessment of CA125, MDK, and EMILIN1 levels provided an accuracy value of 0.862 at its highest. Combined assessment of CA125, MDK, and GM-CSF levels, in turn, provided an accuracy value of 0.916, while combined assessment of CA125, MDK, and PC ae C38:1 and/or PC ae C38:2 levels provided, at its highest, an accuracy value of 0.928. Corresponding AUC values are shown in Table 7.

In addition to a combined determination of CA125, MDK and any one or any combination of EMILIN1, GM-CSF, PC ae C38:1, and PC ae C38:2,

the present method may, in some embodiments, further comprise determination of the level of HE4, particularly for differentiating endometriosis from endometrial cancer and ovarian cancer.

In some embodiments, the present method may further comprise
5 determination of any one or any combination of epidermal growth factor (EGF), interleukin-1 receptor antagonist (IL-1Ra), and interleukin-17 (IL-17).

The endometriosis-associated biomarkers disclosed herein, namely CA125, MDK, EMILIN1, GM-CSF, PC ae C38:1, PC ae C38:2, EGF, IL-1Ra, IL-17, and HE4 were identified among over 50 serum markers including for
10 instance various cytokines, steroids, peptide hormones, and serum metabolites. In some embodiments, these biomarkers are used in the present technique or method depending on availability of reagents for assessing their expression levels. The expression levels of PC.ae.C38.1, PC.ae.C38.2, IL-17, and EMILIN1 were decreased or down-regulated in patients with endometriosis
15 while CA125, IL1RA, HE4, EGF, GMCSF, and MDK were increased or upregulated in patients with endometriosis.

In one aspect, the present disclosure provides a method of determining a subject's endometriosis state on the basis of assessing the level of CA125, MDK, and EMILIN1 in a sample obtained from said subject. Optionally,
20 the level of at least one further marker selected from GM-CSF, PC ae C38:1, PC ae C38:2, EGF, IL-1Ra, IL-17, and HE4 may be used in the analysis. As is apparent to a skilled person, measurements of the present biomarkers may be used alone or combined with other data obtained regarding the subject whose endometriosis state is to be determined. However, in the present aspect, the
25 method *per se* does not involve analyzing any other data, such as clinical variables.

In accordance with the above, the present disclosure also provides use of the disclosed biomarker combinations in determining a subject's endometriosis state.

In a further aspect, the present disclosure provides a method of determining a subject's diagnostic state by obtaining at least three features from said subject, wherein at least one of the features is a clinical variable, and at least two of the features are biomarker levels, such as levels of biomarkers
30 selected from CA125, MDK, EMILIN1, GM-CSF, PC ae C38:1, PC ae C38:2, EGF, IL-1Ra, IL-17, and HE4, or vice versa. In some specific embodiments concerning endometriosis, said clinical variables are selected from menstrual
35

pain, intercourse pain, and defecation pain, the presence of which together with the increased level of any one of CA125, IL1RA, HE4, EGF, GM-CSF, and MDK and/or decreased level of any one of PC.ae.C38.1, PC.ae.C38.2, IL-17 and EMILIN1 are indicative of endometriosis. In some other embodiments, increased level of at least CA125 and/or HE4 together with the presence of relevant clinical variables may be indicative of ovarian cancer. On the other hand, normal level of any one of CA125, MDK, EMILIN1, GM-CSF, PC ae C38:1, PC ae C38:2, EGF, IL-1Ra, IL-17, and HE4 together with the presence of relevant clinical variables may indicate that the subject has or is at risk of developing a lower abdominal pain-associated disease other than endometriosis or ovarian cancer.

In some embodiments of the above aspect, i.e. of a method of determining a subject's endometriosis state on the basis of both clinical variables and biomarkers, the method comprises assessing any one, two or three clinical variables are selected from menstrual pain, intercourse pain, and defecation pain, and assessing the expression level of any one, two, or three biomarkers selected from CA125, MDK, and EMILIN1. The combined presence of the assessed one, two, or three pain symptoms, and increased expression of CA125 or MDK, and decreased expression of EMILIN1 are indicative of the presence of or risk of developing endometriosis.

As used herein, the term "presence of a pain symptom" may refer to a pain score X, on an intuitive scale, such as from 0 to 10. Thus, in some embodiments, the pain score of at least X is considered indicative of endometriosis. In some embodiments the threshold value X may be determined as the value that, based on available data, maximizes the AUC value of the feature or feature combination which depends on the pain score. In some embodiments the threshold value for the pain score may be set to an explicit value, such as at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine or at least 10. Different diseases and/or different pains may have different threshold values.

The present disclosure also provides a kit for use in determining a subject's endometriosis state. Said kit may comprise any reagents or test agents necessary for assessing the level of biomarker combinations disclosed herein. A person skilled in the art can easily determine the reagents to be included depending on the biomarker combination in question and a desired technique for carrying out said assessment. In some embodiments, an appro-

priate control sample or a threshold value may be comprised in the kit. The kit may also comprise a computer readable medium, comprising computer-executable instructions for performing any of the methods of the present disclosure.

5 As is apparent to a skilled person any embodiments, details, advantages, etc. of the present disclosure regarding the method of determining a subject's endometriosis state apply accordingly to other aspects of the present disclosure, including use of the disclosed biomarker combinations in determining a subject's endometriosis state and a kit for use in said determination, and
10 vice versa.

 It will be apparent to a person skilled in the art that, as the technology advances, the inventive concept can be implemented in various ways. The invention and its embodiments are not limited to the examples described below but may vary within the scope of the claims.

15 **EXAMPLE 1**

 All biological samples were obtained with appropriate permissions and informed consents in accordance with the ethical guidelines of the Hospital District of Southwest Finland.

Methods

20 Serum of altogether 102 women with known or suspected endometriosis, and from 45 women with neither history nor suspicion of endometriosis seeking laparoscopic sterilization were prospectively enrolled, and serum was obtained. The exclusion criteria included acute pelvic infection, pregnancy and suspicion of malignancy. Women with suspected endometriosis but no observed lesions and women with unexpected asymptomatic endometriosis
25 among controls were also excluded. The operations were carried out in random phase of the menstrual cycle. The serum samples from all participants were collected within 24 hours prior to the operation into non-heparinized tubes and centrifuged for 15 min at 800 g after being kept at room temperature for 30
30 minutes. The serum was stored at -20°C until analyzed. Serum CA125 concentrations (U/ml) were evaluated using ELISA analysis (Fujirebio Diagnostics Inc, Malvern, PA, USA) according to the manufacturer's instructions. The concentration of Midkine (MDK) was carried out using a sandwich enzyme immunoassay according to the instructions of the
35 manufacturer (Biovendor Reaearch and Diagnostic Products, Czech Republic).

Elastin microfibril interfacier 1 (EMILIN) was measured with an in-house sandwich immunoassay using commercially available antibodies. The granulocyte–macrophage colony-stimulating factor (GMCSF) was measured as part of the LINCOpex Kit (HCYTO-60K-PMX29, LINCO Research Inc., St. Charles, Missouri, USA) according to the manufacturer's instructions. The lipid metabolites (PC.ae.C38.0 and PC.ae.C38.1) being phosphatidylcholines were analysed using targeted ESI-FIA-MS/MS by AbsoluteIDQ p150 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria).

Performance data of the assay combinations

To provide an unbiased estimate of the prediction performance of the multi-assay panel, we use nested five-fold cross-validation, as shown in Figure 1, to train our machine learning classifier. We used Random Forrest as the machine learning classifier (Breiman, Machine learning 45.1 (2001): 5-32) via the randomForest Package (Liaw, "Documentation for R package randomForest" (PDF), <http://cran.r-project.org/web/packages/randomForest/randomForest.pdf>, 16 October 2012, retrieved 18 August 2015). The parameters used were the default parameters in the package except for node and ntree (node =3 and ntree=100). First, we divided the data into five training and validation sets in order to avoid selection bias (Varma and Simon, BMC bioinformatics 7.1 (2006): 91). Only the training data was then again split into five different folds to tune the parameters of the classification model. The model that produced best results on the test data in the inside cross-validation setup was then again evaluated on the validation dataset in the outer cross-validation setup. The final results reported are the mean of the models on outer validation sets.

Results

Results obtained from different assay combinations are summarized in Tables 1 to 5 below. Table 6 shows biomarker levels before and after treatment. Further assay combinations and their respective AUC values will be given in Table 7.

Table 1. Sensitivity, specificity and accuracy analysed for CA125 alone

Threshold	Sensitivity	Specificity	Accuracy
5	0,9565217	0,173913	0,7329193
7	0,8956522	0,5	0,7826087
9	0,8695652	0,6956522	0,8198758
11	0,826087	0,7608696	0,8074534
13	0,7652174	0,8913043	0,8012422
17	0,6347826	0,9565217	0,7267081
21	0,5652174	0,9565217	0,6770186
35	0,3913043	1	0,5652174
37	0,3652174	1	0,5465839
40	0,3391304	1	0,5279503
AUC			0,8687

5 **Table 2. Sensitivity, specificity and accuracy analysed for CA125 in combination with MDK**

Threshold	Sensitivity	Specificity	Accuracy
0,05	1	0,022222222	0,718818681
0,2	0,98	0,308888889	0,787953297
0,4	0,95312253	0,661111111	0,87157967
0,55	0,911093544	0,723333333	0,859793956
0,6	0,902397892	0,748333333	0,861236264
0,65	0,889064559	0,788333333	0,861236264
0,75	0,855924462	0,828333333	0,847293956
0,85	0,795924462	0,868333333	0,814217033
0,9	0,756504172	0,912777778	0,797967033
1	0,410171278	0,96	0,565728022
AUC			0,9

Table 3. Sensitivity, specificity and accuracy analysed for CA125 in combination with MDK and EMILIN1

Threshold	Sensitivity	Specificity	Accuracy
0,2	1	0,308333333	0,786511439
0,3	0,959615385	0,469444444	0,806444894
0,4	0,919230769	0,616111111	0,822433729
0,45	0,919230769	0,674444444	0,841293378
0,5	0,903846154	0,772777778	0,862126712
0,6	0,829895105	0,835	0,829788814
0,7	0,754213287	0,875	0,789480559
0,75	0,711031469	0,897222222	0,765695292
0,85	0,61208042	0,977777778	0,723050377
1	0,161748252	1	0,420693092
AUC			0,92

Table 4. Sensitivity, specificity and accuracy analysed for CA125 in combination with MDK and GMCSF

Threshold	Sensitivity	Specificity	Accuracy
0,35	1	0,377222222	0,813899064
0,45	0,981818182	0,541111111	0,849488706
0,5	0,981818182	0,743333333	0,911507937
0,55	0,95959596	0,808333333	0,916030729
0,6	0,877747729	0,866666667	0,876035307
0,65	0,799092989	0,891666667	0,82785409
0,7	0,751373691	0,925	0,803515466
0,8	0,696789404	0,95	0,771967847
0,85	0,578917782	0,975	0,69656339
1	0,181151561	1	0,424707468
AUC			0,946

5 **Table 5. Sensitivity, specificity and accuracy analysed for CA125 in combination with MDK, and PC ae C38:1 and/or PC ae C38:2**

Threshold	Sensitivity	Specificity	Accuracy
0,2	0,986666667	0,384285714	0,809062771
0,35	0,977971014	0,584285714	0,862255411
0,45	0,966859903	0,682857143	0,882601732
0,5	0,966859903	0,702857143	0,888662338
0,55	0,948678085	0,831428571	0,915222944
0,6	0,928871322	0,926666667	0,928209957
0,65	0,869064559	0,926666667	0,885577922
0,8	0,719367589	0,946666667	0,785495671
0,85	0,662169521	1	0,760612554
AUC			0,954

EXAMPLE 2. CASE STUDIES

The following case examples demonstrate that the algorithm disclosed herein provide a correct diagnosis of endometriosis. In these non-limiting examples, clinical variables obtained by a questionnaire were used
5 either alone or in combination with biomarker data to obtain a risk prediction.

Case 1

32-year-old patient was presented with a 2-year history of infertility. Menstruation was still regular but she had 2-3 days of spotting before her menses are due. She also complained of pain with intercourse and pelvic pain.
10 In reviewing the patient's history, over the past year the patient was repeatedly treated with antibiotics for recurrent microscopic hematuria.

The patient had no history of sexually transmitted infections. She had no urinary urgency, dysuria, nocturia, dyschezia or pain with defecation. Her physical examination was normal.

15 The patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis. Subjecting the clinical variables to the algorithm disclosed herein gave an assessment of 82.4% chance of the disease with a 94% confidence, which result equated to a high predicted risk.

Laparotomy performed confirmed the presence of endometriosis.

20 Case 2

19-year-old null gravida was presented for treatment of chronic pelvic pain. She had the onset of severe dysmenorrhea at 15 years of age. Soon after that she was started on cyclical combined oral contraceptives (OCs) by her pediatrician as a treatment for dysmenorrhea. Over time, her dysmenorrhea worsened, despite continuous treatment with combined OCs.
25 She started experiencing pelvic pain throughout the month, rather than only with menstruation. She rated her pelvic pain at an intensity of 4 to 6 on a scale of 10 on most days, and as a 10 of 10 during menses. Additionally, she became sexually active about 6 months ago and over the past 3 months has had
30 severe pain with intercourse.

The patient had no history of sexually transmitted infections. She had no urinary urgency, dysuria, nocturia, diarrhea, constipation, dyschezia or pain with defecation. Her physical examination was normal except for mild uterine and adnexal tenderness.

Patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis an assessment of 75% risk of disease with a 95% confidence of result which equates to high risk was predicted.

Biomarker measurements added for CA125 u/ml – 18.73 and HE4
5 pmol/l – 34.5 increased the risk of disease from 75% – 77.4% with a confidence of result of 97.14%

Laparotomy performed confirmed the presence of endometriosis there was removal of bilateral endometriomas (6cm & 3cm): ~ 50% left ovary and 80% right ovary retained.

10 Case 3

26-year-old primigravida, para 1 with a history of dysmenorrhea from an early age was put on oral contraceptive pill till she decided to get pregnant. All symptoms were alleviated during pregnancy and while breast feeding. Once breast feeding stopped and her menstrual period returned, the
15 symptoms also returned. She has also been experiencing mild pain with intercourse, diarrhea, and constipation.

The patient has no history of sexually transmitted infections. She has no urinary urgency, dysuria, nocturia, dyschezia or pain with defecation. Her physical examination was normal.

20 Patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis with a prediction of 46% risk of disease with a 94% confidence of result which equates to intermediate risk.

Biomarker measurements added for CA125 – 13.4 u/ml, MDK ng/ml – 0.511, EMILIN ng/ml – 0.85 gave a risk assessment of 49% risk of disease
25 with 98% confidence of result.

Laparotomy performed confirms the presence of endometriosis lesion on the peritoneum and Uterosacral nodularity.

Case 3 is presented as an example wherein the subject's computed risk of having endometriosis was 49%. Because the computed risk alone was
30 very close to 50%, it was insufficient for a definite diagnosis but was sufficient for triggering additional procedures, which then confirmed the presence of endometriosis.

Case 4

21-year-old null gravida with regular menstruation but has 2-3 days
35 of spotting before her menses are due. Complained of persistent abdominal

pain, which is alleviated during menstruation. menstrual pain lasting 3-4 days, with an intensity of 7 on a scale of 10, mild pain with intercourse and severe pelvic pain. Patient history showed no history of sexually transmitted infections, repeated treatment for recurrent microscopic hematuria with antibiotics, she
 5 had no urinary urgency but persistent dysuria and pain with defecation.

Patient took the endometriosis symptom-based questionnaire to assess the risk of endometriosis an intermediate risk was predicted with a 49.2% chance of disease with a 94% confidence of result.

Laparotomy performed confirmed no endometriosis.

10 Similarly to the previous case, case 4 is presented as an example wherein the computed risk of having endometriosis (49.2%) was very close to 50%. This finding triggered additional procedures, which in this case excluded endometriosis.

EXAMPLE 3. RESPONSE TO TREATMENT

15 Three randomly selected laparotomy-treated endometriosis patients out of the initial 102 women of Example 1 were assessed for the level CA125, IL-1Ra, EGF, GM-CSF, and HE4 expression both before and after laparotomy. Owing to a temporary shortage of reagents, the expression levels of no other biomarkers were tested at this point. Nevertheless, the results shown in Table
 20 6 demonstrate that the present biomarkers are suitable not only for diagnosing endometriosis but also for monitoring endometriosis, especially monitoring response to treatment.

TABLE 6. Biomarker levels before and after treatment

Biomarker	P049 Before	P049 After	P088 Before	P088 After	P101 Before	P101 After
CA125	38.27	15.72	57.2	40.44	16.73	12.41
HE4	37.7	27.7	31.3	38.6	56.2	44.8
EGF	191.707	184.337	172.196	80.256	301.939	168.386
GMCSF	87.741	19.341	4.163	4.013	6.331	4.041
IL1RA	574.366	479.932	269.009	209.152	1040.946	796.545
IL-17	72.921	33.217	1.74	2.195	1.455	2.506

Table 7: AUC Values for Combinations of Clinical Variables and Biomarkers

The following abbreviations have been used to conserve space:

ips=intercourse pain strength

5 mps=menstrual pain strength

dps=defecation pain strength

*1=PC.ae.C38.1

*2=PC.ae.C38.2

Index	Feature combination	AUC,%
1	ips, mps	91.797
2	ips, dps	84.588
3	ips, CA125	96.094
4	ips, EMILIN	88.707
5	ips, MDK	89.737
6	ips, *1	88.192
7	ips, EGF	79.883
8	ips, GMCSF	83.274
9	ips, IL1RA	82.173
10	ips, HE4	79.155
11	ips, *2	81.392
12	mps, dps	88.832
13	mps, CA125	95.206
14	mps, EMILIN	94.247
15	mps, MDK	92.614
16	mps, *1	88.53
17	mps, EGF	84.925
18	mps, GMCSF	82.99
19	mps, IL1RA	89.169
20	mps, HE4	84.712
21	mps, *2	87.891
22	dps, CA125	92.756
23	dps, EMILIN	88.281
24	dps, MDK	86.328
25	dps, *1	86.293
26	dps, EGF	81.25
27	dps, GMCSF	75.71
28	dps, IL1RA	79.936
29	dps, HE4	76.563
30	dps, *2	82.209
31	CA125, EMILIN	89.826
32	CA125, MDK	91.122
33	CA125, *1	86.417
34	CA125, EGF	85.227
35	CA125, GMCSF	84.996
36	CA125, IL1RA	88.885
37	CA125, HE4	83.345
38	CA125, *2	86.328

39	EMILIN, MDK	80.771
40	EMILIN, *1	75.799
41	EMILIN, EGF	67.933
42	EMILIN, GMCSF	70.65
43	EMILIN, IL1RA	73.366
44	EMILIN, HE4	71.786
45	EMILIN, *2	72.71
46	MDK, *1	82.386
47	MDK, EGF	73.793
48	MDK, GMCSF	73.118
49	MDK, IL1RA	73.828
50	MDK, HE4	71.52
51	MDK, *2	75.391
52	*1, EGF	64.311
53	*1, GMCSF	62.766
54	*1, IL1RA	63.21
55	*1, HE4	65.98
56	*1, *2	68.679
57	EGF, GMCSF	49.006
58	EGF, IL1RA	51.456
59	EGF, HE4	51.545
60	EGF, *2	47.869
61	GMCSF, IL1RA	50.178
62	GMCSF, HE4	56.605
63	GMCSF, *2	58.984
64	IL1RA, HE4	50.533
65	IL1RA, *2	56.445
66	HE4, *2	53.729
67	ips, mps, dps	93.484
68	ips, mps, CA125	97.124
69	ips, mps, EMILIN	95.455
70	ips, mps, MDK	94.886
71	ips, mps, *1	93.253
72	ips, mps, EGF	92.152
73	ips, mps, GMCSF	91.3
74	ips, mps, IL1RA	93.342
75	ips, mps, HE4	91.3
76	ips, mps, *2	90.749
77	ips, dps, CA125	96.52

78	ips, dps, EMILIN	92.152
79	ips, dps, MDK	92.933
80	ips, dps, *1	91.548
81	ips, dps, EGF	89.293
82	ips, dps, GMCSF	87.784
83	ips, dps, IL1RA	87.109
84	ips, dps, HE4	86.239
85	ips, dps, *2	89.116
86	ips, CA125, EMILIN	95.987
87	ips, CA125, MDK	96.733
88	ips, CA125, *1	95.277
89	ips, CA125, EGF	95.49
90	ips, CA125, GMCSF	95.028
91	ips, CA125, IL1RA	95.17
92	ips, CA125, HE4	94.247
93	ips, CA125, *2	95.028
94	ips, EMILIN, MDK	89.915
95	ips, EMILIN, *1	88.885
96	ips, EMILIN, EGF	87.18
97	ips, EMILIN, GMCSF	87.695
98	ips, EMILIN, IL1RA	87.429
99	ips, EMILIN, HE4	87.198
100	ips, EMILIN, *2	86.754
101	ips, MDK, *1	91.868
102	ips, MDK, EGF	88.672
103	ips, MDK, GMCSF	89.258
104	ips, MDK, IL1RA	88.263
105	ips, MDK, HE4	87.109
106	ips, MDK, *2	89.276
107	ips, *1, EGF	86.967
108	ips, *1, GMCSF	87.056
109	ips, *1, IL1RA	86.523
110	ips, *1, HE4	85.387
111	ips, *1, *2	87.997
112	ips, EGF, GMCSF	84.553
113	ips, EGF, IL1RA	82.227
114	ips, EGF, HE4	82.386
115	ips, EGF, *2	82.937
116	ips, GMCSF, IL1RA	82.28
117	ips, GMCSF, HE4	82.227
118	ips, GMCSF, *2	85.121
119	ips, IL1RA, HE4	80.54
120	ips, IL1RA, *2	83.168
121	ips, HE4, *2	77.752
122	mps, dps, CA125	94.815
123	mps, dps, EMILIN	94.07
124	mps, dps, MDK	92.347
125	mps, dps, *1	91.371
126	mps, dps, EGF	89.631
127	mps, dps, GMCSF	86.648
128	mps, dps, IL1RA	90.661
129	mps, dps, HE4	88.246

130	mps, dps, *2	89.773
131	mps, CA125, EMILIN	96.982
132	mps, CA125, MDK	95.739
133	mps, CA125, *1	93.928
134	mps, CA125, EGF	94.247
135	mps, CA125, GMCSF	93.928
136	mps, CA125, IL1RA	94.78
137	mps, CA125, HE4	94.673
138	mps, CA125, *2	94.815
139	mps, EMILIN, MDK	95.17
140	mps, EMILIN, *1	94.212
141	mps, EMILIN, EGF	91.726
142	mps, EMILIN, GMCSF	92.045
143	mps, EMILIN, IL1RA	94.567
144	mps, EMILIN, HE4	93.111
145	mps, EMILIN, *2	93.111
146	mps, MDK, *1	94.07
147	mps, MDK, EGF	91.584
148	mps, MDK, GMCSF	92.418
149	mps, MDK, IL1RA	93.075
150	mps, MDK, HE4	91.353
151	mps, MDK, *2	92.223
152	mps, *1, EGF	88.956
153	mps, *1, GMCSF	87.482
154	mps, *1, IL1RA	90.447
155	mps, *1, HE4	88.192
156	mps, *1, *2	89.631
157	mps, EGF, GMCSF	85.884
158	mps, EGF, IL1RA	88.601
159	mps, EGF, HE4	84.57
160	mps, EGF, *2	86.719
161	mps, GMCSF, IL1RA	87.145
162	mps, GMCSF, HE4	83.825
163	mps, GMCSF, *2	85.334
164	mps, IL1RA, HE4	89.151
165	mps, IL1RA, *2	89.879
166	mps, HE4, *2	84.677
167	dps, CA125, EMILIN	93.75
168	dps, CA125, MDK	94.212
169	dps, CA125, *1	92.188
170	dps, CA125, EGF	93.501
171	dps, CA125, GMCSF	91.619
172	dps, CA125, IL1RA	92.827
173	dps, CA125, HE4	91.229
174	dps, CA125, *2	93.253
175	dps, EMILIN, MDK	88.459
176	dps, EMILIN, *1	87.571
177	dps, EMILIN, EGF	85.263
178	dps, EMILIN, GMCSF	83.842
179	dps, EMILIN, IL1RA	86.825
180	dps, EMILIN, HE4	86.009
181	dps, EMILIN, *2	87.145

182	dps, MDK, *1	90.376
183	dps, MDK, EGF	86.009
184	dps, MDK, GMCSF	85.866
185	dps, MDK, IL1RA	84.837
186	dps, MDK, HE4	83.771
187	dps, MDK, *2	88.352
188	dps, *1, EGF	88.175
189	dps, *1, GMCSF	83.558
190	dps, *1, IL1RA	85.582
191	dps, *1, HE4	84.411
192	dps, *1, *2	86.399
193	dps, EGF, GMCSF	78.391
194	dps, EGF, IL1RA	81.605
195	dps, EGF, HE4	80.362
196	dps, EGF, *2	83.061
197	dps, GMCSF, IL1RA	77.486
198	dps, GMCSF, HE4	75.923
199	dps, GMCSF, *2	81.729
200	dps, IL1RA, HE4	77.344
201	dps, IL1RA, *2	83.345
202	dps, HE4, *2	78.693
203	CA125, EMILIN, MDK	91.371
204	CA125, EMILIN, *1	90.874
205	CA125, EMILIN, EGF	88.512
206	CA125, EMILIN, GMCSF	89.4
207	CA125, EMILIN, IL1RA	90.412
208	CA125, EMILIN, HE4	89.169
209	CA125, EMILIN, *2	90.341
210	CA125, MDK, *1	91.016
211	CA125, MDK, EGF	90.589
212	CA125, MDK, GMCSF	89.968
213	CA125, MDK, IL1RA	91.193
214	CA125, MDK, HE4	90.163
215	CA125, MDK, *2	90.803
216	CA125, *1, EGF	86.009
217	CA125, *1, GMCSF	85.724
218	CA125, *1, IL1RA	87.997
219	CA125, *1, HE4	85.014
220	CA125, *1, *2	86.967
221	CA125, EGF, GMCSF	85.298
222	CA125, EGF, IL1RA	86.861
223	CA125, EGF, HE4	84.411
224	CA125, EGF, *2	83.487
225	CA125, GMCSF, IL1RA	86.435
226	CA125, GMCSF, HE4	83.913
227	CA125, GMCSF, *2	84.233
228	CA125, IL1RA, HE4	86.559
229	CA125, IL1RA, *2	86.932
230	CA125, HE4, *2	82.209
231	EMILIN, MDK, *1	83.984
232	EMILIN, MDK, EGF	80.824
233	EMILIN, MDK, GMCSF	79.794

234	EMILIN, MDK, IL1RA	81.783
235	EMILIN, MDK, HE4	79.972
236	EMILIN, MDK, *2	81.126
237	EMILIN, *1, EGF	75.178
238	EMILIN, *1, GMCSF	75.746
239	EMILIN, *1, IL1RA	76.332
240	EMILIN, *1, HE4	75.604
241	EMILIN, *1, *2	76.705
242	EMILIN, EGF, GMCSF	68.697
243	EMILIN, EGF, IL1RA	69.602
244	EMILIN, EGF, HE4	68.626
245	EMILIN, EGF, *2	67.915
246	EMILIN, GMCSF, IL1RA	73.793
247	EMILIN, GMCSF, HE4	72.266
248	EMILIN, GMCSF, *2	72.585
249	EMILIN, IL1RA, HE4	73.58
250	EMILIN, IL1RA, *2	73.651
251	EMILIN, HE4, *2	70.881
252	MDK, *1, EGF	80.948
253	MDK, *1, GMCSF	82.138
254	MDK, *1, IL1RA	80.895
255	MDK, *1, HE4	81.428
256	MDK, *1, *2	80.895
257	MDK, EGF, GMCSF	73.26
258	MDK, EGF, IL1RA	74.112
259	MDK, EGF, HE4	72.781
260	MDK, EGF, *2	74.254
261	MDK, GMCSF, IL1RA	73.047
262	MDK, GMCSF, HE4	71.875
263	MDK, GMCSF, *2	75.533
264	MDK, IL1RA, HE4	74.254
265	MDK, IL1RA, *2	74.183
266	MDK, HE4, *2	73.793
267	*1, EGF, GMCSF	64.364
268	*1, EGF, IL1RA	64.134
269	*1, EGF, HE4	64.56
270	*1, EGF, *2	67.667
271	*1, GMCSF, IL1RA	62.891
272	*1, GMCSF, HE4	63.192
273	*1, GMCSF, *2	67.081
274	*1, IL1RA, HE4	63.494
275	*1, IL1RA, *2	63.281
276	*1, HE4, *2	66.886
277	EGF, GMCSF, IL1RA	54.084
278	EGF, GMCSF, HE4	51.598
279	EGF, GMCSF, *2	55.238
280	EGF, IL1RA, HE4	51.776
281	EGF, IL1RA, *2	52.947
282	EGF, HE4, *2	51.065
283	GMCSF, IL1RA, HE4	48.864
284	GMCSF, IL1RA, *2	57.919
285	GMCSF, HE4, *2	48.988

286	IL1RA, HE4, *2	50.533
287	ips, mps, dps, CA125	97.372
288	ips, mps, dps, EMILIN	96.236
289	ips, mps, dps, MDK	95.49
290	ips, mps, dps, *1	93.928
291	ips, mps, dps, EGF	93.661
292	ips, mps, dps, GMCSF	92.987
293	ips, mps, dps, IL1RA	94.229
294	ips, mps, dps, HE4	92.347
295	ips, mps, dps, *2	93.022
296	ips, mps, CA125, EMILIN	98.331
297	ips, mps, CA125, MDK	97.869
298	ips, mps, CA125, *1	97.372
299	ips, mps, CA125, EGF	97.088
300	ips, mps, CA125, GMCSF	97.088
301	ips, mps, CA125, IL1RA	97.195
302	ips, mps, CA125, HE4	97.408
303	ips, mps, CA125, *2	97.159
304	ips, mps, EMILIN, MDK	96.626
305	ips, mps, EMILIN, *1	95.526
306	ips, mps, EMILIN, EGF	95.384
307	ips, mps, EMILIN, GMCSF	95.49
308	ips, mps, EMILIN, IL1RA	96.946
309	ips, mps, EMILIN, HE4	95.597
310	ips, mps, EMILIN, *2	95.099
311	ips, mps, MDK, *1	95.135
312	ips, mps, MDK, EGF	95.064
313	ips, mps, MDK, GMCSF	94.886
314	ips, mps, MDK, IL1RA	95.81
315	ips, mps, MDK, HE4	94.531
316	ips, mps, MDK, *2	94.744
317	ips, mps, *1, EGF	93.146
318	ips, mps, *1, GMCSF	92.454
319	ips, mps, *1, IL1RA	93.466
320	ips, mps, *1, HE4	92.312
321	ips, mps, *1, *2	92.898
322	ips, mps, EGF, GMCSF	91.513
323	ips, mps, EGF, IL1RA	93.572
324	ips, mps, EGF, HE4	92.188
325	ips, mps, EGF, *2	91.868
326	ips, mps, GMCSF, IL1RA	93.395
327	ips, mps, GMCSF, HE4	91.353
328	ips, mps, GMCSF, *2	91.513
329	ips, mps, IL1RA, HE4	93.466
330	ips, mps, IL1RA, *2	93.537
331	ips, mps, HE4, *2	90.696
332	ips, dps, CA125, EMILIN	96.946
333	ips, dps, CA125, MDK	96.839
334	ips, dps, CA125, *1	96.2
335	ips, dps, CA125, EGF	96.875
336	ips, dps, CA125, GMCSF	95.916
337	ips, dps, CA125, IL1RA	95.987

338	ips, dps, CA125, HE4	95.668
339	ips, dps, CA125, *2	96.094
340	ips, dps, EMILIN, MDK	93.288
341	ips, dps, EMILIN, *1	92.152
342	ips, dps, EMILIN, EGF	92.596
343	ips, dps, EMILIN, GMCSF	91.726
344	ips, dps, EMILIN, IL1RA	92.223
345	ips, dps, EMILIN, HE4	91.939
346	ips, dps, EMILIN, *2	92.188
347	ips, dps, MDK, *1	93.288
348	ips, dps, MDK, EGF	92.063
349	ips, dps, MDK, GMCSF	92.116
350	ips, dps, MDK, IL1RA	91.797
351	ips, dps, MDK, HE4	91.548
352	ips, dps, MDK, *2	92.259
353	ips, dps, *1, EGF	91.957
354	ips, dps, *1, GMCSF	91.246
355	ips, dps, *1, IL1RA	90.696
356	ips, dps, *1, HE4	91.033
357	ips, dps, *1, *2	90.554
358	ips, dps, EGF, GMCSF	89.009
359	ips, dps, EGF, IL1RA	89.364
360	ips, dps, EGF, HE4	89.4
361	ips, dps, EGF, *2	89.773
362	ips, dps, GMCSF, IL1RA	87.855
363	ips, dps, GMCSF, HE4	87.802
364	ips, dps, GMCSF, *2	89.347
365	ips, dps, IL1RA, HE4	86.293
366	ips, dps, IL1RA, *2	89.169
367	ips, dps, HE4, *2	87.003
368	ips, CA125, EMILIN, MDK	97.159
369	ips, CA125, EMILIN, *1	95.774
370	ips, CA125, EMILIN, EGF	96.094
371	ips, CA125, EMILIN, GMCSF	95.597
372	ips, CA125, EMILIN, IL1RA	95.881
373	ips, CA125, EMILIN, HE4	96.378
374	ips, CA125, EMILIN, *2	96.307
375	ips, CA125, MDK, *1	96.946
376	ips, CA125, MDK, EGF	96.839
377	ips, CA125, MDK, GMCSF	97.053
378	ips, CA125, MDK, IL1RA	96.911
379	ips, CA125, MDK, HE4	96.626
380	ips, CA125, MDK, *2	96.697
381	ips, CA125, *1, EGF	95.526
382	ips, CA125, *1, GMCSF	95.241
383	ips, CA125, *1, IL1RA	94.993
384	ips, CA125, *1, HE4	94.46
385	ips, CA125, *1, *2	95.17
386	ips, CA125, EGF, GMCSF	95.17
387	ips, CA125, EGF, IL1RA	95.17
388	ips, CA125, EGF, HE4	95.028
389	ips, CA125, EGF, *2	95.526

390	ips, CA125, GMCSF, IL1RA	94.709
391	ips, CA125, GMCSF, HE4	94.851
392	ips, CA125, GMCSF, *2	94.957
393	ips, CA125, IL1RA, HE4	94.567
394	ips, CA125, IL1RA, *2	95.241
395	ips, CA125, HE4, *2	94.247
396	ips, EMILIN, MDK, *1	92.01
397	ips, EMILIN, MDK, EGF	90.874
398	ips, EMILIN, MDK, GMCSF	90.891
399	ips, EMILIN, MDK, IL1RA	90.945
400	ips, EMILIN, MDK, HE4	90.305
401	ips, EMILIN, MDK, *2	91.122
402	ips, EMILIN, *1, EGF	88.601
403	ips, EMILIN, *1, GMCSF	88.814
404	ips, EMILIN, *1, IL1RA	89.045
405	ips, EMILIN, *1, HE4	89.24
406	ips, EMILIN, *1, *2	89.205
407	ips, EMILIN, EGF, GMCSF	86.825
408	ips, EMILIN, EGF, IL1RA	88.139
409	ips, EMILIN, EGF, HE4	86.719
410	ips, EMILIN, EGF, *2	86.168
411	ips, EMILIN, GMCSF, IL1RA	88.743
412	ips, EMILIN, GMCSF, HE4	88.743
413	ips, EMILIN, GMCSF, *2	87.962
414	ips, EMILIN, IL1RA, HE4	88.388
415	ips, EMILIN, IL1RA, *2	87.749
416	ips, EMILIN, HE4, *2	86.79
417	ips, MDK, *1, EGF	91.761
418	ips, MDK, *1, GMCSF	92.188
419	ips, MDK, *1, IL1RA	90.98
420	ips, MDK, *1, HE4	90.838
421	ips, MDK, *1, *2	91.602
422	ips, MDK, EGF, GMCSF	90.199
423	ips, MDK, EGF, IL1RA	89.844
424	ips, MDK, EGF, HE4	87.784
425	ips, MDK, EGF, *2	89.134
426	ips, MDK, GMCSF, IL1RA	89.595
427	ips, MDK, GMCSF, HE4	88.814
428	ips, MDK, GMCSF, *2	89.879
429	ips, MDK, IL1RA, HE4	87.784
430	ips, MDK, IL1RA, *2	88.601
431	ips, MDK, HE4, *2	88.21
432	ips, *1, EGF, GMCSF	86.257
433	ips, *1, EGF, IL1RA	85.973
434	ips, *1, EGF, HE4	85.938
435	ips, *1, EGF, *2	87.784
436	ips, *1, GMCSF, IL1RA	86.701
437	ips, *1, GMCSF, HE4	85.938
438	ips, *1, GMCSF, *2	87.678
439	ips, *1, IL1RA, HE4	85.316
440	ips, *1, IL1RA, *2	86.009
441	ips, *1, HE4, *2	84.872

442	ips, EGF, GMCSF, IL1RA	83.203
443	ips, EGF, GMCSF, HE4	84.624
444	ips, EGF, GMCSF, *2	84.73
445	ips, EGF, IL1RA, HE4	81.286
446	ips, EGF, IL1RA, *2	83.487
447	ips, EGF, HE4, *2	81.463
448	ips, GMCSF, IL1RA, HE4	82.599
449	ips, GMCSF, IL1RA, *2	83.984
450	ips, GMCSF, HE4, *2	82.315
451	ips, IL1RA, HE4, *2	80.433
452	mps, dps, CA125, EMILIN	97.195
453	mps, dps, CA125, MDK	96.342
454	mps, dps, CA125, *1	95.17
455	mps, dps, CA125, EGF	95.419
456	mps, dps, CA125, GMCSF	94.851
457	mps, dps, CA125, IL1RA	95.419
458	mps, dps, CA125, HE4	95.526
459	mps, dps, CA125, *2	95.668
460	mps, dps, EMILIN, MDK	95.313
461	mps, dps, EMILIN, *1	94.993
462	mps, dps, EMILIN, EGF	93.43
463	mps, dps, EMILIN, GMCSF	93.359
464	mps, dps, EMILIN, IL1RA	95.881
465	mps, dps, EMILIN, HE4	94.176
466	mps, dps, EMILIN, *2	93.945
467	mps, dps, MDK, *1	94.656
468	mps, dps, MDK, EGF	92.862
469	mps, dps, MDK, GMCSF	92.631
470	mps, dps, MDK, IL1RA	94.318
471	mps, dps, MDK, HE4	92.188
472	mps, dps, MDK, *2	93.714
473	mps, dps, *1, EGF	91.406
474	mps, dps, *1, GMCSF	89.08
475	mps, dps, *1, IL1RA	91.513
476	mps, dps, *1, HE4	90.376
477	mps, dps, *1, *2	92.081
478	mps, dps, EGF, GMCSF	88.228
479	mps, dps, EGF, IL1RA	90.785
480	mps, dps, EGF, HE4	89.258
481	mps, dps, EGF, *2	90.359
482	mps, dps, GMCSF, IL1RA	89.595
483	mps, dps, GMCSF, HE4	86.612
484	mps, dps, GMCSF, *2	88.21
485	mps, dps, IL1RA, HE4	91.087
486	mps, dps, IL1RA, *2	91.335
487	mps, dps, HE4, *2	87.731
488	mps, CA125, EMILIN, MDK	97.692
489	mps, CA125, EMILIN, *1	96.875
490	mps, CA125, EMILIN, EGF	97.017
491	mps, CA125, EMILIN, GMCSF	97.053
492	mps, CA125, EMILIN, IL1RA	97.266
493	mps, CA125, EMILIN, HE4	97.159

494	mps, CA125, EMILIN, *2	97.159
495	mps, CA125, MDK, *1	96.289
496	mps, CA125, MDK, EGF	95.987
497	mps, CA125, MDK, GMCSF	96.307
498	mps, CA125, MDK, IL1RA	96.449
499	mps, CA125, MDK, HE4	96.378
500	mps, CA125, MDK, *2	96.591
501	mps, CA125, *1, EGF	94.212
502	mps, CA125, *1, GMCSF	94.176
503	mps, CA125, *1, IL1RA	95.099
504	mps, CA125, *1, HE4	94.425
505	mps, CA125, *1, *2	95.099
506	mps, CA125, EGF, GMCSF	94.212
507	mps, CA125, EGF, IL1RA	94.425
508	mps, CA125, EGF, HE4	94.354
509	mps, CA125, EGF, *2	94.389
510	mps, CA125, GMCSF, IL1RA	94.531
511	mps, CA125, GMCSF, HE4	94.496
512	mps, CA125, GMCSF, *2	94.176
513	mps, CA125, IL1RA, HE4	95.295
514	mps, CA125, IL1RA, *2	94.886
515	mps, CA125, HE4, *2	94.709
516	mps, EMILIN, MDK, *1	95.916
517	mps, EMILIN, MDK, EGF	94.638
518	mps, EMILIN, MDK, GMCSF	94.567
519	mps, EMILIN, MDK, IL1RA	94.78
520	mps, EMILIN, MDK, HE4	95.011
521	mps, EMILIN, MDK, *2	95.295
522	mps, EMILIN, *1, EGF	93.75
523	mps, EMILIN, *1, GMCSF	94.407
524	mps, EMILIN, *1, IL1RA	94.886
525	mps, EMILIN, *1, HE4	94.229
526	mps, EMILIN, *1, *2	94.744
527	mps, EMILIN, EGF, GMCSF	91.442
528	mps, EMILIN, EGF, IL1RA	93.732
529	mps, EMILIN, EGF, HE4	90.838
530	mps, EMILIN, EGF, *2	92.188
531	mps, EMILIN, GMCSF, IL1RA	93.679
532	mps, EMILIN, GMCSF, HE4	91.371
533	mps, EMILIN, GMCSF, *2	92.436
534	mps, EMILIN, IL1RA, HE4	94.176
535	mps, EMILIN, IL1RA, *2	94.691
536	mps, EMILIN, HE4, *2	92.436
537	mps, MDK, *1, EGF	93.643
538	mps, MDK, *1, GMCSF	94.212
539	mps, MDK, *1, IL1RA	94.318
540	mps, MDK, *1, HE4	93.182
541	mps, MDK, *1, *2	94.354
542	mps, MDK, EGF, GMCSF	91.832
543	mps, MDK, EGF, IL1RA	92.081
544	mps, MDK, EGF, HE4	91.3
545	mps, MDK, EGF, *2	92.223

546	mps, MDK, GMCSF, IL1RA	92.614
547	mps, MDK, GMCSF, HE4	92.116
548	mps, MDK, GMCSF, *2	92.188
549	mps, MDK, IL1RA, HE4	93.04
550	mps, MDK, IL1RA, *2	93.963
551	mps, MDK, HE4, *2	91.655
552	mps, *1, EGF, GMCSF	88.991
553	mps, *1, EGF, IL1RA	90.128
554	mps, *1, EGF, HE4	87.464
555	mps, *1, EGF, *2	90.128
556	mps, *1, GMCSF, IL1RA	88.565
557	mps, *1, GMCSF, HE4	86.648
558	mps, *1, GMCSF, *2	88.743
559	mps, *1, IL1RA, HE4	90.305
560	mps, *1, IL1RA, *2	90.803
561	mps, *1, HE4, *2	88.388
562	mps, EGF, GMCSF, IL1RA	87.962
563	mps, EGF, GMCSF, HE4	86.239
564	mps, EGF, GMCSF, *2	86.861
565	mps, EGF, IL1RA, HE4	88.139
566	mps, EGF, IL1RA, *2	89.098
567	mps, EGF, HE4, *2	85.476
568	mps, GMCSF, IL1RA, HE4	87.908
569	mps, GMCSF, IL1RA, *2	88.21
570	mps, GMCSF, HE4, *2	83.913
571	mps, IL1RA, HE4, *2	89.205
572	dps, CA125, EMILIN, MDK	94.318
573	dps, CA125, EMILIN, *1	93.857
574	dps, CA125, EMILIN, EGF	93.786
575	dps, CA125, EMILIN, GMCSF	93.43
576	dps, CA125, EMILIN, IL1RA	94.158
577	dps, CA125, EMILIN, HE4	93.963
578	dps, CA125, EMILIN, *2	94.46
579	dps, CA125, MDK, *1	94.673
580	dps, CA125, MDK, EGF	94.744
581	dps, CA125, MDK, GMCSF	94.354
582	dps, CA125, MDK, IL1RA	94.496
583	dps, CA125, MDK, HE4	93.892
584	dps, CA125, MDK, *2	94.496
585	dps, CA125, *1, EGF	93.359
586	dps, CA125, *1, GMCSF	91.531
587	dps, CA125, *1, IL1RA	92.862
588	dps, CA125, *1, HE4	90.98
589	dps, CA125, *1, *2	93.075
590	dps, CA125, EGF, GMCSF	93.04
591	dps, CA125, EGF, IL1RA	93.643
592	dps, CA125, EGF, HE4	92.738
593	dps, CA125, EGF, *2	93.04
594	dps, CA125, GMCSF, IL1RA	91.974
595	dps, CA125, GMCSF, HE4	90.909
596	dps, CA125, GMCSF, *2	92.294
597	dps, CA125, IL1RA, HE4	91.939

598	dps, CA125, IL1RA, *2	92.933
599	dps, CA125, HE4, *2	91.868
600	dps, EMILIN, MDK, *1	91.229
601	dps, EMILIN, MDK, EGF	88.388
602	dps, EMILIN, MDK, GMCSF	87.926
603	dps, EMILIN, MDK, IL1RA	88.406
604	dps, EMILIN, MDK, HE4	88.121
605	dps, EMILIN, MDK, *2	90.163
606	dps, EMILIN, *1, EGF	87.145
607	dps, EMILIN, *1, GMCSF	86.879
608	dps, EMILIN, *1, IL1RA	88.832
609	dps, EMILIN, *1, HE4	88.53
610	dps, EMILIN, *1, *2	90.625
611	dps, EMILIN, EGF, GMCSF	82.741
612	dps, EMILIN, EGF, IL1RA	86.275
613	dps, EMILIN, EGF, HE4	84.268
614	dps, EMILIN, EGF, *2	86.435
615	dps, EMILIN, GMCSF, IL1RA	86.364
616	dps, EMILIN, GMCSF, HE4	85.511
617	dps, EMILIN, GMCSF, *2	86.044
618	dps, EMILIN, IL1RA, HE4	87.784
619	dps, EMILIN, IL1RA, *2	88.317
620	dps, EMILIN, HE4, *2	87.5
621	dps, MDK, *1, EGF	90.767
622	dps, MDK, *1, GMCSF	91.016
623	dps, MDK, *1, IL1RA	91.087
624	dps, MDK, *1, HE4	91.335
625	dps, MDK, *1, *2	91.14
626	dps, MDK, EGF, GMCSF	85.902
627	dps, MDK, EGF, IL1RA	86.399
628	dps, MDK, EGF, HE4	85.21
629	dps, MDK, EGF, *2	88.672
630	dps, MDK, GMCSF, IL1RA	85.653
631	dps, MDK, GMCSF, HE4	85.121
632	dps, MDK, GMCSF, *2	89.311
633	dps, MDK, IL1RA, HE4	85.121
634	dps, MDK, IL1RA, *2	88.814
635	dps, MDK, HE4, *2	88.05
636	dps, *1, EGF, GMCSF	84.624
637	dps, *1, EGF, IL1RA	88.494
638	dps, *1, EGF, HE4	85.902
639	dps, *1, EGF, *2	88.53
640	dps, *1, GMCSF, IL1RA	84.695
641	dps, *1, GMCSF, HE4	82.99
642	dps, *1, GMCSF, *2	85.849
643	dps, *1, IL1RA, HE4	84.251
644	dps, *1, IL1RA, *2	85.76
645	dps, *1, HE4, *2	84.588
646	dps, EGF, GMCSF, IL1RA	81.161
647	dps, EGF, GMCSF, HE4	78.356
648	dps, EGF, GMCSF, *2	82.955
649	dps, EGF, IL1RA, HE4	81.108

650	dps, EGF, IL1RA, *2	84.251
651	dps, EGF, HE4, *2	81.392
652	dps, GMCSF, IL1RA, HE4	77.539
653	dps, GMCSF, IL1RA, *2	82.635
654	dps, GMCSF, HE4, *2	79.634
655	dps, IL1RA, HE4, *2	80.043
656	CA125, EMILIN, MDK, *1	92.205
657	CA125, EMILIN, MDK, EGF	90.874
658	CA125, EMILIN, MDK, GMCSF	90.661
659	CA125, EMILIN, MDK, IL1RA	91.868
660	CA125, EMILIN, MDK, HE4	91.371
661	CA125, EMILIN, MDK, *2	91.104
662	CA125, EMILIN, *1, EGF	88.707
663	CA125, EMILIN, *1, GMCSF	90.092
664	CA125, EMILIN, *1, IL1RA	90.554
665	CA125, EMILIN, *1, HE4	90.589
666	CA125, EMILIN, *1, *2	90.803
667	CA125, EMILIN, EGF, GMCSF	87.891
668	CA125, EMILIN, EGF, IL1RA	88.707
669	CA125, EMILIN, EGF, HE4	87.82
670	CA125, EMILIN, EGF, *2	88.672
671	CA125, EMILIN, GMCSF, IL1RA	89.418
672	CA125, EMILIN, GMCSF, HE4	89.063
673	CA125, EMILIN, GMCSF, *2	89.169
674	CA125, EMILIN, IL1RA, HE4	89.702
675	CA125, EMILIN, IL1RA, *2	90.483
676	CA125, EMILIN, HE4, *2	89.311
677	CA125, MDK, *1, EGF	90.518
678	CA125, MDK, *1, GMCSF	91.033
679	CA125, MDK, *1, IL1RA	91.584
680	CA125, MDK, *1, HE4	90.678
681	CA125, MDK, *1, *2	91.388
682	CA125, MDK, EGF, GMCSF	89.702
683	CA125, MDK, EGF, IL1RA	90.625
684	CA125, MDK, EGF, HE4	89.418
685	CA125, MDK, EGF, *2	89.702
686	CA125, MDK, GMCSF, IL1RA	89.915
687	CA125, MDK, GMCSF, HE4	89.08
688	CA125, MDK, GMCSF, *2	89.844
689	CA125, MDK, IL1RA, HE4	90.11
690	CA125, MDK, IL1RA, *2	91.016
691	CA125, MDK, HE4, *2	90.199
692	CA125, *1, EGF, GMCSF	85.263
693	CA125, *1, EGF, IL1RA	87.003
694	CA125, *1, EGF, HE4	84.411
695	CA125, *1, EGF, *2	85.618
696	CA125, *1, GMCSF, IL1RA	86.754
697	CA125, *1, GMCSF, HE4	84.695
698	CA125, *1, GMCSF, *2	85.813
699	CA125, *1, IL1RA, HE4	86.417
700	CA125, *1, IL1RA, *2	87.393
701	CA125, *1, HE4, *2	85.192

702	CA125, EGF, GMCSF, IL1RA	85.476
703	CA125, EGF, GMCSF, HE4	83.452
704	CA125, EGF, GMCSF, *2	83.505
705	CA125, EGF, IL1RA, HE4	84.837
706	CA125, EGF, IL1RA, *2	85.263
707	CA125, EGF, HE4, *2	82.386
708	CA125, GMCSF, IL1RA, HE4	84.854
709	CA125, GMCSF, IL1RA, *2	85.44
710	CA125, GMCSF, HE4, *2	82.28
711	CA125, IL1RA, HE4, *2	84.819
712	EMILIN, MDK, *1, EGF	84.588
713	EMILIN, MDK, *1, GMCSF	84.233
714	EMILIN, MDK, *1, IL1RA	84.233
715	EMILIN, MDK, *1, HE4	84.126
716	EMILIN, MDK, *1, *2	84.979
717	EMILIN, MDK, EGF, GMCSF	80.256
718	EMILIN, MDK, EGF, IL1RA	81.232
719	EMILIN, MDK, EGF, HE4	80.096
720	EMILIN, MDK, EGF, *2	81.676
721	EMILIN, MDK, GMCSF, IL1RA	81.214
722	EMILIN, MDK, GMCSF, HE4	79.51
723	EMILIN, MDK, GMCSF, *2	81.214
724	EMILIN, MDK, IL1RA, HE4	80.788
725	EMILIN, MDK, IL1RA, *2	82.493
726	EMILIN, MDK, HE4, *2	80.753
727	EMILIN, *1, EGF, GMCSF	75.994
728	EMILIN, *1, EGF, IL1RA	75.746
729	EMILIN, *1, EGF, HE4	75.497
730	EMILIN, *1, EGF, *2	76.314
731	EMILIN, *1, GMCSF, IL1RA	77.876
732	EMILIN, *1, GMCSF, HE4	77.131
733	EMILIN, *1, GMCSF, *2	78.8
734	EMILIN, *1, IL1RA, HE4	78.001
735	EMILIN, *1, IL1RA, *2	77.521
736	EMILIN, *1, HE4, *2	76.634
737	EMILIN, EGF, GMCSF, IL1RA	71.555
738	EMILIN, EGF, GMCSF, HE4	69.957
739	EMILIN, EGF, GMCSF, *2	69.762
740	EMILIN, EGF, IL1RA, HE4	70.863
741	EMILIN, EGF, IL1RA, *2	70.526
742	EMILIN, EGF, HE4, *2	69.016
743	EMILIN, GMCSF, IL1RA, HE4	74.663
744	EMILIN, GMCSF, IL1RA, *2	75.053
745	EMILIN, GMCSF, HE4, *2	74.432
746	EMILIN, IL1RA, HE4, *2	73.722
747	MDK, *1, EGF, GMCSF	81.516
748	MDK, *1, EGF, IL1RA	80.93
749	MDK, *1, EGF, HE4	80.487
750	MDK, *1, EGF, *2	80.469
751	MDK, *1, GMCSF, IL1RA	80.948
752	MDK, *1, GMCSF, HE4	81.641
753	MDK, *1, GMCSF, *2	82.919

754	MDK, *1, IL1RA, HE4	80.611
755	MDK, *1, IL1RA, *2	80.291
756	MDK, *1, HE4, *2	81.747
757	MDK, EGF, GMCSF, IL1RA	73.544
758	MDK, EGF, GMCSF, HE4	71.839
759	MDK, EGF, GMCSF, *2	74.308
760	MDK, EGF, IL1RA, HE4	72.124
761	MDK, EGF, IL1RA, *2	74.112
762	MDK, EGF, HE4, *2	73.082
763	MDK, GMCSF, IL1RA, HE4	72.017
764	MDK, GMCSF, IL1RA, *2	75.16
765	MDK, GMCSF, HE4, *2	73.509
766	MDK, IL1RA, HE4, *2	72.621
767	*1, EGF, GMCSF, IL1RA	64.737
768	*1, EGF, GMCSF, HE4	64.134
769	*1, EGF, GMCSF, *2	67.685
770	*1, EGF, IL1RA, HE4	63.778
771	*1, EGF, IL1RA, *2	64.276
772	*1, EGF, HE4, *2	64.382
773	*1, GMCSF, IL1RA, HE4	62.695
774	*1, GMCSF, IL1RA, *2	65.607
775	*1, GMCSF, HE4, *2	64.489
776	*1, IL1RA, HE4, *2	62.713
777	EGF, GMCSF, IL1RA, HE4	52.734
778	EGF, GMCSF, IL1RA, *2	55.415
779	EGF, GMCSF, HE4, *2	48.633
780	EGF, IL1RA, HE4, *2	48.509
781	GMCSF, IL1RA, HE4, *2	52.095
782	ips, mps, dps, CA125, EMILIN	98.26
783	ips, mps, dps, CA125, MDK	97.94
784	ips, mps, dps, CA125, *1	97.23
785	ips, mps, dps, CA125, EGF	97.585
786	ips, mps, dps, CA125, GMCSF	97.124
787	ips, mps, dps, CA125, IL1RA	97.159
788	ips, mps, dps, CA125, HE4	97.479
789	ips, mps, dps, CA125, *2	97.195
790	ips, mps, dps, EMILIN, MDK	96.555
791	ips, mps, dps, EMILIN, *1	95.774
792	ips, mps, dps, EMILIN, EGF	95.845
793	ips, mps, dps, EMILIN, GMCSF	95.614
794	ips, mps, dps, EMILIN, IL1RA	96.875
795	ips, mps, dps, EMILIN, HE4	95.739
796	ips, mps, dps, EMILIN, *2	95.561
797	ips, mps, dps, MDK, *1	95.455
798	ips, mps, dps, MDK, EGF	95.241
799	ips, mps, dps, MDK, GMCSF	95.206
800	ips, mps, dps, MDK, IL1RA	95.952
801	ips, mps, dps, MDK, HE4	94.886
802	ips, mps, dps, MDK, *2	95.295
803	ips, mps, dps, *1, EGF	93.679
804	ips, mps, dps, *1, GMCSF	93.253
805	ips, mps, dps, *1, IL1RA	94.07

806	ips, mps, dps, *1, HE4	93.324
807	ips, mps, dps, *1, *2	93.821
808	ips, mps, dps, EGF, GMCSF	93.04
809	ips, mps, dps, EGF, IL1RA	94.212
810	ips, mps, dps, EGF, HE4	93.093
811	ips, mps, dps, EGF, *2	93.324
812	ips, mps, dps, GMCSF, IL1RA	93.643
813	ips, mps, dps, GMCSF, HE4	92.756
814	ips, mps, dps, GMCSF, *2	92.933
815	ips, mps, dps, IL1RA, HE4	93.999
816	ips, mps, dps, IL1RA, *2	94.194
817	ips, mps, dps, HE4, *2	92.205
818	ips, mps, CA125, EMILIN, MDK	98.58
819	ips, mps, CA125, EMILIN, *1	98.651
820	ips, mps, CA125, EMILIN, EGF	98.473
821	ips, mps, CA125, EMILIN, GMCSF	98.402
822	ips, mps, CA125, EMILIN, IL1RA	98.686
823	ips, mps, CA125, EMILIN, HE4	98.615
824	ips, mps, CA125, EMILIN, *2	98.58
825	ips, mps, CA125, MDK, *1	98.189
826	ips, mps, CA125, MDK, EGF	98.331
827	ips, mps, CA125, MDK, GMCSF	98.082
828	ips, mps, CA125, MDK, IL1RA	98.011
829	ips, mps, CA125, MDK, HE4	98.153
830	ips, mps, CA125, MDK, *2	98.047
831	ips, mps, CA125, *1, EGF	97.443
832	ips, mps, CA125, *1, GMCSF	96.911
833	ips, mps, CA125, *1, IL1RA	97.443
834	ips, mps, CA125, *1, HE4	97.408
835	ips, mps, CA125, *1, *2	97.266
836	ips, mps, CA125, EGF, GMCSF	97.124
837	ips, mps, CA125, EGF, IL1RA	97.159
838	ips, mps, CA125, EGF, HE4	97.372
839	ips, mps, CA125, EGF, *2	97.266
840	ips, mps, CA125, GMCSF, IL1RA	96.946
841	ips, mps, CA125, GMCSF, HE4	97.053
842	ips, mps, CA125, GMCSF, *2	97.07
843	ips, mps, CA125, IL1RA, HE4	97.692
844	ips, mps, CA125, IL1RA, *2	97.195
845	ips, mps, CA125, HE4, *2	97.337
846	ips, mps, EMILIN, MDK, *1	96.662
847	ips, mps, EMILIN, MDK, EGF	96.839
848	ips, mps, EMILIN, MDK, GMCSF	96.449
849	ips, mps, EMILIN, MDK, IL1RA	97.053
850	ips, mps, EMILIN, MDK, HE4	96.591
851	ips, mps, EMILIN, MDK, *2	96.378
852	ips, mps, EMILIN, *1, EGF	95.419
853	ips, mps, EMILIN, *1, GMCSF	95.384
854	ips, mps, EMILIN, *1, IL1RA	96.804
855	ips, mps, EMILIN, *1, HE4	95.455
856	ips, mps, EMILIN, *1, *2	95.597
857	ips, mps, EMILIN, EGF, GMCSF	95.17

858	ips, mps, EMILIN, EGF, IL1RA	97.053
859	ips, mps, EMILIN, EGF, HE4	95.348
860	ips, mps, EMILIN, EGF, *2	95.241
861	ips, mps, EMILIN, GMCSF, IL1RA	96.839
862	ips, mps, EMILIN, GMCSF, HE4	95.17
863	ips, mps, EMILIN, GMCSF, *2	94.993
864	ips, mps, EMILIN, IL1RA, HE4	96.875
865	ips, mps, EMILIN, IL1RA, *2	96.875
866	ips, mps, EMILIN, HE4, *2	94.957
867	ips, mps, MDK, *1, EGF	95.455
868	ips, mps, MDK, *1, GMCSF	95.313
869	ips, mps, MDK, *1, IL1RA	96.023
870	ips, mps, MDK, *1, HE4	95.241
871	ips, mps, MDK, *1, *2	95.668
872	ips, mps, MDK, EGF, GMCSF	94.886
873	ips, mps, MDK, EGF, IL1RA	95.952
874	ips, mps, MDK, EGF, HE4	94.922
875	ips, mps, MDK, EGF, *2	95.028
876	ips, mps, MDK, GMCSF, IL1RA	95.739
877	ips, mps, MDK, GMCSF, HE4	94.638
878	ips, mps, MDK, GMCSF, *2	94.851
879	ips, mps, MDK, IL1RA, HE4	95.739
880	ips, mps, MDK, IL1RA, *2	95.632
881	ips, mps, MDK, HE4, *2	94.425
882	ips, mps, *1, EGF, GMCSF	92.383
883	ips, mps, *1, EGF, IL1RA	93.679
884	ips, mps, *1, EGF, HE4	92.791
885	ips, mps, *1, EGF, *2	93.466
886	ips, mps, *1, GMCSF, IL1RA	93.111
887	ips, mps, *1, GMCSF, HE4	92.33
888	ips, mps, *1, GMCSF, *2	93.022
889	ips, mps, *1, IL1RA, HE4	93.643
890	ips, mps, *1, IL1RA, *2	93.821
891	ips, mps, *1, HE4, *2	92.401
892	ips, mps, EGF, GMCSF, IL1RA	93.182
893	ips, mps, EGF, GMCSF, HE4	91.868
894	ips, mps, EGF, GMCSF, *2	92.01
895	ips, mps, EGF, IL1RA, HE4	93.217
896	ips, mps, EGF, IL1RA, *2	93.395
897	ips, mps, EGF, HE4, *2	91.655
898	ips, mps, GMCSF, IL1RA, HE4	93.111
899	ips, mps, GMCSF, IL1RA, *2	92.969
900	ips, mps, GMCSF, HE4, *2	91.566
901	ips, mps, IL1RA, HE4, *2	93.004
902	ips, dps, CA125, EMILIN, MDK	97.692
903	ips, dps, CA125, EMILIN, *1	96.591
904	ips, dps, CA125, EMILIN, EGF	96.911
905	ips, dps, CA125, EMILIN, GMCSF	96.484
906	ips, dps, CA125, EMILIN, IL1RA	97.124
907	ips, dps, CA125, EMILIN, HE4	97.159
908	ips, dps, CA125, EMILIN, *2	96.964
909	ips, dps, CA125, MDK, *1	97.266

910	ips, dps, CA125, MDK, EGF	97.159
911	ips, dps, CA125, MDK, GMCSF	97.124
912	ips, dps, CA125, MDK, IL1RA	97.088
913	ips, dps, CA125, MDK, HE4	96.662
914	ips, dps, CA125, MDK, *2	96.982
915	ips, dps, CA125, *1, EGF	96.662
916	ips, dps, CA125, *1, GMCSF	95.792
917	ips, dps, CA125, *1, IL1RA	95.881
918	ips, dps, CA125, *1, HE4	95.561
919	ips, dps, CA125, *1, *2	96.236
920	ips, dps, CA125, EGF, GMCSF	96.449
921	ips, dps, CA125, EGF, IL1RA	96.342
922	ips, dps, CA125, EGF, HE4	96.52
923	ips, dps, CA125, EGF, *2	96.484
924	ips, dps, CA125, GMCSF, IL1RA	95.348
925	ips, dps, CA125, GMCSF, HE4	95.561
926	ips, dps, CA125, GMCSF, *2	95.952
927	ips, dps, CA125, IL1RA, HE4	95.455
928	ips, dps, CA125, IL1RA, *2	95.81
929	ips, dps, CA125, HE4, *2	95.561
930	ips, dps, EMILIN, MDK, *1	93.857
931	ips, dps, EMILIN, MDK, EGF	93.501
932	ips, dps, EMILIN, MDK, GMCSF	93.182
933	ips, dps, EMILIN, MDK, IL1RA	93.359
934	ips, dps, EMILIN, MDK, HE4	92.969
935	ips, dps, EMILIN, MDK, *2	93.786
936	ips, dps, EMILIN, *1, EGF	92.507
937	ips, dps, EMILIN, *1, GMCSF	92.17
938	ips, dps, EMILIN, *1, IL1RA	93.253
939	ips, dps, EMILIN, *1, HE4	92.543
940	ips, dps, EMILIN, *1, *2	92.933
941	ips, dps, EMILIN, EGF, GMCSF	91.371
942	ips, dps, EMILIN, EGF, IL1RA	92.116
943	ips, dps, EMILIN, EGF, HE4	91.832
944	ips, dps, EMILIN, EGF, *2	91.868
945	ips, dps, EMILIN, GMCSF, IL1RA	92.188
946	ips, dps, EMILIN, GMCSF, HE4	91.903
947	ips, dps, EMILIN, GMCSF, *2	91.779
948	ips, dps, EMILIN, IL1RA, HE4	92.33
949	ips, dps, EMILIN, IL1RA, *2	92.614
950	ips, dps, EMILIN, HE4, *2	92.134
951	ips, dps, MDK, *1, EGF	93.501
952	ips, dps, MDK, *1, GMCSF	94.212
953	ips, dps, MDK, *1, IL1RA	93.75
954	ips, dps, MDK, *1, HE4	93.377
955	ips, dps, MDK, *1, *2	93.821
956	ips, dps, MDK, EGF, GMCSF	92.116
957	ips, dps, MDK, EGF, IL1RA	92.347
958	ips, dps, MDK, EGF, HE4	91.371
959	ips, dps, MDK, EGF, *2	92.33
960	ips, dps, MDK, GMCSF, IL1RA	92.188
961	ips, dps, MDK, GMCSF, HE4	92.081

962	ips, dps, MDK, GMCSF, *2	92.56
963	ips, dps, MDK, IL1RA, HE4	91.122
964	ips, dps, MDK, IL1RA, *2	92.188
965	ips, dps, MDK, HE4, *2	92.045
966	ips, dps, *1, EGF, GMCSF	91.619
967	ips, dps, *1, EGF, IL1RA	92.045
968	ips, dps, *1, EGF, HE4	91.477
969	ips, dps, *1, EGF, *2	91.726
970	ips, dps, *1, GMCSF, IL1RA	91.335
971	ips, dps, *1, GMCSF, HE4	90.803
972	ips, dps, *1, GMCSF, *2	91.406
973	ips, dps, *1, IL1RA, HE4	90.341
974	ips, dps, *1, IL1RA, *2	90.696
975	ips, dps, *1, HE4, *2	89.95
976	ips, dps, EGF, GMCSF, IL1RA	88.832
977	ips, dps, EGF, GMCSF, HE4	89.276
978	ips, dps, EGF, GMCSF, *2	90.021
979	ips, dps, EGF, IL1RA, HE4	88.743
980	ips, dps, EGF, IL1RA, *2	90.27
981	ips, dps, EGF, HE4, *2	89.24
982	ips, dps, GMCSF, IL1RA, HE4	87.784
983	ips, dps, GMCSF, IL1RA, *2	89.915
984	ips, dps, GMCSF, HE4, *2	88.743
985	ips, dps, IL1RA, HE4, *2	87.926
986	ips, CA125, EMILIN, MDK, *1	97.195
987	ips, CA125, EMILIN, MDK, EGF	96.804
988	ips, CA125, EMILIN, MDK, GMCSF	97.017
989	ips, CA125, EMILIN, MDK, IL1RA	97.088
990	ips, CA125, EMILIN, MDK, HE4	97.017
991	ips, CA125, EMILIN, MDK, *2	97.053
992	ips, CA125, EMILIN, *1, EGF	95.703
993	ips, CA125, EMILIN, *1, GMCSF	95.81
994	ips, CA125, EMILIN, *1, IL1RA	95.881
995	ips, CA125, EMILIN, *1, HE4	95.774
996	ips, CA125, EMILIN, *1, *2	95.81
997	ips, CA125, EMILIN, EGF, GMCSF	95.455
998	ips, CA125, EMILIN, EGF, IL1RA	95.739
999	ips, CA125, EMILIN, EGF, HE4	95.916
1000	ips, CA125, EMILIN, EGF, *2	95.952
1001	ips, CA125, EMILIN, GMCSF, IL1RA	95.526
1002	ips, CA125, EMILIN, GMCSF, HE4	96.129
1003	ips, CA125, EMILIN, GMCSF, *2	95.774
1004	ips, CA125, EMILIN, IL1RA, HE4	96.2
1005	ips, CA125, EMILIN, IL1RA, *2	96.236
1006	ips, CA125, EMILIN, HE4, *2	96.378
1007	ips, CA125, MDK, *1, EGF	96.857
1008	ips, CA125, MDK, *1, GMCSF	97.159
1009	ips, CA125, MDK, *1, IL1RA	97.017
1010	ips, CA125, MDK, *1, HE4	96.839
1011	ips, CA125, MDK, *1, *2	96.733
1012	ips, CA125, MDK, EGF, GMCSF	97.053

1013	ips, CA125, MDK, EGF, IL1RA	96.768
1014	ips, CA125, MDK, EGF, HE4	96.591
1015	ips, CA125, MDK, EGF, *2	96.626
1016	ips, CA125, MDK, GMCSF, IL1RA	96.911
1017	ips, CA125, MDK, GMCSF, HE4	96.875
1018	ips, CA125, MDK, GMCSF, *2	96.804
1019	ips, CA125, MDK, IL1RA, HE4	96.591
1020	ips, CA125, MDK, IL1RA, *2	96.768
1021	ips, CA125, MDK, HE4, *2	96.378
1022	ips, CA125, *1, EGF, GMCSF	94.957
1023	ips, CA125, *1, EGF, IL1RA	94.993
1024	ips, CA125, *1, EGF, HE4	94.851
1025	ips, CA125, *1, EGF, *2	95.099
1026	ips, CA125, *1, GMCSF, IL1RA	94.851
1027	ips, CA125, *1, GMCSF, HE4	95.117
1028	ips, CA125, *1, GMCSF, *2	95.028
1029	ips, CA125, *1, IL1RA, HE4	94.531
1030	ips, CA125, *1, IL1RA, *2	94.815
1031	ips, CA125, *1, HE4, *2	94.602
1032	ips, CA125, EGF, GMCSF, IL1RA	94.886
1033	ips, CA125, EGF, GMCSF, HE4	95.064
1034	ips, CA125, EGF, GMCSF, *2	94.815
1035	ips, CA125, EGF, IL1RA, HE4	94.709
1036	ips, CA125, EGF, IL1RA, *2	94.94
1037	ips, CA125, EGF, HE4, *2	94.531
1038	ips, CA125, GMCSF, IL1RA, HE4	94.602
1039	ips, CA125, GMCSF, IL1RA, *2	94.886
1040	ips, CA125, GMCSF, HE4, *2	94.993
1041	ips, CA125, IL1RA, HE4, *2	94.336
1042	ips, EMILIN, MDK, *1, EGF	92.188
1043	ips, EMILIN, MDK, *1, GMCSF	92.045
1044	ips, EMILIN, MDK, *1, IL1RA	91.939
1045	ips, EMILIN, MDK, *1, HE4	92.01
1046	ips, EMILIN, MDK, *1, *2	92.223
1047	ips, EMILIN, MDK, EGF, GMCSF	90.518
1048	ips, EMILIN, MDK, EGF, IL1RA	91.46
1049	ips, EMILIN, MDK, EGF, HE4	90.376
1050	ips, EMILIN, MDK, EGF, *2	90.998
1051	ips, EMILIN, MDK, GMCSF, IL1RA	90.98
1052	ips, EMILIN, MDK, GMCSF, HE4	91.122
1053	ips, EMILIN, MDK, GMCSF, *2	91.087
1054	ips, EMILIN, MDK, IL1RA, HE4	91.016
1055	ips, EMILIN, MDK, IL1RA, *2	91.122
1056	ips, EMILIN, MDK, HE4, *2	90.376
1057	ips, EMILIN, *1, EGF, GMCSF	87.713
1058	ips, EMILIN, *1, EGF, IL1RA	88.778
1059	ips, EMILIN, *1, EGF, HE4	88.494
1060	ips, EMILIN, *1, EGF, *2	88.956
1061	ips, EMILIN, *1, GMCSF, IL1RA	89.311
1062	ips, EMILIN, *1, GMCSF, HE4	89.169
1063	ips, EMILIN, *1, GMCSF, *2	89.542
1064	ips, EMILIN, *1, IL1RA, HE4	90.146

1065	ips, EMILIN, *1, IL1RA, *2	89.382
1066	ips, EMILIN, *1, HE4, *2	89.205
1067	ips, EMILIN, EGF, GMCSF, IL1RA	88.068
1068	ips, EMILIN, EGF, GMCSF, HE4	87.678
1069	ips, EMILIN, EGF, GMCSF, *2	86.665
1070	ips, EMILIN, EGF, IL1RA, HE4	87.891
1071	ips, EMILIN, EGF, IL1RA, *2	87.429
1072	ips, EMILIN, EGF, HE4, *2	85.511
1073	ips, EMILIN, GMCSF, IL1RA, HE4	89.382
1074	ips, EMILIN, GMCSF, IL1RA, *2	88.885
1075	ips, EMILIN, GMCSF, HE4, *2	87.749
1076	ips, EMILIN, IL1RA, HE4, *2	87.997
1077	ips, MDK, *1, EGF, GMCSF	91.903
1078	ips, MDK, *1, EGF, IL1RA	91.371
1079	ips, MDK, *1, EGF, HE4	90.874
1080	ips, MDK, *1, EGF, *2	91.158
1081	ips, MDK, *1, GMCSF, IL1RA	92.045
1082	ips, MDK, *1, GMCSF, HE4	91.69
1083	ips, MDK, *1, GMCSF, *2	92.081
1084	ips, MDK, *1, IL1RA, HE4	90.803
1085	ips, MDK, *1, IL1RA, *2	91.158
1086	ips, MDK, *1, HE4, *2	90.98
1087	ips, MDK, EGF, GMCSF, IL1RA	89.418
1088	ips, MDK, EGF, GMCSF, HE4	89.169
1089	ips, MDK, EGF, GMCSF, *2	89.844
1090	ips, MDK, EGF, IL1RA, HE4	88.317
1091	ips, MDK, EGF, IL1RA, *2	89.222
1092	ips, MDK, EGF, HE4, *2	88.494
1093	ips, MDK, GMCSF, IL1RA, HE4	88.636
1094	ips, MDK, GMCSF, IL1RA, *2	89.311
1095	ips, MDK, GMCSF, HE4, *2	88.903
1096	ips, MDK, IL1RA, HE4, *2	87.891
1097	ips, *1, EGF, GMCSF, IL1RA	85.938
1098	ips, *1, EGF, GMCSF, HE4	86.257
1099	ips, *1, EGF, GMCSF, *2	87.251
1100	ips, *1, EGF, IL1RA, HE4	85.05
1101	ips, *1, EGF, IL1RA, *2	86.452
1102	ips, *1, EGF, HE4, *2	85.938
1103	ips, *1, GMCSF, IL1RA, HE4	86.044
1104	ips, *1, GMCSF, IL1RA, *2	86.985
1105	ips, *1, GMCSF, HE4, *2	86.435
1106	ips, *1, IL1RA, HE4, *2	85.05
1107	ips, EGF, GMCSF, IL1RA, HE4	83.203
1108	ips, EGF, GMCSF, IL1RA, *2	83.807
1109	ips, EGF, GMCSF, HE4, *2	83.434
1110	ips, EGF, IL1RA, HE4, *2	81.587
1111	ips, GMCSF, IL1RA, HE4, *2	82.564
1112	mps, dps, CA125, EMILIN, MDK	97.727
1113	mps, dps, CA125, EMILIN, *1	97.337
1114	mps, dps, CA125, EMILIN, EGF	97.514
1115	mps, dps, CA125, EMILIN, GMCSF	97.443
1116	mps, dps, CA125, EMILIN, IL1RA	97.55

1117	mps, dps, CA125, EMILIN, HE4	97.656
1118	mps, dps, CA125, EMILIN, *2	97.727
1119	mps, dps, CA125, MDK, *1	96.733
1120	mps, dps, CA125, MDK, EGF	96.697
1121	mps, dps, CA125, MDK, GMCSF	96.591
1122	mps, dps, CA125, MDK, IL1RA	96.946
1123	mps, dps, CA125, MDK, HE4	96.697
1124	mps, dps, CA125, MDK, *2	96.733
1125	mps, dps, CA125, *1, EGF	95.526
1126	mps, dps, CA125, *1, GMCSF	95.028
1127	mps, dps, CA125, *1, IL1RA	95.792
1128	mps, dps, CA125, *1, HE4	95.561
1129	mps, dps, CA125, *1, *2	95.845
1130	mps, dps, CA125, EGF, GMCSF	95.241
1131	mps, dps, CA125, EGF, IL1RA	95.526
1132	mps, dps, CA125, EGF, HE4	95.703
1133	mps, dps, CA125, EGF, *2	95.668
1134	mps, dps, CA125, GMCSF, IL1RA	95.241
1135	mps, dps, CA125, GMCSF, HE4	95.313
1136	mps, dps, CA125, GMCSF, *2	95.206
1137	mps, dps, CA125, IL1RA, HE4	95.668
1138	mps, dps, CA125, IL1RA, *2	95.703
1139	mps, dps, CA125, HE4, *2	95.597
1140	mps, dps, EMILIN, MDK, *1	95.881
1141	mps, dps, EMILIN, MDK, EGF	94.815
1142	mps, dps, EMILIN, MDK, GMCSF	94.993
1143	mps, dps, EMILIN, MDK, IL1RA	95.668
1144	mps, dps, EMILIN, MDK, HE4	95.028
1145	mps, dps, EMILIN, MDK, *2	95.526
1146	mps, dps, EMILIN, *1, EGF	94.46
1147	mps, dps, EMILIN, *1, GMCSF	94.371
1148	mps, dps, EMILIN, *1, IL1RA	95.81
1149	mps, dps, EMILIN, *1, HE4	94.78
1150	mps, dps, EMILIN, *1, *2	95.668
1151	mps, dps, EMILIN, EGF, GMCSF	93.04
1152	mps, dps, EMILIN, EGF, IL1RA	95.455
1153	mps, dps, EMILIN, EGF, HE4	93.395
1154	mps, dps, EMILIN, EGF, *2	93.714
1155	mps, dps, EMILIN, GMCSF, IL1RA	95.206
1156	mps, dps, EMILIN, GMCSF, HE4	93.643
1157	mps, dps, EMILIN, GMCSF, *2	93.608
1158	mps, dps, EMILIN, IL1RA, HE4	95.916
1159	mps, dps, EMILIN, IL1RA, *2	95.952
1160	mps, dps, EMILIN, HE4, *2	93.874
1161	mps, dps, MDK, *1, EGF	94.283
1162	mps, dps, MDK, *1, GMCSF	94.602
1163	mps, dps, MDK, *1, IL1RA	95.366
1164	mps, dps, MDK, *1, HE4	93.928
1165	mps, dps, MDK, *1, *2	95.028
1166	mps, dps, MDK, EGF, GMCSF	92.543
1167	mps, dps, MDK, EGF, IL1RA	93.928
1168	mps, dps, MDK, EGF, HE4	92.685

1169	mps, dps, MDK, EGF, *2	93.466
1170	mps, dps, MDK, GMCSF, IL1RA	93.288
1171	mps, dps, MDK, GMCSF, HE4	92.33
1172	mps, dps, MDK, GMCSF, *2	93.43
1173	mps, dps, MDK, IL1RA, HE4	93.572
1174	mps, dps, MDK, IL1RA, *2	94.798
1175	mps, dps, MDK, HE4, *2	93.253
1176	mps, dps, *1, EGF, GMCSF	90.199
1177	mps, dps, *1, EGF, IL1RA	91.815
1178	mps, dps, *1, EGF, HE4	91.406
1179	mps, dps, *1, EGF, *2	92.045
1180	mps, dps, *1, GMCSF, IL1RA	90.661
1181	mps, dps, *1, GMCSF, HE4	89.364
1182	mps, dps, *1, GMCSF, *2	91.264
1183	mps, dps, *1, IL1RA, HE4	91.406
1184	mps, dps, *1, IL1RA, *2	91.584
1185	mps, dps, *1, HE4, *2	91.388
1186	mps, dps, EGF, GMCSF, IL1RA	90.075
1187	mps, dps, EGF, GMCSF, HE4	88.21
1188	mps, dps, EGF, GMCSF, *2	89.311
1189	mps, dps, EGF, IL1RA, HE4	90.589
1190	mps, dps, EGF, IL1RA, *2	90.891
1191	mps, dps, EGF, HE4, *2	89.524
1192	mps, dps, GMCSF, IL1RA, HE4	89.844
1193	mps, dps, GMCSF, IL1RA, *2	90.146
1194	mps, dps, GMCSF, HE4, *2	87.642
1195	mps, dps, IL1RA, HE4, *2	90.714
1196	mps, CA125, EMILIN, MDK, *1	97.798
1197	mps, CA125, EMILIN, MDK, EGF	97.621
1198	mps, CA125, EMILIN, MDK, GMCSF	97.656
1199	mps, CA125, EMILIN, MDK, IL1RA	97.727
1200	mps, CA125, EMILIN, MDK, HE4	97.834
1201	mps, CA125, EMILIN, MDK, *2	97.869
1202	mps, CA125, EMILIN, *1, EGF	97.088
1203	mps, CA125, EMILIN, *1, GMCSF	96.911
1204	mps, CA125, EMILIN, *1, IL1RA	97.372
1205	mps, CA125, EMILIN, *1, HE4	96.982
1206	mps, CA125, EMILIN, *1, *2	97.088
1207	mps, CA125, EMILIN, EGF, GMCSF	96.982
1208	mps, CA125, EMILIN, EGF, IL1RA	97.088
1209	mps, CA125, EMILIN, EGF, HE4	96.911
1210	mps, CA125, EMILIN, EGF, *2	96.982
1211	mps, CA125, EMILIN, GMCSF, IL1RA	97.23
1212	mps, CA125, EMILIN, GMCSF, HE4	97.088
1213	mps, CA125, EMILIN, GMCSF, *2	96.982
1214	mps, CA125, EMILIN, IL1RA, HE4	97.443
1215	mps, CA125, EMILIN, IL1RA, *2	97.372
1216	mps, CA125, EMILIN, HE4, *2	97.23

1217	mps, CA125, MDK, *1, EGF	96.271
1218	mps, CA125, MDK, *1, GMCSF	96.413
1219	mps, CA125, MDK, *1, IL1RA	96.626
1220	mps, CA125, MDK, *1, HE4	96.484
1221	mps, CA125, MDK, *1, *2	96.626
1222	mps, CA125, MDK, EGF, GMCSF	96.094
1223	mps, CA125, MDK, EGF, IL1RA	96.342
1224	mps, CA125, MDK, EGF, HE4	96.378
1225	mps, CA125, MDK, EGF, *2	96.2
1226	mps, CA125, MDK, GMCSF, IL1RA	96.342
1227	mps, CA125, MDK, GMCSF, HE4	96.449
1228	mps, CA125, MDK, GMCSF, *2	96.378
1229	mps, CA125, MDK, IL1RA, HE4	96.697
1230	mps, CA125, MDK, IL1RA, *2	96.662
1231	mps, CA125, MDK, HE4, *2	96.484
1232	mps, CA125, *1, EGF, GMCSF	94.354
1233	mps, CA125, *1, EGF, IL1RA	94.869
1234	mps, CA125, *1, EGF, HE4	94.318
1235	mps, CA125, *1, EGF, *2	94.602
1236	mps, CA125, *1, GMCSF, IL1RA	94.815
1237	mps, CA125, *1, GMCSF, HE4	94.247
1238	mps, CA125, *1, GMCSF, *2	94.549
1239	mps, CA125, *1, IL1RA, HE4	95.206
1240	mps, CA125, *1, IL1RA, *2	95.348
1241	mps, CA125, *1, HE4, *2	94.78
1242	mps, CA125, EGF, GMCSF, IL1RA	94.531
1243	mps, CA125, EGF, GMCSF, HE4	94.389
1244	mps, CA125, EGF, GMCSF, *2	94.389
1245	mps, CA125, EGF, IL1RA, HE4	94.531
1246	mps, CA125, EGF, IL1RA, *2	94.602
1247	mps, CA125, EGF, HE4, *2	94.496
1248	mps, CA125, GMCSF, IL1RA, HE4	95.135
1249	mps, CA125, GMCSF, IL1RA, *2	94.638
1250	mps, CA125, GMCSF, HE4, *2	94.318
1251	mps, CA125, IL1RA, HE4, *2	95.135
1252	mps, EMILIN, MDK, *1, EGF	95.703
1253	mps, EMILIN, MDK, *1, GMCSF	95.703
1254	mps, EMILIN, MDK, *1, IL1RA	95.881
1255	mps, EMILIN, MDK, *1, HE4	95.703
1256	mps, EMILIN, MDK, *1, *2	96.342
1257	mps, EMILIN, MDK, EGF, GMCSF	94.212
1258	mps, EMILIN, MDK, EGF, IL1RA	94.425
1259	mps, EMILIN, MDK, EGF, HE4	94.496
1260	mps, EMILIN, MDK, EGF, *2	94.673
1261	mps, EMILIN, MDK, GMCSF, IL1RA	94.496
1262	mps, EMILIN, MDK, GMCSF, HE4	94.46
1263	mps, EMILIN, MDK, GMCSF, *2	94.673
1264	mps, EMILIN, MDK, IL1RA, HE4	94.957
1265	mps, EMILIN, MDK, IL1RA, *2	95.348
1266	mps, EMILIN, MDK, HE4, *2	94.957
1267	mps, EMILIN, *1, EGF, GMCSF	93.732

1268	mps, EMILIN, *1, EGF, IL1RA	94.638
1269	mps, EMILIN, *1, EGF, HE4	93.129
1270	mps, EMILIN, *1, EGF, *2	94.176
1271	mps, EMILIN, *1, GMCSF, IL1RA	94.744
1272	mps, EMILIN, *1, GMCSF, HE4	93.501
1273	mps, EMILIN, *1, GMCSF, *2	94.354
1274	mps, EMILIN, *1, IL1RA, HE4	94.513
1275	mps, EMILIN, *1, IL1RA, *2	95.153
1276	mps, EMILIN, *1, HE4, *2	94.496
1277	mps, EMILIN, EGF, GMCSF, IL1RA	93.182
1278	mps, EMILIN, EGF, GMCSF, HE4	90.696
1279	mps, EMILIN, EGF, GMCSF, *2	91.584
1280	mps, EMILIN, EGF, IL1RA, HE4	93.643
1281	mps, EMILIN, EGF, IL1RA, *2	93.75
1282	mps, EMILIN, EGF, HE4, *2	91.282
1283	mps, EMILIN, GMCSF, IL1RA, HE4	93.857
1284	mps, EMILIN, GMCSF, IL1RA, *2	93.803
1285	mps, EMILIN, GMCSF, HE4, *2	91.868
1286	mps, EMILIN, IL1RA, HE4, *2	94.389
1287	mps, MDK, *1, EGF, GMCSF	94.07
1288	mps, MDK, *1, EGF, IL1RA	93.786
1289	mps, MDK, *1, EGF, HE4	93.324
1290	mps, MDK, *1, EGF, *2	94.105
1291	mps, MDK, *1, GMCSF, IL1RA	94.141
1292	mps, MDK, *1, GMCSF, HE4	93.786
1293	mps, MDK, *1, GMCSF, *2	94.247
1294	mps, MDK, *1, IL1RA, HE4	94.194
1295	mps, MDK, *1, IL1RA, *2	94.602
1296	mps, MDK, *1, HE4, *2	93.999
1297	mps, MDK, EGF, GMCSF, IL1RA	91.85
1298	mps, MDK, EGF, GMCSF, HE4	91.797
1299	mps, MDK, EGF, GMCSF, *2	92.152
1300	mps, MDK, EGF, IL1RA, HE4	92.294
1301	mps, MDK, EGF, IL1RA, *2	92.72
1302	mps, MDK, EGF, HE4, *2	91.868
1303	mps, MDK, GMCSF, IL1RA, HE4	92.827
1304	mps, MDK, GMCSF, IL1RA, *2	93.04
1305	mps, MDK, GMCSF, HE4, *2	92.276
1306	mps, MDK, IL1RA, HE4, *2	93.537
1307	mps, *1, EGF, GMCSF, IL1RA	89.595
1308	mps, *1, EGF, GMCSF, HE4	88.139
1309	mps, *1, EGF, GMCSF, *2	89.684
1310	mps, *1, EGF, IL1RA, HE4	90.483
1311	mps, *1, EGF, IL1RA, *2	90.803
1312	mps, *1, EGF, HE4, *2	89.205
1313	mps, *1, GMCSF, IL1RA, HE4	89.169
1314	mps, *1, GMCSF, IL1RA, *2	89.311
1315	mps, *1, GMCSF, HE4, *2	87.82
1316	mps, *1, IL1RA, HE4, *2	90.039
1317	mps, EGF, GMCSF, IL1RA, HE4	88.707
1318	mps, EGF, GMCSF, IL1RA, *2	88.672
1319	mps, EGF, GMCSF, HE4, *2	86.932

1320	mps, EGF, IL1RA, HE4, *2	88.814
1321	mps, GMCSF, IL1RA, HE4, *2	88.139
1322	dps, CA125, EMILIN, MDK, *1	95.064
1323	dps, CA125, EMILIN, MDK, EGF	94.602
1324	dps, CA125, EMILIN, MDK, GMCSF	94.318
1325	dps, CA125, EMILIN, MDK, IL1RA	94.638
1326	dps, CA125, EMILIN, MDK, HE4	94.318
1327	dps, CA125, EMILIN, MDK, *2	95.313
1328	dps, CA125, EMILIN, *1, EGF	93.501
1329	dps, CA125, EMILIN, *1, GMCSF	93.395
1330	dps, CA125, EMILIN, *1, IL1RA	94.034
1331	dps, CA125, EMILIN, *1, HE4	93.679
1332	dps, CA125, EMILIN, *1, *2	94.389
1333	dps, CA125, EMILIN, EGF, GMCSF	93.288
1334	dps, CA125, EMILIN, EGF, IL1RA	94.212
1335	dps, CA125, EMILIN, EGF, HE4	93.43
1336	dps, CA125, EMILIN, EGF, *2	94.07
1337	dps, CA125, EMILIN, GMCSF, IL1RA	93.892
1338	dps, CA125, EMILIN, GMCSF, HE4	93.572
1339	dps, CA125, EMILIN, GMCSF, *2	93.679
1340	dps, CA125, EMILIN, IL1RA, HE4	94.141
1341	dps, CA125, EMILIN, IL1RA, *2	94.638
1342	dps, CA125, EMILIN, HE4, *2	94.283
1343	dps, CA125, MDK, *1, EGF	94.602
1344	dps, CA125, MDK, *1, GMCSF	94.673
1345	dps, CA125, MDK, *1, IL1RA	95.064
1346	dps, CA125, MDK, *1, HE4	94.531
1347	dps, CA125, MDK, *1, *2	95.028
1348	dps, CA125, MDK, EGF, GMCSF	94.176
1349	dps, CA125, MDK, EGF, IL1RA	94.354
1350	dps, CA125, MDK, EGF, HE4	94.176
1351	dps, CA125, MDK, EGF, *2	94.744
1352	dps, CA125, MDK, GMCSF, IL1RA	93.928
1353	dps, CA125, MDK, GMCSF, HE4	93.75
1354	dps, CA125, MDK, GMCSF, *2	94.318
1355	dps, CA125, MDK, IL1RA, HE4	93.714
1356	dps, CA125, MDK, IL1RA, *2	94.78
1357	dps, CA125, MDK, HE4, *2	94.141
1358	dps, CA125, *1, EGF, GMCSF	92.33
1359	dps, CA125, *1, EGF, IL1RA	93.288
1360	dps, CA125, *1, EGF, HE4	92.294
1361	dps, CA125, *1, EGF, *2	93.271
1362	dps, CA125, *1, GMCSF, IL1RA	92.223
1363	dps, CA125, *1, GMCSF, HE4	90.98
1364	dps, CA125, *1, GMCSF, *2	92.188
1365	dps, CA125, *1, IL1RA, HE4	92.17
1366	dps, CA125, *1, IL1RA, *2	92.933
1367	dps, CA125, *1, HE4, *2	92.152
1368	dps, CA125, EGF, GMCSF, IL1RA	92.933
1369	dps, CA125, EGF, GMCSF, HE4	91.992

1370	dps, CA125, EGF, GMCSF, *2	92.507
1371	dps, CA125, EGF, IL1RA, HE4	92.862
1372	dps, CA125, EGF, IL1RA, *2	93.395
1373	dps, CA125, EGF, HE4, *2	92.116
1374	dps, CA125, GMCSF, IL1RA, HE4	90.412
1375	dps, CA125, GMCSF, IL1RA, *2	92.188
1376	dps, CA125, GMCSF, HE4, *2	91.3
1377	dps, CA125, IL1RA, HE4, *2	92.045
1378	dps, EMILIN, MDK, *1, EGF	91.122
1379	dps, EMILIN, MDK, *1, GMCSF	90.589
1380	dps, EMILIN, MDK, *1, IL1RA	91.158
1381	dps, EMILIN, MDK, *1, HE4	91.158
1382	dps, EMILIN, MDK, *1, *2	92.685
1383	dps, EMILIN, MDK, EGF, GMCSF	87.571
1384	dps, EMILIN, MDK, EGF, IL1RA	88.459
1385	dps, EMILIN, MDK, EGF, HE4	87.66
1386	dps, EMILIN, MDK, EGF, *2	90.341
1387	dps, EMILIN, MDK, GMCSF, IL1RA	88.459
1388	dps, EMILIN, MDK, GMCSF, HE4	87.962
1389	dps, EMILIN, MDK, GMCSF, *2	89.56
1390	dps, EMILIN, MDK, IL1RA, HE4	88.601
1391	dps, EMILIN, MDK, IL1RA, *2	90.128
1392	dps, EMILIN, MDK, HE4, *2	90.234
1393	dps, EMILIN, *1, EGF, GMCSF	85.547
1394	dps, EMILIN, *1, EGF, IL1RA	88.423
1395	dps, EMILIN, *1, EGF, HE4	87.5
1396	dps, EMILIN, *1, EGF, *2	88.938
1397	dps, EMILIN, *1, GMCSF, IL1RA	88.086
1398	dps, EMILIN, *1, GMCSF, HE4	88.21
1399	dps, EMILIN, *1, GMCSF, *2	88.743
1400	dps, EMILIN, *1, IL1RA, HE4	89.524
1401	dps, EMILIN, *1, IL1RA, *2	90.341
1402	dps, EMILIN, *1, HE4, *2	90.11
1403	dps, EMILIN, EGF, GMCSF, IL1RA	85.121
1404	dps, EMILIN, EGF, GMCSF, HE4	83.061
1405	dps, EMILIN, EGF, GMCSF, *2	84.073
1406	dps, EMILIN, EGF, IL1RA, HE4	86.275
1407	dps, EMILIN, EGF, IL1RA, *2	87.926
1408	dps, EMILIN, EGF, HE4, *2	86.168
1409	dps, EMILIN, GMCSF, IL1RA, HE4	86.861
1410	dps, EMILIN, GMCSF, IL1RA, *2	87.571
1411	dps, EMILIN, GMCSF, HE4, *2	86.683
1412	dps, EMILIN, IL1RA, HE4, *2	89.276
1413	dps, MDK, *1, EGF, GMCSF	90.483
1414	dps, MDK, *1, EGF, IL1RA	91.513
1415	dps, MDK, *1, EGF, HE4	90.483
1416	dps, MDK, *1, EGF, *2	91.584
1417	dps, MDK, *1, GMCSF, IL1RA	90.607
1418	dps, MDK, *1, GMCSF, HE4	90.589
1419	dps, MDK, *1, GMCSF, *2	92.223
1420	dps, MDK, *1, IL1RA, HE4	91.264
1421	dps, MDK, *1, IL1RA, *2	91.477

1422	dps, MDK, *1, HE4, *2	91.335
1423	dps, MDK, EGF, GMCSF, IL1RA	86.754
1424	dps, MDK, EGF, GMCSF, HE4	84.339
1425	dps, MDK, EGF, GMCSF, *2	88.601
1426	dps, MDK, EGF, IL1RA, HE4	85.938
1427	dps, MDK, EGF, IL1RA, *2	89.063
1428	dps, MDK, EGF, HE4, *2	87.66
1429	dps, MDK, GMCSF, IL1RA, HE4	85.724
1430	dps, MDK, GMCSF, IL1RA, *2	89.169
1431	dps, MDK, GMCSF, HE4, *2	88.352
1432	dps, MDK, IL1RA, HE4, *2	88.246
1433	dps, *1, EGF, GMCSF, IL1RA	86.754
1434	dps, *1, EGF, GMCSF, HE4	83.381
1435	dps, *1, EGF, GMCSF, *2	86.381
1436	dps, *1, EGF, IL1RA, HE4	86.648
1437	dps, *1, EGF, IL1RA, *2	87.891
1438	dps, *1, EGF, HE4, *2	85.795
1439	dps, *1, GMCSF, IL1RA, HE4	84.215
1440	dps, *1, GMCSF, IL1RA, *2	85.547
1441	dps, *1, GMCSF, HE4, *2	84.126
1442	dps, *1, IL1RA, HE4, *2	84.588
1443	dps, EGF, GMCSF, IL1RA, HE4	79.439
1444	dps, EGF, GMCSF, IL1RA, *2	83.345
1445	dps, EGF, GMCSF, HE4, *2	80.646
1446	dps, EGF, IL1RA, HE4, *2	82.457
1447	dps, GMCSF, IL1RA, HE4, *2	80.806
1448	CA125, EMILIN, MDK, *1, EGF	91.939
1449	CA125, EMILIN, MDK, *1, GMCSF	92.17
1450	CA125, EMILIN, MDK, *1, IL1RA	92.614
1451	CA125, EMILIN, MDK, *1, HE4	92.152
1452	CA125, EMILIN, MDK, *1, *2	92.294
1453	CA125, EMILIN, MDK, EGF, GMCSF	90.341
1454	CA125, EMILIN, MDK, EGF, IL1RA	91.3
1455	CA125, EMILIN, MDK, EGF, HE4	90.803
1456	CA125, EMILIN, MDK, EGF, *2	91.122
1457	CA125, EMILIN, MDK, GMCSF, IL1RA	91.477
1458	CA125, EMILIN, MDK, GMCSF, HE4	90.767
1459	CA125, EMILIN, MDK, GMCSF, *2	91.016
1460	CA125, EMILIN, MDK, IL1RA, HE4	91.513
1461	CA125, EMILIN, MDK, IL1RA, *2	92.01
1462	CA125, EMILIN, MDK, HE4, *2	91.264
1463	CA125, EMILIN, *1, EGF, GMCSF	88.423
1464	CA125, EMILIN, *1, EGF, IL1RA	89.364
1465	CA125, EMILIN, *1, EGF, HE4	88.565
1466	CA125, EMILIN, *1, EGF, *2	88.991
1467	CA125, EMILIN, *1, GMCSF, IL1RA	89.95
1468	CA125, EMILIN, *1, GMCSF, HE4	89.844
1469	CA125, EMILIN, *1, GMCSF, *2	89.986
1470	CA125, EMILIN, *1, IL1RA, HE4	90.305

1471	CA125, EMILIN, *1, IL1RA, *2	90.696
1472	CA125, EMILIN, *1, HE4, *2	90.128
1473	CA125, EMILIN, EGF, GMCSF, IL1RA	88.352
1474	CA125, EMILIN, EGF, GMCSF, HE4	87.571
1475	CA125, EMILIN, EGF, GMCSF, *2	87.536
1476	CA125, EMILIN, EGF, IL1RA, HE4	87.713
1477	CA125, EMILIN, EGF, IL1RA, *2	88.849
1478	CA125, EMILIN, EGF, HE4, *2	87.766
1479	CA125, EMILIN, GMCSF, IL1RA, HE4	89.187
1480	CA125, EMILIN, GMCSF, IL1RA, *2	89.382
1481	CA125, EMILIN, GMCSF, HE4, *2	88.956
1482	CA125, EMILIN, IL1RA, HE4, *2	89.808
1483	CA125, MDK, *1, EGF, GMCSF	90.447
1484	CA125, MDK, *1, EGF, IL1RA	90.874
1485	CA125, MDK, *1, EGF, HE4	89.631
1486	CA125, MDK, *1, EGF, *2	90.554
1487	CA125, MDK, *1, GMCSF, IL1RA	91.016
1488	CA125, MDK, *1, GMCSF, HE4	90.749
1489	CA125, MDK, *1, GMCSF, *2	91.087
1490	CA125, MDK, *1, IL1RA, HE4	91.158
1491	CA125, MDK, *1, IL1RA, *2	91.371
1492	CA125, MDK, *1, HE4, *2	90.874
1493	CA125, MDK, EGF, GMCSF, IL1RA	89.524
1494	CA125, MDK, EGF, GMCSF, HE4	88.707
1495	CA125, MDK, EGF, GMCSF, *2	89.027
1496	CA125, MDK, EGF, IL1RA, HE4	89.577
1497	CA125, MDK, EGF, IL1RA, *2	90.092
1498	CA125, MDK, EGF, HE4, *2	88.459
1499	CA125, MDK, GMCSF, IL1RA, HE4	89.276
1500	CA125, MDK, GMCSF, IL1RA, *2	89.702
1501	CA125, MDK, GMCSF, HE4, *2	88.849
1502	CA125, MDK, IL1RA, HE4, *2	89.595
1503	CA125, *1, EGF, GMCSF, IL1RA	85.263
1504	CA125, *1, EGF, GMCSF, HE4	83.807
1505	CA125, *1, EGF, GMCSF, *2	84.801
1506	CA125, *1, EGF, IL1RA, HE4	85.21
1507	CA125, *1, EGF, IL1RA, *2	85.76
1508	CA125, *1, EGF, HE4, *2	83.984
1509	CA125, *1, GMCSF, IL1RA, HE4	85.334
1510	CA125, *1, GMCSF, IL1RA, *2	86.47
1511	CA125, *1, GMCSF, HE4, *2	84.411
1512	CA125, *1, IL1RA, HE4, *2	85.44
1513	CA125, EGF, GMCSF, IL1RA, HE4	83.878
1514	CA125, EGF, GMCSF, IL1RA, *2	84.091
1515	CA125, EGF, GMCSF, HE4, *2	81.286
1516	CA125, EGF, IL1RA, HE4, *2	82.99
1517	CA125, GMCSF, IL1RA, HE4, *2	83.292
1518	EMILIN, MDK, *1, EGF, GMCSF	84.197
1519	EMILIN, MDK, *1, EGF, IL1RA	84.677

1520	EMILIN, MDK, *1, EGF, HE4	84.339
1521	EMILIN, MDK, *1, EGF, *2	85.085
1522	EMILIN, MDK, *1, GMCSF, IL1RA	83.842
1523	EMILIN, MDK, *1, GMCSF, HE4	84.233
1524	EMILIN, MDK, *1, GMCSF, *2	84.659
1525	EMILIN, MDK, *1, IL1RA, HE4	84.091
1526	EMILIN, MDK, *1, IL1RA, *2	84.766
1527	EMILIN, MDK, *1, HE4, *2	85.067
1528	EMILIN, MDK, EGF, GMCSF, IL1RA	80.824
1529	EMILIN, MDK, EGF, GMCSF, HE4	78.942
1530	EMILIN, MDK, EGF, GMCSF, *2	80.717
1531	EMILIN, MDK, EGF, IL1RA, HE4	80.398
1532	EMILIN, MDK, EGF, IL1RA, *2	81.978
1533	EMILIN, MDK, EGF, HE4, *2	80.504
1534	EMILIN, MDK, GMCSF, IL1RA, HE4	80.362
1535	EMILIN, MDK, GMCSF, IL1RA, *2	82.191
1536	EMILIN, MDK, GMCSF, HE4, *2	80.895
1537	EMILIN, MDK, IL1RA, HE4, *2	81.286
1538	EMILIN, *1, EGF, GMCSF, IL1RA	76.598
1539	EMILIN, *1, EGF, GMCSF, HE4	75.639
1540	EMILIN, *1, EGF, GMCSF, *2	76.989
1541	EMILIN, *1, EGF, IL1RA, HE4	76.971
1542	EMILIN, *1, EGF, IL1RA, *2	76.527
1543	EMILIN, *1, EGF, HE4, *2	75.906
1544	EMILIN, *1, GMCSF, IL1RA, HE4	78.445
1545	EMILIN, *1, GMCSF, IL1RA, *2	79.35
1546	EMILIN, *1, GMCSF, HE4, *2	78.853
1547	EMILIN, *1, IL1RA, HE4, *2	78.232
1548	EMILIN, EGF, GMCSF, IL1RA, HE4	71.573
1549	EMILIN, EGF, GMCSF, IL1RA, *2	71.839
1550	EMILIN, EGF, GMCSF, HE4, *2	70.508
1551	EMILIN, EGF, IL1RA, HE4, *2	71.129
1552	EMILIN, GMCSF, IL1RA, HE4, *2	75.355
1553	MDK, *1, EGF, GMCSF, IL1RA	80.469
1554	MDK, *1, EGF, GMCSF, HE4	80.291
1555	MDK, *1, EGF, GMCSF, *2	81.818
1556	MDK, *1, EGF, IL1RA, HE4	79.723
1557	MDK, *1, EGF, IL1RA, *2	79.794
1558	MDK, *1, EGF, HE4, *2	79.83
1559	MDK, *1, GMCSF, IL1RA, HE4	80.611
1560	MDK, *1, GMCSF, IL1RA, *2	81.072
1561	MDK, *1, GMCSF, HE4, *2	81.481
1562	MDK, *1, IL1RA, HE4, *2	80.078
1563	MDK, EGF, GMCSF, IL1RA, HE4	72.088
1564	MDK, EGF, GMCSF, IL1RA, *2	74.006
1565	MDK, EGF, GMCSF, HE4, *2	72.94
1566	MDK, EGF, IL1RA, HE4, *2	72.301
1567	MDK, GMCSF, IL1RA, HE4, *2	73.295
1568	*1, EGF, GMCSF, IL1RA, HE4	63.991
1569	*1, EGF, GMCSF, IL1RA, *2	64.95

1570	*1, EGF, GMCSF, HE4, *2	65.181
1571	*1, EGF, IL1RA, HE4, *2	63.157
1572	*1, GMCSF, IL1RA, HE4, *2	63.299
1573	EGF, GMCSF, IL1RA, HE4, *2	47.656
1574	ips, mps, dps, CA125, EMILIN, MDK	98.473
1575	ips, mps, dps, CA125, EMILIN, *1	98.438
1576	ips, mps, dps, CA125, EMILIN, EGF	98.438
1577	ips, mps, dps, CA125, EMILIN, GMCSF	98.26
1578	ips, mps, dps, CA125, EMILIN, IL1RA	98.295
1579	ips, mps, dps, CA125, EMILIN, HE4	98.438
1580	ips, mps, dps, CA125, EMILIN, *2	98.473
1581	ips, mps, dps, CA125, MDK, *1	98.011
1582	ips, mps, dps, CA125, MDK, EGF	97.976
1583	ips, mps, dps, CA125, MDK, GMCSF	97.869
1584	ips, mps, dps, CA125, MDK, IL1RA	98.011
1585	ips, mps, dps, CA125, MDK, HE4	98.153
1586	ips, mps, dps, CA125, MDK, *2	97.976
1587	ips, mps, dps, CA125, *1, EGF	97.372
1588	ips, mps, dps, CA125, *1, GMCSF	96.946
1589	ips, mps, dps, CA125, *1, IL1RA	97.266
1590	ips, mps, dps, CA125, *1, HE4	97.408
1591	ips, mps, dps, CA125, *1, *2	97.159
1592	ips, mps, dps, CA125, EGF, GMCSF	96.839
1593	ips, mps, dps, CA125, EGF, IL1RA	97.337
1594	ips, mps, dps, CA125, EGF, HE4	97.514
1595	ips, mps, dps, CA125, EGF, *2	97.443
1596	ips, mps, dps, CA125, GMCSF, IL1RA	97.088
1597	ips, mps, dps, CA125, GMCSF, HE4	97.124
1598	ips, mps, dps, CA125, GMCSF, *2	96.804
1599	ips, mps, dps, CA125, IL1RA, HE4	97.408
1600	ips, mps, dps, CA125, IL1RA, *2	97.088
1601	ips, mps, dps, CA125, HE4, *2	97.266
1602	ips, mps, dps, EMILIN, MDK, *1	96.378
1603	ips, mps, dps, EMILIN, MDK, EGF	96.449
1604	ips, mps, dps, EMILIN, MDK, GMCSF	96.449
1605	ips, mps, dps, EMILIN, MDK, IL1RA	97.266
1606	ips, mps, dps, EMILIN, MDK, HE4	96.342
1607	ips, mps, dps, EMILIN, MDK, *2	96.591
1608	ips, mps, dps, EMILIN, *1, EGF	95.561
1609	ips, mps, dps, EMILIN, *1, GMCSF	95.632
1610	ips, mps, dps, EMILIN, *1, IL1RA	96.768
1611	ips, mps, dps, EMILIN, *1, HE4	95.579
1612	ips, mps, dps, EMILIN, *1, *2	95.881
1613	ips, mps, dps, EMILIN, EGF,	95.49

	GMCSF	
1614	ips, mps, dps, EMILIN, EGF, IL1RA	96.982
1615	ips, mps, dps, EMILIN, EGF, HE4	95.561
1616	ips, mps, dps, EMILIN, EGF, *2	95.526
1617	ips, mps, dps, EMILIN, GMCSF, IL1RA	96.733
1618	ips, mps, dps, EMILIN, GMCSF, HE4	95.241
1619	ips, mps, dps, EMILIN, GMCSF, *2	95.384
1620	ips, mps, dps, EMILIN, IL1RA, HE4	96.911
1621	ips, mps, dps, EMILIN, IL1RA, *2	96.662
1622	ips, mps, dps, EMILIN, HE4, *2	95.17
1623	ips, mps, dps, MDK, *1, EGF	95.437
1624	ips, mps, dps, MDK, *1, GMCSF	95.597
1625	ips, mps, dps, MDK, *1, IL1RA	96.2
1626	ips, mps, dps, MDK, *1, HE4	95.703
1627	ips, mps, dps, MDK, *1, *2	95.952
1628	ips, mps, dps, MDK, EGF, GMCSF	95.135
1629	ips, mps, dps, MDK, EGF, IL1RA	95.952
1630	ips, mps, dps, MDK, EGF, HE4	95.277
1631	ips, mps, dps, MDK, EGF, *2	95.384
1632	ips, mps, dps, MDK, GMCSF, IL1RA	95.81
1633	ips, mps, dps, MDK, GMCSF, HE4	95.17
1634	ips, mps, dps, MDK, GMCSF, *2	95.028
1635	ips, mps, dps, MDK, IL1RA, HE4	95.845
1636	ips, mps, dps, MDK, IL1RA, *2	95.845
1637	ips, mps, dps, MDK, HE4, *2	94.957
1638	ips, mps, dps, *1, EGF, GMCSF	93.43
1639	ips, mps, dps, *1, EGF, IL1RA	94.46
1640	ips, mps, dps, *1, EGF, HE4	93.217
1641	ips, mps, dps, *1, EGF, *2	93.874
1642	ips, mps, dps, *1, GMCSF, IL1RA	94.034
1643	ips, mps, dps, *1, GMCSF, HE4	93.217
1644	ips, mps, dps, *1, GMCSF, *2	93.786
1645	ips, mps, dps, *1, IL1RA, HE4	94.07
1646	ips, mps, dps, *1, IL1RA, *2	94.425
1647	ips, mps, dps, *1, HE4, *2	93.501
1648	ips, mps, dps, EGF, GMCSF, IL1RA	93.857
1649	ips, mps, dps, EGF, GMCSF, HE4	92.915
1650	ips, mps, dps, EGF, GMCSF, *2	93.111
1651	ips, mps, dps, EGF, IL1RA, HE4	94.141
1652	ips, mps, dps, EGF, IL1RA, *2	94.052
1653	ips, mps, dps, EGF, HE4, *2	93.004
1654	ips, mps, dps, GMCSF, IL1RA, HE4	93.714
1655	ips, mps, dps, GMCSF, IL1RA, *2	93.857
1656	ips, mps, dps, GMCSF, HE4, *2	92.791
1657	ips, mps, dps, IL1RA, HE4, *2	93.608
1658	ips, mps, CA125, EMILIN, MDK, *1	98.651
1659	ips, mps, CA125, EMILIN, MDK, EGF	98.793
1660	ips, mps, CA125, EMILIN, MDK,	98.793

	GMCSF	
1661	ips, mps, CA125, EMILIN, MDK, IL1RA	98.899
1662	ips, mps, CA125, EMILIN, MDK, HE4	98.757
1663	ips, mps, CA125, EMILIN, MDK, *2	98.828
1664	ips, mps, CA125, EMILIN, *1, EGF	98.509
1665	ips, mps, CA125, EMILIN, *1, GMCSF	98.438
1666	ips, mps, CA125, EMILIN, *1, IL1RA	98.615
1667	ips, mps, CA125, EMILIN, *1, HE4	98.793
1668	ips, mps, CA125, EMILIN, *1, *2	98.651
1669	ips, mps, CA125, EMILIN, EGF, GMCSF	98.402
1670	ips, mps, CA125, EMILIN, EGF, IL1RA	98.58
1671	ips, mps, CA125, EMILIN, EGF, HE4	98.651
1672	ips, mps, CA125, EMILIN, EGF, *2	98.473
1673	ips, mps, CA125, EMILIN, GMCSF, IL1RA	98.651
1674	ips, mps, CA125, EMILIN, GMCSF, HE4	98.686
1675	ips, mps, CA125, EMILIN, GMCSF, *2	98.402
1676	ips, mps, CA125, EMILIN, IL1RA, HE4	98.793
1677	ips, mps, CA125, EMILIN, IL1RA, *2	98.651
1678	ips, mps, CA125, EMILIN, HE4, *2	98.615
1679	ips, mps, CA125, MDK, *1, EGF	98.224
1680	ips, mps, CA125, MDK, *1, GMCSF	98.295
1681	ips, mps, CA125, MDK, *1, IL1RA	98.224
1682	ips, mps, CA125, MDK, *1, HE4	98.295
1683	ips, mps, CA125, MDK, *1, *2	98.26
1684	ips, mps, CA125, MDK, EGF, GMCSF	98.295
1685	ips, mps, CA125, MDK, EGF, IL1RA	98.331
1686	ips, mps, CA125, MDK, EGF, HE4	98.295
1687	ips, mps, CA125, MDK, EGF, *2	98.26
1688	ips, mps, CA125, MDK, GMCSF, IL1RA	98.082
1689	ips, mps, CA125, MDK, GMCSF, HE4	98.402
1690	ips, mps, CA125, MDK, GMCSF, *2	98.26
1691	ips, mps, CA125, MDK, IL1RA, HE4	98.331
1692	ips, mps, CA125, MDK, IL1RA, *2	98.26
1693	ips, mps, CA125, MDK, HE4, *2	98.26
1694	ips, mps, CA125, *1, EGF, GMCSF	97.159
1695	ips, mps, CA125, *1, EGF, IL1RA	97.443
1696	ips, mps, CA125, *1, EGF, HE4	97.372

1697	ips, mps, CA125, *1, EGF, *2	97.408
1698	ips, mps, CA125, *1, GMCSF, IL1RA	97.23
1699	ips, mps, CA125, *1, GMCSF, HE4	97.301
1700	ips, mps, CA125, *1, GMCSF, *2	97.195
1701	ips, mps, CA125, *1, IL1RA, HE4	97.621
1702	ips, mps, CA125, *1, IL1RA, *2	97.408
1703	ips, mps, CA125, *1, HE4, *2	97.372
1704	ips, mps, CA125, EGF, GMCSF, IL1RA	97.177
1705	ips, mps, CA125, EGF, GMCSF, HE4	97.408
1706	ips, mps, CA125, EGF, GMCSF, *2	97.053
1707	ips, mps, CA125, EGF, IL1RA, HE4	97.621
1708	ips, mps, CA125, EGF, IL1RA, *2	97.124
1709	ips, mps, CA125, EGF, HE4, *2	97.479
1710	ips, mps, CA125, GMCSF, IL1RA, HE4	97.337
1711	ips, mps, CA125, GMCSF, IL1RA, *2	96.946
1712	ips, mps, CA125, GMCSF, HE4, *2	97.195
1713	ips, mps, CA125, IL1RA, HE4, *2	97.443
1714	ips, mps, EMILIN, MDK, *1, EGF	96.733
1715	ips, mps, EMILIN, MDK, *1, GMCSF	96.555
1716	ips, mps, EMILIN, MDK, *1, IL1RA	97.159
1717	ips, mps, EMILIN, MDK, *1, HE4	96.626
1718	ips, mps, EMILIN, MDK, *1, *2	96.946
1719	ips, mps, EMILIN, MDK, EGF, GMCSF	96.413
1720	ips, mps, EMILIN, MDK, EGF, IL1RA	97.159
1721	ips, mps, EMILIN, MDK, EGF, HE4	96.662
1722	ips, mps, EMILIN, MDK, EGF, *2	96.52
1723	ips, mps, EMILIN, MDK, GMCSF, IL1RA	97.124
1724	ips, mps, EMILIN, MDK, GMCSF, HE4	96.307
1725	ips, mps, EMILIN, MDK, GMCSF, *2	96.307
1726	ips, mps, EMILIN, MDK, IL1RA, HE4	97.301
1727	ips, mps, EMILIN, MDK, IL1RA, *2	97.053
1728	ips, mps, EMILIN, MDK, HE4, *2	96.342
1729	ips, mps, EMILIN, *1, EGF, GMCSF	95.419
1730	ips, mps, EMILIN, *1, EGF, IL1RA	96.768
1731	ips, mps, EMILIN, *1, EGF, HE4	95.277
1732	ips, mps, EMILIN, *1, EGF, *2	95.739
1733	ips, mps, EMILIN, *1, GMCSF, IL1RA	96.449
1734	ips, mps, EMILIN, *1, GMCSF, HE4	95.17
1735	ips, mps, EMILIN, *1, GMCSF, *2	95.685
1736	ips, mps, EMILIN, *1, IL1RA, HE4	96.768

1737	ips, mps, EMILIN, *1, IL1RA, *2	96.626
1738	ips, mps, EMILIN, *1, HE4, *2	95.206
1739	ips, mps, EMILIN, EGF, GMCSF, IL1RA	97.017
1740	ips, mps, EMILIN, EGF, GMCSF, HE4	95.028
1741	ips, mps, EMILIN, EGF, GMCSF, *2	95.028
1742	ips, mps, EMILIN, EGF, IL1RA, HE4	96.982
1743	ips, mps, EMILIN, EGF, IL1RA, *2	96.982
1744	ips, mps, EMILIN, EGF, HE4, *2	94.851
1745	ips, mps, EMILIN, GMCSF, IL1RA, HE4	96.875
1746	ips, mps, EMILIN, GMCSF, IL1RA, *2	96.555
1747	ips, mps, EMILIN, GMCSF, HE4, *2	94.886
1748	ips, mps, EMILIN, IL1RA, HE4, *2	96.555
1749	ips, mps, MDK, *1, EGF, GMCSF	95.419
1750	ips, mps, MDK, *1, EGF, IL1RA	96.058
1751	ips, mps, MDK, *1, EGF, HE4	95.384
1752	ips, mps, MDK, *1, EGF, *2	95.81
1753	ips, mps, MDK, *1, GMCSF, IL1RA	95.845
1754	ips, mps, MDK, *1, GMCSF, HE4	95.099
1755	ips, mps, MDK, *1, GMCSF, *2	95.632
1756	ips, mps, MDK, *1, IL1RA, HE4	95.703
1757	ips, mps, MDK, *1, IL1RA, *2	95.952
1758	ips, mps, MDK, *1, HE4, *2	95.241
1759	ips, mps, MDK, EGF, GMCSF, IL1RA	95.739
1760	ips, mps, MDK, EGF, GMCSF, HE4	94.922
1761	ips, mps, MDK, EGF, GMCSF, *2	94.78
1762	ips, mps, MDK, EGF, IL1RA, HE4	95.881
1763	ips, mps, MDK, EGF, IL1RA, *2	95.845
1764	ips, mps, MDK, EGF, HE4, *2	94.673
1765	ips, mps, MDK, GMCSF, IL1RA, HE4	95.455
1766	ips, mps, MDK, GMCSF, IL1RA, *2	95.135
1767	ips, mps, MDK, GMCSF, HE4, *2	94.318
1768	ips, mps, MDK, IL1RA, HE4, *2	95.419
1769	ips, mps, *1, EGF, GMCSF, IL1RA	93.395
1770	ips, mps, *1, EGF, GMCSF, HE4	92.081
1771	ips, mps, *1, EGF, GMCSF, *2	93.146
1772	ips, mps, *1, EGF, IL1RA, HE4	93.75
1773	ips, mps, *1, EGF, IL1RA, *2	94.212
1774	ips, mps, *1, EGF, HE4, *2	92.72
1775	ips, mps, *1, GMCSF, IL1RA, HE4	93.075
1776	ips, mps, *1, GMCSF, IL1RA, *2	93.288
1777	ips, mps, *1, GMCSF, HE4, *2	92.631
1778	ips, mps, *1, IL1RA, HE4, *2	93.608
1779	ips, mps, EGF, GMCSF, IL1RA, HE4	93.359
1780	ips, mps, EGF, GMCSF, IL1RA, *2	93.182
1781	ips, mps, EGF, GMCSF, HE4, *2	91.761

1782	ips, mps, EGF, IL1RA, HE4, *2	93.075
1783	ips, mps, GMCSF, IL1RA, HE4, *2	92.969
1784	ips, dps, CA125, EMILIN, MDK, *1	97.621
1785	ips, dps, CA125, EMILIN, MDK, EGF	97.301
1786	ips, dps, CA125, EMILIN, MDK, GMCSF	97.124
1787	ips, dps, CA125, EMILIN, MDK, IL1RA	97.656
1788	ips, dps, CA125, EMILIN, MDK, HE4	97.372
1789	ips, dps, CA125, EMILIN, MDK, *2	97.727
1790	ips, dps, CA125, EMILIN, *1, EGF	96.555
1791	ips, dps, CA125, EMILIN, *1, GMCSF	96.484
1792	ips, dps, CA125, EMILIN, *1, IL1RA	96.804
1793	ips, dps, CA125, EMILIN, *1, HE4	96.768
1794	ips, dps, CA125, EMILIN, *1, *2	97.017
1795	ips, dps, CA125, EMILIN, EGF, GMCSF	96.378
1796	ips, dps, CA125, EMILIN, EGF, IL1RA	97.159
1797	ips, dps, CA125, EMILIN, EGF, HE4	96.875
1798	ips, dps, CA125, EMILIN, EGF, *2	96.768
1799	ips, dps, CA125, EMILIN, GMCSF, IL1RA	96.555
1800	ips, dps, CA125, EMILIN, GMCSF, HE4	96.733
1801	ips, dps, CA125, EMILIN, GMCSF, *2	96.52
1802	ips, dps, CA125, EMILIN, IL1RA, HE4	97.23
1803	ips, dps, CA125, EMILIN, IL1RA, *2	97.124
1804	ips, dps, CA125, EMILIN, HE4, *2	96.946
1805	ips, dps, CA125, MDK, *1, EGF	97.23
1806	ips, dps, CA125, MDK, *1, GMCSF	97.266
1807	ips, dps, CA125, MDK, *1, IL1RA	97.159
1808	ips, dps, CA125, MDK, *1, HE4	97.088
1809	ips, dps, CA125, MDK, *1, *2	96.946
1810	ips, dps, CA125, MDK, EGF, GMCSF	97.159
1811	ips, dps, CA125, MDK, EGF, IL1RA	97.053
1812	ips, dps, CA125, MDK, EGF, HE4	96.804
1813	ips, dps, CA125, MDK, EGF, *2	97.053
1814	ips, dps, CA125, MDK, GMCSF, IL1RA	97.053
1815	ips, dps, CA125, MDK, GMCSF, HE4	96.875
1816	ips, dps, CA125, MDK, GMCSF, *2	97.159
1817	ips, dps, CA125, MDK, IL1RA, HE4	96.662
1818	ips, dps, CA125, MDK, IL1RA, *2	96.875
1819	ips, dps, CA125, MDK, HE4, *2	96.626

1820	ips, dps, CA125, *1, EGF, GMCSF	96.271
1821	ips, dps, CA125, *1, EGF, IL1RA	96.662
1822	ips, dps, CA125, *1, EGF, HE4	96.129
1823	ips, dps, CA125, *1, EGF, *2	96.52
1824	ips, dps, CA125, *1, GMCSF, IL1RA	96.023
1825	ips, dps, CA125, *1, GMCSF, HE4	95.526
1826	ips, dps, CA125, *1, GMCSF, *2	96.058
1827	ips, dps, CA125, *1, IL1RA, HE4	95.597
1828	ips, dps, CA125, *1, IL1RA, *2	95.668
1829	ips, dps, CA125, *1, HE4, *2	95.881
1830	ips, dps, CA125, EGF, GMCSF, IL1RA	96.236
1831	ips, dps, CA125, EGF, GMCSF, HE4	96.52
1832	ips, dps, CA125, EGF, GMCSF, *2	96.307
1833	ips, dps, CA125, EGF, IL1RA, HE4	96.023
1834	ips, dps, CA125, EGF, IL1RA, *2	96.236
1835	ips, dps, CA125, EGF, HE4, *2	95.881
1836	ips, dps, CA125, GMCSF, IL1RA, HE4	95.277
1837	ips, dps, CA125, GMCSF, IL1RA, *2	95.668
1838	ips, dps, CA125, GMCSF, HE4, *2	95.703
1839	ips, dps, CA125, IL1RA, HE4, *2	95.455
1840	ips, dps, EMILIN, MDK, *1, EGF	93.963
1841	ips, dps, EMILIN, MDK, *1, GMCSF	94.07
1842	ips, dps, EMILIN, MDK, *1, IL1RA	94.318
1843	ips, dps, EMILIN, MDK, *1, HE4	93.839
1844	ips, dps, EMILIN, MDK, *1, *2	94.425
1845	ips, dps, EMILIN, MDK, EGF, GMCSF	92.72
1846	ips, dps, EMILIN, MDK, EGF, IL1RA	93.111
1847	ips, dps, EMILIN, MDK, EGF, HE4	92.738
1848	ips, dps, EMILIN, MDK, EGF, *2	93.466
1849	ips, dps, EMILIN, MDK, GMCSF, IL1RA	93.253
1850	ips, dps, EMILIN, MDK, GMCSF, HE4	93.146
1851	ips, dps, EMILIN, MDK, GMCSF, *2	93.75
1852	ips, dps, EMILIN, MDK, IL1RA, HE4	93.288
1853	ips, dps, EMILIN, MDK, IL1RA, *2	94.034
1854	ips, dps, EMILIN, MDK, HE4, *2	93.395
1855	ips, dps, EMILIN, *1, EGF, GMCSF	92.045
1856	ips, dps, EMILIN, *1, EGF, IL1RA	93.253
1857	ips, dps, EMILIN, *1, EGF, HE4	92.578
1858	ips, dps, EMILIN, *1, EGF, *2	93.075
1859	ips, dps, EMILIN, *1, GMCSF, IL1RA	93.217
1860	ips, dps, EMILIN, *1, GMCSF, HE4	92.827
1861	ips, dps, EMILIN, *1, GMCSF, *2	93.04
1862	ips, dps, EMILIN, *1, IL1RA, HE4	93.43

1863	ips, dps, EMILIN, *1, IL1RA, *2	93.572
1864	ips, dps, EMILIN, *1, HE4, *2	93.182
1865	ips, dps, EMILIN, EGF, GMCSF, IL1RA	91.477
1866	ips, dps, EMILIN, EGF, GMCSF, HE4	91.122
1867	ips, dps, EMILIN, EGF, GMCSF, *2	91.016
1868	ips, dps, EMILIN, EGF, IL1RA, HE4	91.477
1869	ips, dps, EMILIN, EGF, IL1RA, *2	92.223
1870	ips, dps, EMILIN, EGF, HE4, *2	91.797
1871	ips, dps, EMILIN, GMCSF, IL1RA, HE4	92.614
1872	ips, dps, EMILIN, GMCSF, IL1RA, *2	92.791
1873	ips, dps, EMILIN, GMCSF, HE4, *2	92.188
1874	ips, dps, EMILIN, IL1RA, HE4, *2	92.631
1875	ips, dps, MDK, *1, EGF, GMCSF	94.034
1876	ips, dps, MDK, *1, EGF, IL1RA	93.999
1877	ips, dps, MDK, *1, EGF, HE4	93.501
1878	ips, dps, MDK, *1, EGF, *2	94.034
1879	ips, dps, MDK, *1, GMCSF, IL1RA	94.318
1880	ips, dps, MDK, *1, GMCSF, HE4	94.141
1881	ips, dps, MDK, *1, GMCSF, *2	94.531
1882	ips, dps, MDK, *1, IL1RA, HE4	93.395
1883	ips, dps, MDK, *1, IL1RA, *2	94.141
1884	ips, dps, MDK, *1, HE4, *2	93.643
1885	ips, dps, MDK, EGF, GMCSF, IL1RA	92.56
1886	ips, dps, MDK, EGF, GMCSF, HE4	91.797
1887	ips, dps, MDK, EGF, GMCSF, *2	92.365
1888	ips, dps, MDK, EGF, IL1RA, HE4	91.335
1889	ips, dps, MDK, EGF, IL1RA, *2	92.844
1890	ips, dps, MDK, EGF, HE4, *2	92.116
1891	ips, dps, MDK, GMCSF, IL1RA, HE4	92.365
1892	ips, dps, MDK, GMCSF, IL1RA, *2	92.88
1893	ips, dps, MDK, GMCSF, HE4, *2	92.507
1894	ips, dps, MDK, IL1RA, HE4, *2	91.726
1895	ips, dps, *1, EGF, GMCSF, IL1RA	91.797
1896	ips, dps, *1, EGF, GMCSF, HE4	91.655
1897	ips, dps, *1, EGF, GMCSF, *2	91.371
1898	ips, dps, *1, EGF, IL1RA, HE4	91.335
1899	ips, dps, *1, EGF, IL1RA, *2	91.726
1900	ips, dps, *1, EGF, HE4, *2	91.513
1901	ips, dps, *1, GMCSF, IL1RA, HE4	90.98
1902	ips, dps, *1, GMCSF, IL1RA, *2	91.442
1903	ips, dps, *1, GMCSF, HE4, *2	91.122
1904	ips, dps, *1, IL1RA, HE4, *2	90.376
1905	ips, dps, EGF, GMCSF, IL1RA, HE4	88.778
1906	ips, dps, EGF, GMCSF, IL1RA, *2	90.021
1907	ips, dps, EGF, GMCSF, HE4, *2	89.897
1908	ips, dps, EGF, IL1RA, HE4, *2	89.453

1909	ips, dps, GMCSF, IL1RA, HE4, *2	88.92
1910	ips, CA125, EMILIN, MDK, *1, EGF	97.088
1911	ips, CA125, EMILIN, MDK, *1, GMCSF	97.053
1912	ips, CA125, EMILIN, MDK, *1, IL1RA	97.23
1913	ips, CA125, EMILIN, MDK, *1, HE4	96.911
1914	ips, CA125, EMILIN, MDK, *1, *2	97.159
1915	ips, CA125, EMILIN, MDK, EGF, GMCSF	96.697
1916	ips, CA125, EMILIN, MDK, EGF, IL1RA	96.982
1917	ips, CA125, EMILIN, MDK, EGF, HE4	96.768
1918	ips, CA125, EMILIN, MDK, EGF, *2	96.768
1919	ips, CA125, EMILIN, MDK, GMCSF, IL1RA	96.999
1920	ips, CA125, EMILIN, MDK, GMCSF, HE4	96.982
1921	ips, CA125, EMILIN, MDK, GMCSF, *2	96.946
1922	ips, CA125, EMILIN, MDK, IL1RA, HE4	97.053
1923	ips, CA125, EMILIN, MDK, IL1RA, *2	97.195
1924	ips, CA125, EMILIN, MDK, HE4, *2	96.875
1925	ips, CA125, EMILIN, *1, EGF, GMCSF	95.419
1926	ips, CA125, EMILIN, *1, EGF, IL1RA	95.579
1927	ips, CA125, EMILIN, *1, EGF, HE4	95.455
1928	ips, CA125, EMILIN, *1, EGF, *2	95.739
1929	ips, CA125, EMILIN, *1, GMCSF, IL1RA	95.703
1930	ips, CA125, EMILIN, *1, GMCSF, HE4	95.774
1931	ips, CA125, EMILIN, *1, GMCSF, *2	95.597
1932	ips, CA125, EMILIN, *1, IL1RA, HE4	96.005
1933	ips, CA125, EMILIN, *1, IL1RA, *2	96.005
1934	ips, CA125, EMILIN, *1, HE4, *2	96.023
1935	ips, CA125, EMILIN, EGF, GMCSF, IL1RA	95.206
1936	ips, CA125, EMILIN, EGF, GMCSF, HE4	95.597
1937	ips, CA125, EMILIN, EGF, GMCSF, *2	95.277
1938	ips, CA125, EMILIN, EGF, IL1RA, HE4	95.668
1939	ips, CA125, EMILIN, EGF, IL1RA, *2	95.845
1940	ips, CA125, EMILIN, EGF, HE4, *2	95.49
1941	ips, CA125, EMILIN, GMCSF, *2	95.952

	IL1RA, HE4	
1942	ips, CA125, EMILIN, GMCSF, IL1RA, *2	95.632
1943	ips, CA125, EMILIN, GMCSF, HE4, *2	96.058
1944	ips, CA125, EMILIN, IL1RA, HE4, *2	96.147
1945	ips, CA125, MDK, *1, EGF, GMCSF	96.839
1946	ips, CA125, MDK, *1, EGF, IL1RA	96.662
1947	ips, CA125, MDK, *1, EGF, HE4	96.52
1948	ips, CA125, MDK, *1, EGF, *2	96.484
1949	ips, CA125, MDK, *1, GMCSF, IL1RA	97.053
1950	ips, CA125, MDK, *1, GMCSF, HE4	97.053
1951	ips, CA125, MDK, *1, GMCSF, *2	97.017
1952	ips, CA125, MDK, *1, IL1RA, HE4	96.555
1953	ips, CA125, MDK, *1, IL1RA, *2	96.662
1954	ips, CA125, MDK, *1, HE4, *2	96.804
1955	ips, CA125, MDK, EGF, GMCSF, IL1RA	96.768
1956	ips, CA125, MDK, EGF, GMCSF, HE4	96.626
1957	ips, CA125, MDK, EGF, GMCSF, *2	96.662
1958	ips, CA125, MDK, EGF, IL1RA, HE4	96.413
1959	ips, CA125, MDK, EGF, IL1RA, *2	96.342
1960	ips, CA125, MDK, EGF, HE4, *2	96.165
1961	ips, CA125, MDK, GMCSF, IL1RA, HE4	96.715
1962	ips, CA125, MDK, GMCSF, IL1RA, *2	96.555
1963	ips, CA125, MDK, GMCSF, HE4, *2	96.449
1964	ips, CA125, MDK, IL1RA, HE4, *2	96.165
1965	ips, CA125, *1, EGF, GMCSF, IL1RA	94.709
1966	ips, CA125, *1, EGF, GMCSF, HE4	94.815
1967	ips, CA125, *1, EGF, GMCSF, *2	94.851
1968	ips, CA125, *1, EGF, IL1RA, HE4	94.265
1969	ips, CA125, *1, EGF, IL1RA, *2	94.744
1970	ips, CA125, *1, EGF, HE4, *2	94.496
1971	ips, CA125, *1, GMCSF, IL1RA, HE4	94.602
1972	ips, CA125, *1, GMCSF, IL1RA, *2	94.851
1973	ips, CA125, *1, GMCSF, HE4, *2	94.744
1974	ips, CA125, *1, IL1RA, HE4, *2	94.123
1975	ips, CA125, EGF, GMCSF, IL1RA, HE4	94.744
1976	ips, CA125, EGF, GMCSF, IL1RA, *2	94.105
1977	ips, CA125, EGF, GMCSF, HE4, *2	94.496
1978	ips, CA125, EGF, IL1RA, HE4, *2	94.212
1979	ips, CA125, GMCSF, IL1RA, HE4, *2	94.354

1980	ips, EMILIN, MDK, *1, EGF, GMCSF	91.797
1981	ips, EMILIN, MDK, *1, EGF, IL1RA	92.152
1982	ips, EMILIN, MDK, *1, EGF, HE4	92.081
1983	ips, EMILIN, MDK, *1, EGF, *2	92.116
1984	ips, EMILIN, MDK, *1, GMCSF, IL1RA	91.957
1985	ips, EMILIN, MDK, *1, GMCSF, HE4	91.992
1986	ips, EMILIN, MDK, *1, GMCSF, *2	92.259
1987	ips, EMILIN, MDK, *1, IL1RA, HE4	92.223
1988	ips, EMILIN, MDK, *1, IL1RA, *2	91.868
1989	ips, EMILIN, MDK, *1, HE4, *2	92.33
1990	ips, EMILIN, MDK, EGF, GMCSF, IL1RA	90.945
1991	ips, EMILIN, MDK, EGF, GMCSF, HE4	90.518
1992	ips, EMILIN, MDK, EGF, GMCSF, *2	90.625
1993	ips, EMILIN, MDK, EGF, IL1RA, HE4	90.998
1994	ips, EMILIN, MDK, EGF, IL1RA, *2	91.122
1995	ips, EMILIN, MDK, EGF, HE4, *2	90.217
1996	ips, EMILIN, MDK, GMCSF, IL1RA, HE4	91.051
1997	ips, EMILIN, MDK, GMCSF, IL1RA, *2	91.246
1998	ips, EMILIN, MDK, GMCSF, HE4, *2	90.98
1999	ips, EMILIN, MDK, IL1RA, HE4, *2	91.158
2000	ips, EMILIN, *1, EGF, GMCSF, IL1RA	88.388
2001	ips, EMILIN, *1, EGF, GMCSF, HE4	88.281
2002	ips, EMILIN, *1, EGF, GMCSF, *2	88.388
2003	ips, EMILIN, *1, EGF, IL1RA, HE4	88.974
2004	ips, EMILIN, *1, EGF, IL1RA, *2	88.388
2005	ips, EMILIN, *1, EGF, HE4, *2	88.565
2006	ips, EMILIN, *1, GMCSF, IL1RA, HE4	90.128
2007	ips, EMILIN, *1, GMCSF, IL1RA, *2	89.293
2008	ips, EMILIN, *1, GMCSF, HE4, *2	89.489
2009	ips, EMILIN, *1, IL1RA, HE4, *2	89.595
2010	ips, EMILIN, EGF, GMCSF, IL1RA, HE4	87.784
2011	ips, EMILIN, EGF, GMCSF, IL1RA, *2	87.5
2012	ips, EMILIN, EGF, GMCSF, HE4, *2	86.186
2013	ips, EMILIN, EGF, IL1RA, HE4, *2	86.648
2014	ips, EMILIN, GMCSF, IL1RA, HE4, *2	88.725
2015	ips, MDK, *1, EGF, GMCSF, IL1RA	91.797
2016	ips, MDK, *1, EGF, GMCSF, HE4	91.548
2017	ips, MDK, *1, EGF, GMCSF, *2	91.673

2018	ips, MDK, *1, EGF, IL1RA, HE4	90.767
2019	ips, MDK, *1, EGF, IL1RA, *2	90.874
2020	ips, MDK, *1, EGF, HE4, *2	90.589
2021	ips, MDK, *1, GMCSF, IL1RA, HE4	91.584
2022	ips, MDK, *1, GMCSF, IL1RA, *2	92.045
2023	ips, MDK, *1, GMCSF, HE4, *2	91.868
2024	ips, MDK, *1, IL1RA, HE4, *2	90.661
2025	ips, MDK, EGF, GMCSF, IL1RA, HE4	88.672
2026	ips, MDK, EGF, GMCSF, IL1RA, *2	89.24
2027	ips, MDK, EGF, GMCSF, HE4, *2	88.92
2028	ips, MDK, EGF, IL1RA, HE4, *2	88.21
2029	ips, MDK, GMCSF, IL1RA, HE4, *2	88.619
2030	ips, *1, EGF, GMCSF, IL1RA, HE4	85.618
2031	ips, *1, EGF, GMCSF, IL1RA, *2	86.222
2032	ips, *1, EGF, GMCSF, HE4, *2	86.044
2033	ips, *1, EGF, IL1RA, HE4, *2	84.872
2034	ips, *1, GMCSF, IL1RA, HE4, *2	85.724
2035	ips, EGF, GMCSF, IL1RA, HE4, *2	82.386
2036	mps, dps, CA125, EMILIN, MDK, *1	97.869
2037	mps, dps, CA125, EMILIN, MDK, EGF	97.798
2038	mps, dps, CA125, EMILIN, MDK, GMCSF	97.834
2039	mps, dps, CA125, EMILIN, MDK, IL1RA	98.118
2040	mps, dps, CA125, EMILIN, MDK, HE4	98.082
2041	mps, dps, CA125, EMILIN, MDK, *2	97.976
2042	mps, dps, CA125, EMILIN, *1, EGF	97.337
2043	mps, dps, CA125, EMILIN, *1, GMCSF	97.266
2044	mps, dps, CA125, EMILIN, *1, IL1RA	97.514
2045	mps, dps, CA125, EMILIN, *1, HE4	97.301
2046	mps, dps, CA125, EMILIN, *1, *2	97.443
2047	mps, dps, CA125, EMILIN, EGF, GMCSF	97.354
2048	mps, dps, CA125, EMILIN, EGF, IL1RA	97.408
2049	mps, dps, CA125, EMILIN, EGF, HE4	97.372
2050	mps, dps, CA125, EMILIN, EGF, *2	97.55
2051	mps, dps, CA125, EMILIN, GMCSF, IL1RA	97.372
2052	mps, dps, CA125, EMILIN, GMCSF, HE4	97.301
2053	mps, dps, CA125, EMILIN, GMCSF, *2	97.514
2054	mps, dps, CA125, EMILIN, IL1RA, HE4	97.656
2055	mps, dps, CA125, EMILIN, IL1RA, *2	97.585

2056	mps, dps, CA125, EMILIN, HE4, *2	97.656
2057	mps, dps, CA125, MDK, *1, EGF	97.017
2058	mps, dps, CA125, MDK, *1, GMCSF	96.946
2059	mps, dps, CA125, MDK, *1, IL1RA	96.911
2060	mps, dps, CA125, MDK, *1, HE4	96.911
2061	mps, dps, CA125, MDK, *1, *2	97.017
2062	mps, dps, CA125, MDK, EGF, GMCSF	96.733
2063	mps, dps, CA125, MDK, EGF, IL1RA	96.946
2064	mps, dps, CA125, MDK, EGF, HE4	96.875
2065	mps, dps, CA125, MDK, EGF, *2	96.911
2066	mps, dps, CA125, MDK, GMCSF, IL1RA	96.804
2067	mps, dps, CA125, MDK, GMCSF, HE4	96.626
2068	mps, dps, CA125, MDK, GMCSF, *2	96.697
2069	mps, dps, CA125, MDK, IL1RA, HE4	96.946
2070	mps, dps, CA125, MDK, IL1RA, *2	96.946
2071	mps, dps, CA125, MDK, HE4, *2	96.751
2072	mps, dps, CA125, *1, EGF, GMCSF	95.384
2073	mps, dps, CA125, *1, EGF, IL1RA	95.881
2074	mps, dps, CA125, *1, EGF, HE4	95.632
2075	mps, dps, CA125, *1, EGF, *2	95.81
2076	mps, dps, CA125, *1, GMCSF, IL1RA	95.668
2077	mps, dps, CA125, *1, GMCSF, HE4	95.135
2078	mps, dps, CA125, *1, GMCSF, *2	95.348
2079	mps, dps, CA125, *1, IL1RA, HE4	95.739
2080	mps, dps, CA125, *1, IL1RA, *2	95.881
2081	mps, dps, CA125, *1, HE4, *2	95.703
2082	mps, dps, CA125, EGF, GMCSF, IL1RA	95.526
2083	mps, dps, CA125, EGF, GMCSF, HE4	95.561
2084	mps, dps, CA125, EGF, GMCSF, *2	95.419
2085	mps, dps, CA125, EGF, IL1RA, HE4	95.881
2086	mps, dps, CA125, EGF, IL1RA, *2	95.81
2087	mps, dps, CA125, EGF, HE4, *2	95.774
2088	mps, dps, CA125, GMCSF, IL1RA, HE4	95.49
2089	mps, dps, CA125, GMCSF, IL1RA, *2	95.455
2090	mps, dps, CA125, GMCSF, HE4, *2	95.135
2091	mps, dps, CA125, IL1RA, HE4, *2	95.561
2092	mps, dps, EMILIN, MDK, *1, EGF	95.668
2093	mps, dps, EMILIN, MDK, *1, GMCSF	95.455
2094	mps, dps, EMILIN, MDK, *1, IL1RA	96.342

2095	mps, dps, EMILIN, MDK, *1, HE4	95.987
2096	mps, dps, EMILIN, MDK, *1, *2	96.289
2097	mps, dps, EMILIN, MDK, EGF, GMCSF	94.531
2098	mps, dps, EMILIN, MDK, EGF, IL1RA	95.49
2099	mps, dps, EMILIN, MDK, EGF, HE4	94.886
2100	mps, dps, EMILIN, MDK, EGF, *2	95.206
2101	mps, dps, EMILIN, MDK, GMCSF, IL1RA	95.384
2102	mps, dps, EMILIN, MDK, GMCSF, HE4	94.922
2103	mps, dps, EMILIN, MDK, GMCSF, *2	95.241
2104	mps, dps, EMILIN, MDK, IL1RA, HE4	95.987
2105	mps, dps, EMILIN, MDK, IL1RA, *2	96.236
2106	mps, dps, EMILIN, MDK, HE4, *2	95.348
2107	mps, dps, EMILIN, *1, EGF, GMCSF	93.999
2108	mps, dps, EMILIN, *1, EGF, IL1RA	95.561
2109	mps, dps, EMILIN, *1, EGF, HE4	94.07
2110	mps, dps, EMILIN, *1, EGF, *2	95.135
2111	mps, dps, EMILIN, *1, GMCSF, IL1RA	95.739
2112	mps, dps, EMILIN, *1, GMCSF, HE4	94.105
2113	mps, dps, EMILIN, *1, GMCSF, *2	95.011
2114	mps, dps, EMILIN, *1, IL1RA, HE4	96.076
2115	mps, dps, EMILIN, *1, IL1RA, *2	96.058
2116	mps, dps, EMILIN, *1, HE4, *2	95.348
2117	mps, dps, EMILIN, EGF, GMCSF, IL1RA	94.78
2118	mps, dps, EMILIN, EGF, GMCSF, HE4	92.969
2119	mps, dps, EMILIN, EGF, GMCSF, *2	93.04
2120	mps, dps, EMILIN, EGF, IL1RA, HE4	95.49
2121	mps, dps, EMILIN, EGF, IL1RA, *2	95.526
2122	mps, dps, EMILIN, EGF, HE4, *2	93.643
2123	mps, dps, EMILIN, GMCSF, IL1RA, HE4	95.135
2124	mps, dps, EMILIN, GMCSF, IL1RA, *2	95.632
2125	mps, dps, EMILIN, GMCSF, HE4, *2	93.555
2126	mps, dps, EMILIN, IL1RA, HE4, *2	95.774
2127	mps, dps, MDK, *1, EGF, GMCSF	94.176
2128	mps, dps, MDK, *1, EGF, IL1RA	94.851
2129	mps, dps, MDK, *1, EGF, HE4	94.034
2130	mps, dps, MDK, *1, EGF, *2	94.762
2131	mps, dps, MDK, *1, GMCSF, IL1RA	94.886

2132	mps, dps, MDK, *1, GMCSF, HE4	94.07
2133	mps, dps, MDK, *1, GMCSF, *2	94.815
2134	mps, dps, MDK, *1, IL1RA, HE4	95.099
2135	mps, dps, MDK, *1, IL1RA, *2	95.455
2136	mps, dps, MDK, *1, HE4, *2	94.709
2137	mps, dps, MDK, EGF, GMCSF, IL1RA	93.324
2138	mps, dps, MDK, EGF, GMCSF, HE4	92.614
2139	mps, dps, MDK, EGF, GMCSF, *2	92.898
2140	mps, dps, MDK, EGF, IL1RA, HE4	93.359
2141	mps, dps, MDK, EGF, IL1RA, *2	94.336
2142	mps, dps, MDK, EGF, HE4, *2	93.04
2143	mps, dps, MDK, GMCSF, IL1RA, HE4	93.501
2144	mps, dps, MDK, GMCSF, IL1RA, *2	93.928
2145	mps, dps, MDK, GMCSF, HE4, *2	92.898
2146	mps, dps, MDK, IL1RA, HE4, *2	94.673
2147	mps, dps, *1, EGF, GMCSF, IL1RA	91.442
2148	mps, dps, *1, EGF, GMCSF, HE4	90.27
2149	mps, dps, *1, EGF, GMCSF, *2	90.98
2150	mps, dps, *1, EGF, IL1RA, HE4	92.116
2151	mps, dps, *1, EGF, IL1RA, *2	92.525
2152	mps, dps, *1, EGF, HE4, *2	91.406
2153	mps, dps, *1, GMCSF, IL1RA, HE4	90.927
2154	mps, dps, *1, GMCSF, IL1RA, *2	91.335
2155	mps, dps, *1, GMCSF, HE4, *2	90.536
2156	mps, dps, *1, IL1RA, HE4, *2	91.761
2157	mps, dps, EGF, GMCSF, IL1RA, HE4	90.057
2158	mps, dps, EGF, GMCSF, IL1RA, *2	90.305
2159	mps, dps, EGF, GMCSF, HE4, *2	89.134
2160	mps, dps, EGF, IL1RA, HE4, *2	90.874
2161	mps, dps, GMCSF, IL1RA, HE4, *2	89.773
2162	mps, CA125, EMILIN, MDK, *1, EGF	97.763
2163	mps, CA125, EMILIN, MDK, *1, GMCSF	97.834
2164	mps, CA125, EMILIN, MDK, *1, IL1RA	98.082
2165	mps, CA125, EMILIN, MDK, *1, HE4	97.905
2166	mps, CA125, EMILIN, MDK, *1, *2	97.905
2167	mps, CA125, EMILIN, MDK, EGF, GMCSF	97.585
2168	mps, CA125, EMILIN, MDK, EGF, IL1RA	97.55
2169	mps, CA125, EMILIN, MDK, EGF, HE4	97.798
2170	mps, CA125, EMILIN, MDK, EGF, *2	97.656
2171	mps, CA125, EMILIN, MDK, GMCSF, IL1RA	97.55

2172	mps, CA125, EMILIN, MDK, GMCSF, HE4	97.905
2173	mps, CA125, EMILIN, MDK, GMCSF, *2	97.798
2174	mps, CA125, EMILIN, MDK, IL1RA, HE4	97.94
2175	mps, CA125, EMILIN, MDK, IL1RA, *2	97.905
2176	mps, CA125, EMILIN, MDK, HE4, *2	98.011
2177	mps, CA125, EMILIN, *1, EGF, GMCSF	96.768
2178	mps, CA125, EMILIN, *1, EGF, IL1RA	97.088
2179	mps, CA125, EMILIN, *1, EGF, HE4	96.946
2180	mps, CA125, EMILIN, *1, EGF, *2	97.088
2181	mps, CA125, EMILIN, *1, GMCSF, IL1RA	97.337
2182	mps, CA125, EMILIN, *1, GMCSF, HE4	96.982
2183	mps, CA125, EMILIN, *1, GMCSF, *2	97.159
2184	mps, CA125, EMILIN, *1, IL1RA, HE4	97.337
2185	mps, CA125, EMILIN, *1, IL1RA, *2	97.443
2186	mps, CA125, EMILIN, *1, HE4, *2	97.053
2187	mps, CA125, EMILIN, EGF, GMCSF, IL1RA	96.839
2188	mps, CA125, EMILIN, EGF, GMCSF, HE4	96.946
2189	mps, CA125, EMILIN, EGF, GMCSF, *2	96.804
2190	mps, CA125, EMILIN, EGF, IL1RA, HE4	97.053
2191	mps, CA125, EMILIN, EGF, IL1RA, *2	97.195
2192	mps, CA125, EMILIN, EGF, HE4, *2	96.911
2193	mps, CA125, EMILIN, GMCSF, IL1RA, HE4	97.266
2194	mps, CA125, EMILIN, GMCSF, IL1RA, *2	97.195
2195	mps, CA125, EMILIN, GMCSF, HE4, *2	97.088
2196	mps, CA125, EMILIN, IL1RA, HE4, *2	97.55
2197	mps, CA125, MDK, *1, EGF, GMCSF	96.378
2198	mps, CA125, MDK, *1, EGF, IL1RA	96.413
2199	mps, CA125, MDK, *1, EGF, HE4	96.555
2200	mps, CA125, MDK, *1, EGF, *2	96.378
2201	mps, CA125, MDK, *1, GMCSF,	96.591

	IL1RA	
2202	mps, CA125, MDK, *1, GMCSF, HE4	96.52
2203	mps, CA125, MDK, *1, GMCSF, *2	96.484
2204	mps, CA125, MDK, *1, IL1RA, HE4	96.733
2205	mps, CA125, MDK, *1, IL1RA, *2	96.946
2206	mps, CA125, MDK, *1, HE4, *2	96.555
2207	mps, CA125, MDK, EGF, GMCSF, IL1RA	96.378
2208	mps, CA125, MDK, EGF, GMCSF, HE4	96.271
2209	mps, CA125, MDK, EGF, GMCSF, *2	95.952
2210	mps, CA125, MDK, EGF, IL1RA, HE4	96.342
2211	mps, CA125, MDK, EGF, IL1RA, *2	96.52
2212	mps, CA125, MDK, EGF, HE4, *2	96.36
2213	mps, CA125, MDK, GMCSF, IL1RA, HE4	96.555
2214	mps, CA125, MDK, GMCSF, IL1RA, *2	96.449
2215	mps, CA125, MDK, GMCSF, HE4, *2	96.484
2216	mps, CA125, MDK, IL1RA, HE4, *2	96.768
2217	mps, CA125, *1, EGF, GMCSF, IL1RA	94.673
2218	mps, CA125, *1, EGF, GMCSF, HE4	94.247
2219	mps, CA125, *1, EGF, GMCSF, *2	94.851
2220	mps, CA125, *1, EGF, IL1RA, HE4	94.602
2221	mps, CA125, *1, EGF, IL1RA, *2	94.993
2222	mps, CA125, *1, EGF, HE4, *2	94.425
2223	mps, CA125, *1, GMCSF, IL1RA, HE4	94.798
2224	mps, CA125, *1, GMCSF, IL1RA, *2	94.886
2225	mps, CA125, *1, GMCSF, HE4, *2	94.496
2226	mps, CA125, *1, IL1RA, HE4, *2	95.241
2227	mps, CA125, EGF, GMCSF, IL1RA, HE4	94.638
2228	mps, CA125, EGF, GMCSF, IL1RA, *2	94.602
2229	mps, CA125, EGF, GMCSF, HE4, *2	94.425
2230	mps, CA125, EGF, IL1RA, HE4, *2	94.531
2231	mps, CA125, GMCSF, IL1RA, HE4, *2	94.851
2232	mps, EMILIN, MDK, *1, EGF, GMCSF	95.526
2233	mps, EMILIN, MDK, *1, EGF, IL1RA	95.597
2234	mps, EMILIN, MDK, *1, EGF, HE4	95.49
2235	mps, EMILIN, MDK, *1, EGF, *2	95.916

2236	mps, EMILIN, MDK, *1, GMCSF, IL1RA	95.543
2237	mps, EMILIN, MDK, *1, GMCSF, HE4	95.313
2238	mps, EMILIN, MDK, *1, GMCSF, *2	95.916
2239	mps, EMILIN, MDK, *1, IL1RA, HE4	95.969
2240	mps, EMILIN, MDK, *1, IL1RA, *2	96.165
2241	mps, EMILIN, MDK, *1, HE4, *2	96.094
2242	mps, EMILIN, MDK, EGF, GMCSF, IL1RA	94.247
2243	mps, EMILIN, MDK, EGF, GMCSF, HE4	93.821
2244	mps, EMILIN, MDK, EGF, GMCSF, *2	94.105
2245	mps, EMILIN, MDK, EGF, IL1RA, HE4	94.212
2246	mps, EMILIN, MDK, EGF, IL1RA, *2	94.46
2247	mps, EMILIN, MDK, EGF, HE4, *2	94.354
2248	mps, EMILIN, MDK, GMCSF, IL1RA, HE4	94.283
2249	mps, EMILIN, MDK, GMCSF, IL1RA, *2	94.691
2250	mps, EMILIN, MDK, GMCSF, HE4, *2	94.531
2251	mps, EMILIN, MDK, IL1RA, HE4, *2	95.277
2252	mps, EMILIN, *1, EGF, GMCSF, IL1RA	94.247
2253	mps, EMILIN, *1, EGF, GMCSF, HE4	92.72
2254	mps, EMILIN, *1, EGF, GMCSF, *2	94.034
2255	mps, EMILIN, *1, EGF, IL1RA, HE4	94.283
2256	mps, EMILIN, *1, EGF, IL1RA, *2	94.815
2257	mps, EMILIN, *1, EGF, HE4, *2	93.466
2258	mps, EMILIN, *1, GMCSF, IL1RA, HE4	94.531
2259	mps, EMILIN, *1, GMCSF, IL1RA, *2	94.851
2260	mps, EMILIN, *1, GMCSF, HE4, *2	93.714
2261	mps, EMILIN, *1, IL1RA, HE4, *2	94.78
2262	mps, EMILIN, EGF, GMCSF, IL1RA, HE4	92.898
2263	mps, EMILIN, EGF, GMCSF, IL1RA, *2	92.969
2264	mps, EMILIN, EGF, GMCSF, HE4, *2	90.82
2265	mps, EMILIN, EGF, IL1RA, HE4, *2	93.537
2266	mps, EMILIN, GMCSF, IL1RA, HE4, *2	94.212
2267	mps, MDK, *1, EGF, GMCSF, IL1RA	93.714
2268	mps, MDK, *1, EGF, GMCSF, HE4	93.661
2269	mps, MDK, *1, EGF, GMCSF, *2	94.105

2270	mps, MDK, *1, EGF, IL1RA, HE4	93.608
2271	mps, MDK, *1, EGF, IL1RA, *2	94.247
2272	mps, MDK, *1, EGF, HE4, *2	93.714
2273	mps, MDK, *1, GMCSF, IL1RA, HE4	93.821
2274	mps, MDK, *1, GMCSF, IL1RA, *2	94.389
2275	mps, MDK, *1, GMCSF, HE4, *2	94.212
2276	mps, MDK, *1, IL1RA, HE4, *2	94.212
2277	mps, MDK, EGF, GMCSF, IL1RA, HE4	91.903
2278	mps, MDK, EGF, GMCSF, IL1RA, *2	91.726
2279	mps, MDK, EGF, GMCSF, HE4, *2	91.868
2280	mps, MDK, EGF, IL1RA, HE4, *2	92.578
2281	mps, MDK, GMCSF, IL1RA, HE4, *2	93.04
2282	mps, *1, EGF, GMCSF, IL1RA, HE4	90.128
2283	mps, *1, EGF, GMCSF, IL1RA, *2	90.092
2284	mps, *1, EGF, GMCSF, HE4, *2	89.382
2285	mps, *1, EGF, IL1RA, HE4, *2	90.518
2286	mps, *1, GMCSF, IL1RA, HE4, *2	89.205
2287	mps, EGF, GMCSF, IL1RA, HE4, *2	88.672
2288	dps, CA125, EMILIN, MDK, *1, EGF	94.78
2289	dps, CA125, EMILIN, MDK, *1, GMCSF	94.993
2290	dps, CA125, EMILIN, MDK, *1, IL1RA	94.957
2291	dps, CA125, EMILIN, MDK, *1, HE4	95.028
2292	dps, CA125, EMILIN, MDK, *1, *2	95.366
2293	dps, CA125, EMILIN, MDK, EGF, GMCSF	93.963
2294	dps, CA125, EMILIN, MDK, EGF, IL1RA	94.46
2295	dps, CA125, EMILIN, MDK, EGF, HE4	94.105
2296	dps, CA125, EMILIN, MDK, EGF, *2	94.673
2297	dps, CA125, EMILIN, MDK, GMCSF, IL1RA	94.105
2298	dps, CA125, EMILIN, MDK, GMCSF, HE4	94.141
2299	dps, CA125, EMILIN, MDK, GMCSF, *2	94.922
2300	dps, CA125, EMILIN, MDK, IL1RA, HE4	94.141
2301	dps, CA125, EMILIN, MDK, IL1RA, *2	95.099
2302	dps, CA125, EMILIN, MDK, HE4, *2	94.922
2303	dps, CA125, EMILIN, *1, EGF, GMCSF	93.395

2304	dps, CA125, EMILIN, *1, EGF, IL1RA	93.91
2305	dps, CA125, EMILIN, *1, EGF, HE4	93.395
2306	dps, CA125, EMILIN, *1, EGF, *2	93.963
2307	dps, CA125, EMILIN, *1, GMCSF, IL1RA	93.768
2308	dps, CA125, EMILIN, *1, GMCSF, HE4	93.608
2309	dps, CA125, EMILIN, *1, GMCSF, *2	93.75
2310	dps, CA125, EMILIN, *1, IL1RA, HE4	93.999
2311	dps, CA125, EMILIN, *1, IL1RA, *2	94.407
2312	dps, CA125, EMILIN, *1, HE4, *2	94.052
2313	dps, CA125, EMILIN, EGF, GMCSF, IL1RA	93.43
2314	dps, CA125, EMILIN, EGF, GMCSF, HE4	92.933
2315	dps, CA125, EMILIN, EGF, GMCSF, *2	93.288
2316	dps, CA125, EMILIN, EGF, IL1RA, HE4	93.714
2317	dps, CA125, EMILIN, EGF, IL1RA, *2	94.425
2318	dps, CA125, EMILIN, EGF, HE4, *2	93.679
2319	dps, CA125, EMILIN, GMCSF, IL1RA, HE4	93.679
2320	dps, CA125, EMILIN, GMCSF, IL1RA, *2	94.141
2321	dps, CA125, EMILIN, GMCSF, HE4, *2	93.608
2322	dps, CA125, EMILIN, IL1RA, HE4, *2	94.105
2323	dps, CA125, MDK, *1, EGF, GMCSF	94.638
2324	dps, CA125, MDK, *1, EGF, IL1RA	95.046
2325	dps, CA125, MDK, *1, EGF, HE4	94.407
2326	dps, CA125, MDK, *1, EGF, *2	94.851
2327	dps, CA125, MDK, *1, GMCSF, IL1RA	94.709
2328	dps, CA125, MDK, *1, GMCSF, HE4	94.389
2329	dps, CA125, MDK, *1, GMCSF, *2	94.922
2330	dps, CA125, MDK, *1, IL1RA, HE4	94.709
2331	dps, CA125, MDK, *1, IL1RA, *2	94.957
2332	dps, CA125, MDK, *1, HE4, *2	94.709
2333	dps, CA125, MDK, EGF, GMCSF, IL1RA	94.105
2334	dps, CA125, MDK, EGF, GMCSF, HE4	93.714
2335	dps, CA125, MDK, EGF, GMCSF, *2	94.531
2336	dps, CA125, MDK, EGF, IL1RA,	94.141

	HE4	
2337	dps, CA125, MDK, EGF, IL1RA, *2	94.886
2338	dps, CA125, MDK, EGF, HE4, *2	94.212
2339	dps, CA125, MDK, GMCSF, IL1RA, HE4	93.572
2340	dps, CA125, MDK, GMCSF, IL1RA, *2	94.567
2341	dps, CA125, MDK, GMCSF, HE4, *2	93.999
2342	dps, CA125, MDK, IL1RA, HE4, *2	94.141
2343	dps, CA125, *1, EGF, GMCSF, IL1RA	92.614
2344	dps, CA125, *1, EGF, GMCSF, HE4	91.726
2345	dps, CA125, *1, EGF, GMCSF, *2	92.294
2346	dps, CA125, *1, EGF, IL1RA, HE4	92.596
2347	dps, CA125, *1, EGF, IL1RA, *2	93.359
2348	dps, CA125, *1, EGF, HE4, *2	92.614
2349	dps, CA125, *1, GMCSF, IL1RA, HE4	91.513
2350	dps, CA125, *1, GMCSF, IL1RA, *2	92.294
2351	dps, CA125, *1, GMCSF, HE4, *2	91.406
2352	dps, CA125, *1, IL1RA, HE4, *2	92.152
2353	dps, CA125, EGF, GMCSF, IL1RA, HE4	92.01
2354	dps, CA125, EGF, GMCSF, IL1RA, *2	92.401
2355	dps, CA125, EGF, GMCSF, HE4, *2	91.3
2356	dps, CA125, EGF, IL1RA, HE4, *2	92.294
2357	dps, CA125, GMCSF, IL1RA, HE4, *2	91.317
2358	dps, EMILIN, MDK, *1, EGF, GMCSF	90.483
2359	dps, EMILIN, MDK, *1, EGF, IL1RA	91.087
2360	dps, EMILIN, MDK, *1, EGF, HE4	90.589
2361	dps, EMILIN, MDK, *1, EGF, *2	92.045
2362	dps, EMILIN, MDK, *1, GMCSF, IL1RA	91.016
2363	dps, EMILIN, MDK, *1, GMCSF, HE4	90.874
2364	dps, EMILIN, MDK, *1, GMCSF, *2	91.832
2365	dps, EMILIN, MDK, *1, IL1RA, HE4	91.229
2366	dps, EMILIN, MDK, *1, IL1RA, *2	92.401
2367	dps, EMILIN, MDK, *1, HE4, *2	92.152
2368	dps, EMILIN, MDK, EGF, GMCSF, IL1RA	87.5
2369	dps, EMILIN, MDK, EGF, GMCSF, HE4	87.251
2370	dps, EMILIN, MDK, EGF, GMCSF, *2	88.707
2371	dps, EMILIN, MDK, EGF, IL1RA, HE4	88.388

2372	dps, EMILIN, MDK, EGF, IL1RA, *2	89.879
2373	dps, EMILIN, MDK, EGF, HE4, *2	89.631
2374	dps, EMILIN, MDK, GMCSF, IL1RA, HE4	88.636
2375	dps, EMILIN, MDK, GMCSF, IL1RA, *2	90.217
2376	dps, EMILIN, MDK, GMCSF, HE4, *2	89.631
2377	dps, EMILIN, MDK, IL1RA, HE4, *2	90.376
2378	dps, EMILIN, *1, EGF, GMCSF, IL1RA	86.896
2379	dps, EMILIN, *1, EGF, GMCSF, HE4	86.523
2380	dps, EMILIN, *1, EGF, GMCSF, *2	87.216
2381	dps, EMILIN, *1, EGF, IL1RA, HE4	88.565
2382	dps, EMILIN, *1, EGF, IL1RA, *2	89.063
2383	dps, EMILIN, *1, EGF, HE4, *2	88.317
2384	dps, EMILIN, *1, GMCSF, IL1RA, HE4	88.636
2385	dps, EMILIN, *1, GMCSF, IL1RA, *2	88.814
2386	dps, EMILIN, *1, GMCSF, HE4, *2	88.53
2387	dps, EMILIN, *1, IL1RA, HE4, *2	90.305
2388	dps, EMILIN, EGF, GMCSF, IL1RA, HE4	84.428
2389	dps, EMILIN, EGF, GMCSF, IL1RA, *2	85.369
2390	dps, EMILIN, EGF, GMCSF, HE4, *2	84.499
2391	dps, EMILIN, EGF, IL1RA, HE4, *2	87.678
2392	dps, EMILIN, GMCSF, IL1RA, HE4, *2	88.406
2393	dps, MDK, *1, EGF, GMCSF, IL1RA	90.554
2394	dps, MDK, *1, EGF, GMCSF, HE4	89.311
2395	dps, MDK, *1, EGF, GMCSF, *2	91.406
2396	dps, MDK, *1, EGF, IL1RA, HE4	90.288
2397	dps, MDK, *1, EGF, IL1RA, *2	91.619
2398	dps, MDK, *1, EGF, HE4, *2	90.732
2399	dps, MDK, *1, GMCSF, IL1RA, HE4	90.376
2400	dps, MDK, *1, GMCSF, IL1RA, *2	91.442
2401	dps, MDK, *1, GMCSF, HE4, *2	91.477
2402	dps, MDK, *1, IL1RA, HE4, *2	91.282
2403	dps, MDK, EGF, GMCSF, IL1RA, HE4	84.961
2404	dps, MDK, EGF, GMCSF, IL1RA, *2	88.246
2405	dps, MDK, EGF, GMCSF, HE4, *2	87.393
2406	dps, MDK, EGF, IL1RA, HE4, *2	87.926
2407	dps, MDK, GMCSF, IL1RA, HE4, *2	88.175
2408	dps, *1, EGF, GMCSF, IL1RA, HE4	85.245
2409	dps, *1, EGF, GMCSF, IL1RA, *2	86.506
2410	dps, *1, EGF, GMCSF, HE4, *2	84.197

2411	dps, *1, EGF, IL1RA, HE4, *2	86.275
2412	dps, *1, GMCSF, IL1RA, HE4, *2	84.375
2413	dps, EGF, GMCSF, IL1RA, HE4, *2	81.445
2414	CA125, EMILIN, MDK, *1, EGF, GMCSF	91.371
2415	CA125, EMILIN, MDK, *1, EGF, IL1RA	91.797
2416	CA125, EMILIN, MDK, *1, EGF, HE4	91.619
2417	CA125, EMILIN, MDK, *1, EGF, *2	91.868
2418	CA125, EMILIN, MDK, *1, GMCSF, IL1RA	92.045
2419	CA125, EMILIN, MDK, *1, GMCSF, HE4	92.081
2420	CA125, EMILIN, MDK, *1, GMCSF, *2	92.045
2421	CA125, EMILIN, MDK, *1, IL1RA, HE4	92.259
2422	CA125, EMILIN, MDK, *1, IL1RA, *2	92.543
2423	CA125, EMILIN, MDK, *1, HE4, *2	92.294
2424	CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	91.051
2425	CA125, EMILIN, MDK, EGF, GMCSF, HE4	90.199
2426	CA125, EMILIN, MDK, EGF, GMCSF, *2	90.625
2427	CA125, EMILIN, MDK, EGF, IL1RA, HE4	90.909
2428	CA125, EMILIN, MDK, EGF, IL1RA, *2	91.477
2429	CA125, EMILIN, MDK, EGF, HE4, *2	90.661
2430	CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	91.193
2431	CA125, EMILIN, MDK, GMCSF, IL1RA, *2	91.406
2432	CA125, EMILIN, MDK, GMCSF, HE4, *2	90.945
2433	CA125, EMILIN, MDK, IL1RA, HE4, *2	91.69
2434	CA125, EMILIN, *1, EGF, GMCSF, IL1RA	88.938
2435	CA125, EMILIN, *1, EGF, GMCSF, HE4	88.885
2436	CA125, EMILIN, *1, EGF, GMCSF, *2	88.903
2437	CA125, EMILIN, *1, EGF, IL1RA, HE4	88.707
2438	CA125, EMILIN, *1, EGF, IL1RA, *2	89.116
2439	CA125, EMILIN, *1, EGF, HE4, *2	88.494
2440	CA125, EMILIN, *1, GMCSF, IL1RA, HE4	89.595

2441	CA125, EMILIN, *1, GMCSF, IL1RA, *2	90.199
2442	CA125, EMILIN, *1, GMCSF, HE4, *2	89.879
2443	CA125, EMILIN, *1, IL1RA, HE4, *2	90.021
2444	CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	87.979
2445	CA125, EMILIN, EGF, GMCSF, IL1RA, *2	88.033
2446	CA125, EMILIN, EGF, GMCSF, HE4, *2	87.607
2447	CA125, EMILIN, EGF, IL1RA, HE4, *2	87.997
2448	CA125, EMILIN, GMCSF, IL1RA, HE4, *2	89.205
2449	CA125, MDK, *1, EGF, GMCSF, IL1RA	90.341
2450	CA125, MDK, *1, EGF, GMCSF, HE4	90.27
2451	CA125, MDK, *1, EGF, GMCSF, *2	90.341
2452	CA125, MDK, *1, EGF, IL1RA, HE4	90.376
2453	CA125, MDK, *1, EGF, IL1RA, *2	90.767
2454	CA125, MDK, *1, EGF, HE4, *2	89.702
2455	CA125, MDK, *1, GMCSF, IL1RA, HE4	90.732
2456	CA125, MDK, *1, GMCSF, IL1RA, *2	90.696
2457	CA125, MDK, *1, GMCSF, HE4, *2	90.856
2458	CA125, MDK, *1, IL1RA, HE4, *2	90.518
2459	CA125, MDK, EGF, GMCSF, IL1RA, HE4	88.459
2460	CA125, MDK, EGF, GMCSF, IL1RA, *2	89.063
2461	CA125, MDK, EGF, GMCSF, HE4, *2	87.926
2462	CA125, MDK, EGF, IL1RA, HE4, *2	89.116
2463	CA125, MDK, GMCSF, IL1RA, HE4, *2	88.459
2464	CA125, *1, EGF, GMCSF, IL1RA, HE4	84.197
2465	CA125, *1, EGF, GMCSF, IL1RA, *2	84.766
2466	CA125, *1, EGF, GMCSF, HE4, *2	83.487
2467	CA125, *1, EGF, IL1RA, HE4, *2	84.357
2468	CA125, *1, GMCSF, IL1RA, HE4, *2	84.73
2469	CA125, EGF, GMCSF, IL1RA, HE4, *2	82.138
2470	EMILIN, MDK, *1, EGF, GMCSF, IL1RA	83.629
2471	EMILIN, MDK, *1, EGF, GMCSF, HE4	83.594
2472	EMILIN, MDK, *1, EGF, GMCSF, *2	84.233

2473	EMILIN, MDK, *1, EGF, IL1RA, HE4	83.665
2474	EMILIN, MDK, *1, EGF, IL1RA, *2	84.588
2475	EMILIN, MDK, *1, EGF, HE4, *2	84.091
2476	EMILIN, MDK, *1, GMCSF, IL1RA, HE4	84.162
2477	EMILIN, MDK, *1, GMCSF, IL1RA, *2	84.411
2478	EMILIN, MDK, *1, GMCSF, HE4, *2	84.783
2479	EMILIN, MDK, *1, IL1RA, HE4, *2	84.482
2480	EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	79.048
2481	EMILIN, MDK, EGF, GMCSF, IL1RA, *2	80.842
2482	EMILIN, MDK, EGF, GMCSF, HE4, *2	80.114
2483	EMILIN, MDK, EGF, IL1RA, HE4, *2	79.936
2484	EMILIN, MDK, GMCSF, IL1RA, HE4, *2	81.499
2485	EMILIN, *1, EGF, GMCSF, IL1RA, HE4	76.349
2486	EMILIN, *1, EGF, GMCSF, IL1RA, *2	76.864
2487	EMILIN, *1, EGF, GMCSF, HE4, *2	75.888
2488	EMILIN, *1, EGF, IL1RA, HE4, *2	76.598
2489	EMILIN, *1, GMCSF, IL1RA, HE4, *2	79.084
2490	EMILIN, EGF, GMCSF, IL1RA, HE4, *2	71.982
2491	MDK, *1, EGF, GMCSF, IL1RA, HE4	78.8
2492	MDK, *1, EGF, GMCSF, IL1RA, *2	79.936
2493	MDK, *1, EGF, GMCSF, HE4, *2	80.398
2494	MDK, *1, EGF, IL1RA, HE4, *2	78.871
2495	MDK, *1, GMCSF, IL1RA, HE4, *2	79.599
2496	MDK, EGF, GMCSF, IL1RA, HE4, *2	72.55
2497	*1, EGF, GMCSF, IL1RA, HE4, *2	62.979
2498	ips, mps, dps, CA125, EMILIN, MDK, *1	98.58
2499	ips, mps, dps, CA125, EMILIN, MDK, EGF	98.544
2500	ips, mps, dps, CA125, EMILIN, MDK, GMCSF	98.544
2501	ips, mps, dps, CA125, EMILIN, MDK, IL1RA	98.686
2502	ips, mps, dps, CA125, EMILIN, MDK, HE4	98.615
2503	ips, mps, dps, CA125, EMILIN, MDK, *2	98.544
2504	ips, mps, dps, CA125, EMILIN, *1, EGF	98.295

2505	ips, mps, dps, CA125, EMILIN, *1, GMCSF	98.295
2506	ips, mps, dps, CA125, EMILIN, *1, IL1RA	98.438
2507	ips, mps, dps, CA125, EMILIN, *1, HE4	98.402
2508	ips, mps, dps, CA125, EMILIN, *1, *2	98.544
2509	ips, mps, dps, CA125, EMILIN, EGF, GMCSF	98.153
2510	ips, mps, dps, CA125, EMILIN, EGF, IL1RA	98.242
2511	ips, mps, dps, CA125, EMILIN, EGF, HE4	98.438
2512	ips, mps, dps, CA125, EMILIN, EGF, *2	98.295
2513	ips, mps, dps, CA125, EMILIN, GMCSF, IL1RA	98.26
2514	ips, mps, dps, CA125, EMILIN, GMCSF, HE4	98.26
2515	ips, mps, dps, CA125, EMILIN, GMCSF, *2	98.295
2516	ips, mps, dps, CA125, EMILIN, IL1RA, HE4	98.509
2517	ips, mps, dps, CA125, EMILIN, IL1RA, *2	98.438
2518	ips, mps, dps, CA125, EMILIN, HE4, *2	98.509
2519	ips, mps, dps, CA125, MDK, *1, EGF	98.047
2520	ips, mps, dps, CA125, MDK, *1, GMCSF	97.976
2521	ips, mps, dps, CA125, MDK, *1, IL1RA	98.118
2522	ips, mps, dps, CA125, MDK, *1, HE4	98.082
2523	ips, mps, dps, CA125, MDK, *1, *2	98.082
2524	ips, mps, dps, CA125, MDK, EGF, GMCSF	97.976
2525	ips, mps, dps, CA125, MDK, EGF, IL1RA	98.047
2526	ips, mps, dps, CA125, MDK, EGF, HE4	98.295
2527	ips, mps, dps, CA125, MDK, EGF, *2	98.011
2528	ips, mps, dps, CA125, MDK, GMCSF, IL1RA	97.869
2529	ips, mps, dps, CA125, MDK, GMCSF, HE4	98.047
2530	ips, mps, dps, CA125, MDK, GMCSF, *2	98.011
2531	ips, mps, dps, CA125, MDK, IL1RA, HE4	97.976

2532	ips, mps, dps, CA125, MDK, IL1RA, *2	97.905
2533	ips, mps, dps, CA125, MDK, HE4, *2	97.976
2534	ips, mps, dps, CA125, *1, EGF, GMCSF	97.053
2535	ips, mps, dps, CA125, *1, EGF, IL1RA	97.301
2536	ips, mps, dps, CA125, *1, EGF, HE4	97.479
2537	ips, mps, dps, CA125, *1, EGF, *2	97.408
2538	ips, mps, dps, CA125, *1, GMCSF, IL1RA	97.23
2539	ips, mps, dps, CA125, *1, GMCSF, HE4	96.982
2540	ips, mps, dps, CA125, *1, GMCSF, *2	96.982
2541	ips, mps, dps, CA125, *1, IL1RA, HE4	97.372
2542	ips, mps, dps, CA125, *1, IL1RA, *2	97.372
2543	ips, mps, dps, CA125, *1, HE4, *2	97.159
2544	ips, mps, dps, CA125, EGF, GMCSF, IL1RA	97.159
2545	ips, mps, dps, CA125, EGF, GMCSF, HE4	97.159
2546	ips, mps, dps, CA125, EGF, GMCSF, *2	96.839
2547	ips, mps, dps, CA125, EGF, IL1RA, HE4	97.337
2548	ips, mps, dps, CA125, EGF, IL1RA, *2	97.124
2549	ips, mps, dps, CA125, EGF, HE4, *2	97.55
2550	ips, mps, dps, CA125, GMCSF, IL1RA, HE4	97.195
2551	ips, mps, dps, CA125, GMCSF, IL1RA, *2	96.911
2552	ips, mps, dps, CA125, GMCSF, HE4, *2	97.07
2553	ips, mps, dps, CA125, IL1RA, HE4, *2	97.23
2554	ips, mps, dps, EMILIN, MDK, *1, EGF	96.36
2555	ips, mps, dps, EMILIN, MDK, *1, GMCSF	96.378
2556	ips, mps, dps, EMILIN, MDK, *1, IL1RA	97.195
2557	ips, mps, dps, EMILIN, MDK, *1, HE4	96.484
2558	ips, mps, dps, EMILIN, MDK, *1, *2	96.626
2559	ips, mps, dps, EMILIN, MDK, EGF, GMCSF	96.413
2560	ips, mps, dps, EMILIN, MDK, EGF, *2	97.159

	IL1RA	
2561	ips, mps, dps, EMILIN, MDK, EGF, HE4	96.271
2562	ips, mps, dps, EMILIN, MDK, EGF, *2	96.342
2563	ips, mps, dps, EMILIN, MDK, GMCSF, IL1RA	97.23
2564	ips, mps, dps, EMILIN, MDK, GMCSF, HE4	96.147
2565	ips, mps, dps, EMILIN, MDK, GMCSF, *2	96.165
2566	ips, mps, dps, EMILIN, MDK, IL1RA, HE4	97.266
2567	ips, mps, dps, EMILIN, MDK, IL1RA, *2	97.124
2568	ips, mps, dps, EMILIN, MDK, HE4, *2	96.254
2569	ips, mps, dps, EMILIN, *1, EGF, GMCSF	95.313
2570	ips, mps, dps, EMILIN, *1, EGF, IL1RA	96.449
2571	ips, mps, dps, EMILIN, *1, EGF, HE4	95.561
2572	ips, mps, dps, EMILIN, *1, EGF, *2	95.916
2573	ips, mps, dps, EMILIN, *1, GMCSF, IL1RA	96.626
2574	ips, mps, dps, EMILIN, *1, GMCSF, HE4	95.455
2575	ips, mps, dps, EMILIN, *1, GMCSF, *2	95.703
2576	ips, mps, dps, EMILIN, *1, IL1RA, HE4	96.804
2577	ips, mps, dps, EMILIN, *1, IL1RA, *2	96.768
2578	ips, mps, dps, EMILIN, *1, HE4, *2	95.721
2579	ips, mps, dps, EMILIN, EGF, GMCSF, IL1RA	96.662
2580	ips, mps, dps, EMILIN, EGF, GMCSF, HE4	95.384
2581	ips, mps, dps, EMILIN, EGF, GMCSF, *2	95.028
2582	ips, mps, dps, EMILIN, EGF, IL1RA, HE4	96.839
2583	ips, mps, dps, EMILIN, EGF, IL1RA, *2	96.449
2584	ips, mps, dps, EMILIN, EGF, HE4, *2	95.277
2585	ips, mps, dps, EMILIN, GMCSF, IL1RA, HE4	96.626
2586	ips, mps, dps, EMILIN, GMCSF, IL1RA, *2	96.52
2587	ips, mps, dps, EMILIN, GMCSF, HE4, *2	95.224

2588	ips, mps, dps, EMILIN, IL1RA, HE4, *2	96.484
2589	ips, mps, dps, MDK, *1, EGF, GMCSF	95.739
2590	ips, mps, dps, MDK, *1, EGF, IL1RA	96.129
2591	ips, mps, dps, MDK, *1, EGF, HE4	95.419
2592	ips, mps, dps, MDK, *1, EGF, *2	95.668
2593	ips, mps, dps, MDK, *1, GMCSF, IL1RA	96.183
2594	ips, mps, dps, MDK, *1, GMCSF, HE4	95.49
2595	ips, mps, dps, MDK, *1, GMCSF, *2	95.916
2596	ips, mps, dps, MDK, *1, IL1RA, HE4	96.094
2597	ips, mps, dps, MDK, *1, IL1RA, *2	96.271
2598	ips, mps, dps, MDK, *1, HE4, *2	95.774
2599	ips, mps, dps, MDK, EGF, GMCSF, IL1RA	95.561
2600	ips, mps, dps, MDK, EGF, GMCSF, HE4	94.922
2601	ips, mps, dps, MDK, EGF, GMCSF, *2	95.064
2602	ips, mps, dps, MDK, EGF, IL1RA, HE4	95.632
2603	ips, mps, dps, MDK, EGF, IL1RA, *2	95.774
2604	ips, mps, dps, MDK, EGF, HE4, *2	95.241
2605	ips, mps, dps, MDK, GMCSF, IL1RA, HE4	95.668
2606	ips, mps, dps, MDK, GMCSF, IL1RA, *2	95.703
2607	ips, mps, dps, MDK, GMCSF, HE4, *2	94.957
2608	ips, mps, dps, MDK, IL1RA, HE4, *2	95.987
2609	ips, mps, dps, *1, EGF, GMCSF, IL1RA	94.034
2610	ips, mps, dps, *1, EGF, GMCSF, HE4	93.146
2611	ips, mps, dps, *1, EGF, GMCSF, *2	93.608
2612	ips, mps, dps, *1, EGF, IL1RA, HE4	94.034
2613	ips, mps, dps, *1, EGF, IL1RA, *2	94.638
2614	ips, mps, dps, *1, EGF, HE4, *2	93.501
2615	ips, mps, dps, *1, GMCSF, IL1RA, HE4	93.786
2616	ips, mps, dps, *1, GMCSF, IL1RA, *2	94.07
2617	ips, mps, dps, *1, GMCSF, HE4, *2	93.892
2618	ips, mps, dps, *1, IL1RA, HE4, *2	94.247
2619	ips, mps, dps, EGF, GMCSF, IL1RA, HE4	93.928
2620	ips, mps, dps, EGF, GMCSF, *2	93.786

	IL1RA, *2	
2621	ips, mps, dps, EGF, GMCSF, HE4, *2	92.72
2622	ips, mps, dps, EGF, IL1RA, HE4, *2	93.608
2623	ips, mps, dps, GMCSF, IL1RA, HE4, *2	93.608
2624	ips, mps, CA125, EMILIN, MDK, *1, EGF	98.757
2625	ips, mps, CA125, EMILIN, MDK, *1, GMCSF	98.651
2626	ips, mps, CA125, EMILIN, MDK, *1, IL1RA	98.935
2627	ips, mps, CA125, EMILIN, MDK, *1, HE4	98.828
2628	ips, mps, CA125, EMILIN, MDK, *1, *2	98.828
2629	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF	98.793
2630	ips, mps, CA125, EMILIN, MDK, EGF, IL1RA	98.864
2631	ips, mps, CA125, EMILIN, MDK, EGF, HE4	98.828
2632	ips, mps, CA125, EMILIN, MDK, EGF, *2	98.864
2633	ips, mps, CA125, EMILIN, MDK, GMCSF, IL1RA	99.006
2634	ips, mps, CA125, EMILIN, MDK, GMCSF, HE4	98.828
2635	ips, mps, CA125, EMILIN, MDK, GMCSF, *2	98.828
2636	ips, mps, CA125, EMILIN, MDK, IL1RA, HE4	98.97
2637	ips, mps, CA125, EMILIN, MDK, IL1RA, *2	98.97
2638	ips, mps, CA125, EMILIN, MDK, HE4, *2	98.935
2639	ips, mps, CA125, EMILIN, *1, EGF, GMCSF	98.224
2640	ips, mps, CA125, EMILIN, *1, EGF, IL1RA	98.651
2641	ips, mps, CA125, EMILIN, *1, EGF, HE4	98.473
2642	ips, mps, CA125, EMILIN, *1, EGF, *2	98.509
2643	ips, mps, CA125, EMILIN, *1, GMCSF, IL1RA	98.615
2644	ips, mps, CA125, EMILIN, *1, GMCSF, HE4	98.366
2645	ips, mps, CA125, EMILIN, *1, GMCSF, *2	98.402
2646	ips, mps, CA125, EMILIN, *1, IL1RA, HE4	98.757
2647	ips, mps, CA125, EMILIN, *1,	98.651

	IL1RA, *2	
2648	ips, mps, CA125, EMILIN, *1, HE4, *2	98.757
2649	ips, mps, CA125, EMILIN, EGF, GMCSF, IL1RA	98.544
2650	ips, mps, CA125, EMILIN, EGF, GMCSF, HE4	98.473
2651	ips, mps, CA125, EMILIN, EGF, GMCSF, *2	98.295
2652	ips, mps, CA125, EMILIN, EGF, IL1RA, HE4	98.757
2653	ips, mps, CA125, EMILIN, EGF, IL1RA, *2	98.615
2654	ips, mps, CA125, EMILIN, EGF, HE4, *2	98.544
2655	ips, mps, CA125, EMILIN, GMCSF, IL1RA, HE4	98.81
2656	ips, mps, CA125, EMILIN, GMCSF, IL1RA, *2	98.473
2657	ips, mps, CA125, EMILIN, GMCSF, HE4, *2	98.473
2658	ips, mps, CA125, EMILIN, IL1RA, HE4, *2	98.722
2659	ips, mps, CA125, MDK, *1, EGF, GMCSF	98.438
2660	ips, mps, CA125, MDK, *1, EGF, IL1RA	98.509
2661	ips, mps, CA125, MDK, *1, EGF, HE4	98.295
2662	ips, mps, CA125, MDK, *1, EGF, *2	98.366
2663	ips, mps, CA125, MDK, *1, GMCSF, IL1RA	98.331
2664	ips, mps, CA125, MDK, *1, GMCSF, HE4	98.473
2665	ips, mps, CA125, MDK, *1, GMCSF, *2	98.366
2666	ips, mps, CA125, MDK, *1, IL1RA, HE4	98.473
2667	ips, mps, CA125, MDK, *1, IL1RA, *2	98.331
2668	ips, mps, CA125, MDK, *1, HE4, *2	98.26
2669	ips, mps, CA125, MDK, EGF, GMCSF, IL1RA	98.26
2670	ips, mps, CA125, MDK, EGF, GMCSF, HE4	98.438
2671	ips, mps, CA125, MDK, EGF, GMCSF, *2	98.331
2672	ips, mps, CA125, MDK, EGF, IL1RA, HE4	98.544
2673	ips, mps, CA125, MDK, EGF, IL1RA, *2	98.295
2674	ips, mps, CA125, MDK, EGF, HE4, *2	98.331

2675	ips, mps, CA125, MDK, GMCSF, IL1RA, HE4	98.295
2676	ips, mps, CA125, MDK, GMCSF, IL1RA, *2	98.153
2677	ips, mps, CA125, MDK, GMCSF, HE4, *2	98.295
2678	ips, mps, CA125, MDK, IL1RA, HE4, *2	98.224
2679	ips, mps, CA125, *1, EGF, GMCSF, IL1RA	97.372
2680	ips, mps, CA125, *1, EGF, GMCSF, HE4	97.23
2681	ips, mps, CA125, *1, EGF, GMCSF, *2	97.124
2682	ips, mps, CA125, *1, EGF, IL1RA, HE4	97.479
2683	ips, mps, CA125, *1, EGF, IL1RA, *2	97.55
2684	ips, mps, CA125, *1, EGF, HE4, *2	97.443
2685	ips, mps, CA125, *1, GMCSF, IL1RA, HE4	97.372
2686	ips, mps, CA125, *1, GMCSF, IL1RA, *2	97.053
2687	ips, mps, CA125, *1, GMCSF, HE4, *2	97.301
2688	ips, mps, CA125, *1, IL1RA, HE4, *2	97.55
2689	ips, mps, CA125, EGF, GMCSF, IL1RA, HE4	97.372
2690	ips, mps, CA125, EGF, GMCSF, IL1RA, *2	96.946
2691	ips, mps, CA125, EGF, GMCSF, HE4, *2	97.088
2692	ips, mps, CA125, EGF, IL1RA, HE4, *2	97.301
2693	ips, mps, CA125, GMCSF, IL1RA, HE4, *2	97.283
2694	ips, mps, EMILIN, MDK, *1, EGF, GMCSF	96.768
2695	ips, mps, EMILIN, MDK, *1, EGF, IL1RA	97.23
2696	ips, mps, EMILIN, MDK, *1, EGF, HE4	96.555
2697	ips, mps, EMILIN, MDK, *1, EGF, *2	97.053
2698	ips, mps, EMILIN, MDK, *1, GMCSF, IL1RA	97.159
2699	ips, mps, EMILIN, MDK, *1, GMCSF, HE4	96.236
2700	ips, mps, EMILIN, MDK, *1, GMCSF, *2	96.591
2701	ips, mps, EMILIN, MDK, *1, IL1RA, HE4	97.212

2702	ips, mps, EMILIN, MDK, *1, IL1RA, *2	97.195
2703	ips, mps, EMILIN, MDK, *1, HE4, *2	96.786
2704	ips, mps, EMILIN, MDK, EGF, GMCSF, IL1RA	97.017
2705	ips, mps, EMILIN, MDK, EGF, GMCSF, HE4	96.555
2706	ips, mps, EMILIN, MDK, EGF, GMCSF, *2	96.591
2707	ips, mps, EMILIN, MDK, EGF, IL1RA, HE4	97.337
2708	ips, mps, EMILIN, MDK, EGF, IL1RA, *2	97.159
2709	ips, mps, EMILIN, MDK, EGF, HE4, *2	96.342
2710	ips, mps, EMILIN, MDK, GMCSF, IL1RA, HE4	97.017
2711	ips, mps, EMILIN, MDK, GMCSF, IL1RA, *2	96.875
2712	ips, mps, EMILIN, MDK, GMCSF, HE4, *2	95.916
2713	ips, mps, EMILIN, MDK, IL1RA, HE4, *2	97.017
2714	ips, mps, EMILIN, *1, EGF, GMCSF, IL1RA	96.076
2715	ips, mps, EMILIN, *1, EGF, GMCSF, HE4	95.028
2716	ips, mps, EMILIN, *1, EGF, GMCSF, *2	95.419
2717	ips, mps, EMILIN, *1, EGF, IL1RA, HE4	96.928
2718	ips, mps, EMILIN, *1, EGF, IL1RA, *2	96.911
2719	ips, mps, EMILIN, *1, EGF, HE4, *2	95.49
2720	ips, mps, EMILIN, *1, GMCSF, IL1RA, HE4	96.626
2721	ips, mps, EMILIN, *1, GMCSF, IL1RA, *2	96.378
2722	ips, mps, EMILIN, *1, GMCSF, HE4, *2	95.348
2723	ips, mps, EMILIN, *1, IL1RA, HE4, *2	96.768
2724	ips, mps, EMILIN, EGF, GMCSF, IL1RA, HE4	96.662
2725	ips, mps, EMILIN, EGF, GMCSF, IL1RA, *2	96.52
2726	ips, mps, EMILIN, EGF, GMCSF, HE4, *2	94.531
2727	ips, mps, EMILIN, EGF, IL1RA, HE4, *2	96.697
2728	ips, mps, EMILIN, GMCSF, IL1RA, HE4, *2	96.271
2729	ips, mps, MDK, *1, EGF, GMCSF, *2	95.774

	IL1RA	
2730	ips, mps, MDK, *1, EGF, GMCSF, HE4	95.313
2731	ips, mps, MDK, *1, EGF, GMCSF, *2	95.81
2732	ips, mps, MDK, *1, EGF, IL1RA, HE4	95.81
2733	ips, mps, MDK, *1, EGF, IL1RA, *2	96.058
2734	ips, mps, MDK, *1, EGF, HE4, *2	95.561
2735	ips, mps, MDK, *1, GMCSF, IL1RA, HE4	95.455
2736	ips, mps, MDK, *1, GMCSF, IL1RA, *2	95.668
2737	ips, mps, MDK, *1, GMCSF, HE4, *2	95.206
2738	ips, mps, MDK, *1, IL1RA, HE4, *2	95.703
2739	ips, mps, MDK, EGF, GMCSF, IL1RA, HE4	95.632
2740	ips, mps, MDK, EGF, GMCSF, IL1RA, *2	95.241
2741	ips, mps, MDK, EGF, GMCSF, HE4, *2	94.549
2742	ips, mps, MDK, EGF, IL1RA, HE4, *2	95.561
2743	ips, mps, MDK, GMCSF, IL1RA, HE4, *2	94.851
2744	ips, mps, *1, EGF, GMCSF, IL1RA, HE4	93.04
2745	ips, mps, *1, EGF, GMCSF, IL1RA, *2	93.821
2746	ips, mps, *1, EGF, GMCSF, HE4, *2	92.507
2747	ips, mps, *1, EGF, IL1RA, HE4, *2	93.679
2748	ips, mps, *1, GMCSF, IL1RA, HE4, *2	93.288
2749	ips, mps, EGF, GMCSF, IL1RA, HE4, *2	93.04
2750	ips, dps, CA125, EMILIN, MDK, *1, EGF	97.567
2751	ips, dps, CA125, EMILIN, MDK, *1, GMCSF	97.372
2752	ips, dps, CA125, EMILIN, MDK, *1, IL1RA	97.798
2753	ips, dps, CA125, EMILIN, MDK, *1, HE4	97.337
2754	ips, dps, CA125, EMILIN, MDK, *1, *2	97.621
2755	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF	97.088
2756	ips, dps, CA125, EMILIN, MDK, EGF, IL1RA	97.372
2757	ips, dps, CA125, EMILIN, MDK, EGF, HE4	97.266

2758	ips, dps, CA125, EMILIN, MDK, EGF, *2	97.479
2759	ips, dps, CA125, EMILIN, MDK, GMCSF, IL1RA	97.195
2760	ips, dps, CA125, EMILIN, MDK, GMCSF, HE4	97.266
2761	ips, dps, CA125, EMILIN, MDK, GMCSF, *2	97.337
2762	ips, dps, CA125, EMILIN, MDK, IL1RA, HE4	97.443
2763	ips, dps, CA125, EMILIN, MDK, IL1RA, *2	97.621
2764	ips, dps, CA125, EMILIN, MDK, HE4, *2	97.514
2765	ips, dps, CA125, EMILIN, *1, EGF, GMCSF	96.129
2766	ips, dps, CA125, EMILIN, *1, EGF, IL1RA	96.839
2767	ips, dps, CA125, EMILIN, *1, EGF, HE4	96.342
2768	ips, dps, CA125, EMILIN, *1, EGF, *2	96.413
2769	ips, dps, CA125, EMILIN, *1, GMCSF, IL1RA	96.555
2770	ips, dps, CA125, EMILIN, *1, GMCSF, HE4	96.555
2771	ips, dps, CA125, EMILIN, *1, GMCSF, *2	96.52
2772	ips, dps, CA125, EMILIN, *1, IL1RA, HE4	96.946
2773	ips, dps, CA125, EMILIN, *1, IL1RA, *2	96.839
2774	ips, dps, CA125, EMILIN, *1, HE4, *2	96.768
2775	ips, dps, CA125, EMILIN, EGF, GMCSF, IL1RA	96.413
2776	ips, dps, CA125, EMILIN, EGF, GMCSF, HE4	96.555
2777	ips, dps, CA125, EMILIN, EGF, GMCSF, *2	96.094
2778	ips, dps, CA125, EMILIN, EGF, IL1RA, HE4	97.159
2779	ips, dps, CA125, EMILIN, EGF, IL1RA, *2	97.124
2780	ips, dps, CA125, EMILIN, EGF, HE4, *2	96.697
2781	ips, dps, CA125, EMILIN, GMCSF, IL1RA, HE4	96.768
2782	ips, dps, CA125, EMILIN, GMCSF, IL1RA, *2	96.591
2783	ips, dps, CA125, EMILIN, GMCSF, HE4, *2	96.733
2784	ips, dps, CA125, EMILIN, IL1RA, *2	97.195

	HE4, *2	
2785	ips, dps, CA125, MDK, *1, EGF, GMCSF	97.337
2786	ips, dps, CA125, MDK, *1, EGF, IL1RA	97.124
2787	ips, dps, CA125, MDK, *1, EGF, HE4	96.982
2788	ips, dps, CA125, MDK, *1, EGF, *2	97.159
2789	ips, dps, CA125, MDK, *1, GMCSF, IL1RA	97.408
2790	ips, dps, CA125, MDK, *1, GMCSF, HE4	97.195
2791	ips, dps, CA125, MDK, *1, GMCSF, *2	97.354
2792	ips, dps, CA125, MDK, *1, IL1RA, HE4	96.982
2793	ips, dps, CA125, MDK, *1, IL1RA, *2	97.212
2794	ips, dps, CA125, MDK, *1, HE4, *2	96.875
2795	ips, dps, CA125, MDK, EGF, GMCSF, IL1RA	97.159
2796	ips, dps, CA125, MDK, EGF, GMCSF, HE4	96.946
2797	ips, dps, CA125, MDK, EGF, GMCSF, *2	97.195
2798	ips, dps, CA125, MDK, EGF, IL1RA, HE4	96.768
2799	ips, dps, CA125, MDK, EGF, IL1RA, *2	96.946
2800	ips, dps, CA125, MDK, EGF, HE4, *2	96.804
2801	ips, dps, CA125, MDK, GMCSF, IL1RA, HE4	96.662
2802	ips, dps, CA125, MDK, GMCSF, IL1RA, *2	96.911
2803	ips, dps, CA125, MDK, GMCSF, HE4, *2	96.697
2804	ips, dps, CA125, MDK, IL1RA, HE4, *2	96.626
2805	ips, dps, CA125, *1, EGF, GMCSF, IL1RA	96.058
2806	ips, dps, CA125, *1, EGF, GMCSF, HE4	96.094
2807	ips, dps, CA125, *1, EGF, GMCSF, *2	96.342
2808	ips, dps, CA125, *1, EGF, IL1RA, HE4	96.378
2809	ips, dps, CA125, *1, EGF, IL1RA, *2	96.378
2810	ips, dps, CA125, *1, EGF, HE4, *2	95.881
2811	ips, dps, CA125, *1, GMCSF, IL1RA, HE4	95.739
2812	ips, dps, CA125, *1, GMCSF,	95.916

	IL1RA, *2	
2813	ips, dps, CA125, *1, GMCSF, HE4, *2	95.81
2814	ips, dps, CA125, *1, IL1RA, HE4, *2	95.384
2815	ips, dps, CA125, EGF, GMCSF, IL1RA, HE4	96.2
2816	ips, dps, CA125, EGF, GMCSF, IL1RA, *2	95.987
2817	ips, dps, CA125, EGF, GMCSF, HE4, *2	95.916
2818	ips, dps, CA125, EGF, IL1RA, HE4, *2	95.952
2819	ips, dps, CA125, GMCSF, IL1RA, HE4, *2	95.597
2820	ips, dps, EMILIN, MDK, *1, EGF, GMCSF	93.999
2821	ips, dps, EMILIN, MDK, *1, EGF, IL1RA	93.999
2822	ips, dps, EMILIN, MDK, *1, EGF, HE4	93.697
2823	ips, dps, EMILIN, MDK, *1, EGF, *2	94.034
2824	ips, dps, EMILIN, MDK, *1, GMCSF, IL1RA	94.283
2825	ips, dps, EMILIN, MDK, *1, GMCSF, HE4	94.212
2826	ips, dps, EMILIN, MDK, *1, GMCSF, *2	94.141
2827	ips, dps, EMILIN, MDK, *1, IL1RA, HE4	94.389
2828	ips, dps, EMILIN, MDK, *1, IL1RA, *2	94.567
2829	ips, dps, EMILIN, MDK, *1, HE4, *2	94.389
2830	ips, dps, EMILIN, MDK, EGF, GMCSF, IL1RA	92.862
2831	ips, dps, EMILIN, MDK, EGF, GMCSF, HE4	92.56
2832	ips, dps, EMILIN, MDK, EGF, GMCSF, *2	93.146
2833	ips, dps, EMILIN, MDK, EGF, IL1RA, HE4	92.862
2834	ips, dps, EMILIN, MDK, EGF, IL1RA, *2	93.572
2835	ips, dps, EMILIN, MDK, EGF, HE4, *2	93.04
2836	ips, dps, EMILIN, MDK, GMCSF, IL1RA, HE4	93.466
2837	ips, dps, EMILIN, MDK, GMCSF, IL1RA, *2	94.141
2838	ips, dps, EMILIN, MDK, GMCSF, HE4, *2	93.271
2839	ips, dps, EMILIN, MDK, IL1RA, HE4, *2	93.679
2840	ips, dps, EMILIN, *1, EGF, GMCSF,	92.738

	IL1RA	
2841	ips, dps, EMILIN, *1, EGF, GMCSF, HE4	92.33
2842	ips, dps, EMILIN, *1, EGF, GMCSF, *2	92.543
2843	ips, dps, EMILIN, *1, EGF, IL1RA, HE4	93.324
2844	ips, dps, EMILIN, *1, EGF, IL1RA, *2	93.501
2845	ips, dps, EMILIN, *1, EGF, HE4, *2	92.969
2846	ips, dps, EMILIN, *1, GMCSF, IL1RA, HE4	93.271
2847	ips, dps, EMILIN, *1, GMCSF, IL1RA, *2	93.466
2848	ips, dps, EMILIN, *1, GMCSF, HE4, *2	93.075
2849	ips, dps, EMILIN, *1, IL1RA, HE4, *2	93.608
2850	ips, dps, EMILIN, EGF, GMCSF, IL1RA, HE4	91.442
2851	ips, dps, EMILIN, EGF, GMCSF, IL1RA, *2	91.69
2852	ips, dps, EMILIN, EGF, GMCSF, HE4, *2	91.211
2853	ips, dps, EMILIN, EGF, IL1RA, HE4, *2	91.832
2854	ips, dps, EMILIN, GMCSF, IL1RA, HE4, *2	92.756
2855	ips, dps, MDK, *1, EGF, GMCSF, IL1RA	94.567
2856	ips, dps, MDK, *1, EGF, GMCSF, HE4	93.963
2857	ips, dps, MDK, *1, EGF, GMCSF, *2	94.176
2858	ips, dps, MDK, *1, EGF, IL1RA, HE4	93.608
2859	ips, dps, MDK, *1, EGF, IL1RA, *2	94.034
2860	ips, dps, MDK, *1, EGF, HE4, *2	93.501
2861	ips, dps, MDK, *1, GMCSF, IL1RA, HE4	94.318
2862	ips, dps, MDK, *1, GMCSF, IL1RA, *2	94.531
2863	ips, dps, MDK, *1, GMCSF, HE4, *2	93.963
2864	ips, dps, MDK, *1, IL1RA, HE4, *2	93.359
2865	ips, dps, MDK, EGF, GMCSF, IL1RA, HE4	92.01
2866	ips, dps, MDK, EGF, GMCSF, IL1RA, *2	93.04
2867	ips, dps, MDK, EGF, GMCSF, HE4, *2	92.507
2868	ips, dps, MDK, EGF, IL1RA, HE4, *2	92.028
2869	ips, dps, MDK, GMCSF, IL1RA,	92.543

	HE4, *2	
2870	ips, dps, *1, EGF, GMCSF, IL1RA, HE4	91.761
2871	ips, dps, *1, EGF, GMCSF, IL1RA, *2	91.619
2872	ips, dps, *1, EGF, GMCSF, HE4, *2	91.442
2873	ips, dps, *1, EGF, IL1RA, HE4, *2	91.158
2874	ips, dps, *1, GMCSF, IL1RA, HE4, *2	90.909
2875	ips, dps, EGF, GMCSF, IL1RA, HE4, *2	90.021
2876	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF	96.697
2877	ips, CA125, EMILIN, MDK, *1, EGF, IL1RA	97.124
2878	ips, CA125, EMILIN, MDK, *1, EGF, HE4	96.946
2879	ips, CA125, EMILIN, MDK, *1, EGF, *2	97.124
2880	ips, CA125, EMILIN, MDK, *1, GMCSF, IL1RA	96.733
2881	ips, CA125, EMILIN, MDK, *1, GMCSF, HE4	96.928
2882	ips, CA125, EMILIN, MDK, *1, GMCSF, *2	96.982
2883	ips, CA125, EMILIN, MDK, *1, IL1RA, HE4	97.053
2884	ips, CA125, EMILIN, MDK, *1, IL1RA, *2	97.266
2885	ips, CA125, EMILIN, MDK, *1, HE4, *2	97.088
2886	ips, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	96.662
2887	ips, CA125, EMILIN, MDK, EGF, GMCSF, HE4	96.626
2888	ips, CA125, EMILIN, MDK, EGF, GMCSF, *2	96.413
2889	ips, CA125, EMILIN, MDK, EGF, IL1RA, HE4	96.697
2890	ips, CA125, EMILIN, MDK, EGF, IL1RA, *2	96.839
2891	ips, CA125, EMILIN, MDK, EGF, HE4, *2	96.662
2892	ips, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	96.697
2893	ips, CA125, EMILIN, MDK, GMCSF, IL1RA, *2	96.733
2894	ips, CA125, EMILIN, MDK, GMCSF, HE4, *2	96.804
2895	ips, CA125, EMILIN, MDK, IL1RA, HE4, *2	96.875
2896	ips, CA125, EMILIN, *1, EGF, GMCSF, IL1RA	95.17

2897	ips, CA125, EMILIN, *1, EGF, GMCSF, HE4	94.957
2898	ips, CA125, EMILIN, *1, EGF, GMCSF, *2	95.241
2899	ips, CA125, EMILIN, *1, EGF, IL1RA, HE4	95.277
2900	ips, CA125, EMILIN, *1, EGF, IL1RA, *2	95.721
2901	ips, CA125, EMILIN, *1, EGF, HE4, *2	95.384
2902	ips, CA125, EMILIN, *1, GMCSF, IL1RA, HE4	95.721
2903	ips, CA125, EMILIN, *1, GMCSF, IL1RA, *2	95.739
2904	ips, CA125, EMILIN, *1, GMCSF, HE4, *2	95.632
2905	ips, CA125, EMILIN, *1, IL1RA, HE4, *2	95.916
2906	ips, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	95.206
2907	ips, CA125, EMILIN, EGF, GMCSF, IL1RA, *2	95.17
2908	ips, CA125, EMILIN, EGF, GMCSF, HE4, *2	95.455
2909	ips, CA125, EMILIN, EGF, IL1RA, HE4, *2	95.348
2910	ips, CA125, EMILIN, GMCSF, IL1RA, HE4, *2	95.703
2911	ips, CA125, MDK, *1, EGF, GMCSF, IL1RA	96.911
2912	ips, CA125, MDK, *1, EGF, GMCSF, HE4	96.804
2913	ips, CA125, MDK, *1, EGF, GMCSF, *2	96.804
2914	ips, CA125, MDK, *1, EGF, IL1RA, HE4	96.591
2915	ips, CA125, MDK, *1, EGF, IL1RA, *2	96.733
2916	ips, CA125, MDK, *1, EGF, HE4, *2	96.307
2917	ips, CA125, MDK, *1, GMCSF, IL1RA, HE4	96.911
2918	ips, CA125, MDK, *1, GMCSF, IL1RA, *2	96.768
2919	ips, CA125, MDK, *1, GMCSF, HE4, *2	96.768
2920	ips, CA125, MDK, *1, IL1RA, HE4, *2	96.555
2921	ips, CA125, MDK, EGF, GMCSF, IL1RA, HE4	96.555
2922	ips, CA125, MDK, EGF, GMCSF, IL1RA, *2	96.449
2923	ips, CA125, MDK, EGF, GMCSF, HE4, *2	96.094

2924	ips, CA125, MDK, EGF, IL1RA, HE4, *2	96.2
2925	ips, CA125, MDK, GMCSF, IL1RA, HE4, *2	96.307
2926	ips, CA125, *1, EGF, GMCSF, IL1RA, HE4	94.389
2927	ips, CA125, *1, EGF, GMCSF, IL1RA, *2	94.247
2928	ips, CA125, *1, EGF, GMCSF, HE4, *2	94.425
2929	ips, CA125, *1, EGF, IL1RA, HE4, *2	93.981
2930	ips, CA125, *1, GMCSF, IL1RA, HE4, *2	94.46
2931	ips, CA125, EGF, GMCSF, IL1RA, HE4, *2	94.034
2932	ips, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	91.903
2933	ips, EMILIN, MDK, *1, EGF, GMCSF, HE4	91.868
2934	ips, EMILIN, MDK, *1, EGF, GMCSF, *2	91.761
2935	ips, EMILIN, MDK, *1, EGF, IL1RA, HE4	91.797
2936	ips, EMILIN, MDK, *1, EGF, IL1RA, *2	91.797
2937	ips, EMILIN, MDK, *1, EGF, HE4, *2	92.01
2938	ips, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	92.436
2939	ips, EMILIN, MDK, *1, GMCSF, IL1RA, *2	91.903
2940	ips, EMILIN, MDK, *1, GMCSF, HE4, *2	92.116
2941	ips, EMILIN, MDK, *1, IL1RA, HE4, *2	92.276
2942	ips, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	90.927
2943	ips, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	90.625
2944	ips, EMILIN, MDK, EGF, GMCSF, HE4, *2	90.057
2945	ips, EMILIN, MDK, EGF, IL1RA, HE4, *2	90.554
2946	ips, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	91.193
2947	ips, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	88.849
2948	ips, EMILIN, *1, EGF, GMCSF, IL1RA, *2	88.228
2949	ips, EMILIN, *1, EGF, GMCSF, HE4, *2	88.033
2950	ips, EMILIN, *1, EGF, IL1RA, HE4, *2	88.317

	*2	
2951	ips, EMILIN, *1, GMCSF, IL1RA, HE4, *2	89.808
2952	ips, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	86.47
2953	ips, MDK, *1, EGF, GMCSF, IL1RA, HE4	91.158
2954	ips, MDK, *1, EGF, GMCSF, IL1RA, *2	91.264
2955	ips, MDK, *1, EGF, GMCSF, HE4, *2	91.229
2956	ips, MDK, *1, EGF, IL1RA, HE4, *2	90.447
2957	ips, MDK, *1, GMCSF, IL1RA, HE4, *2	91.442
2958	ips, MDK, EGF, GMCSF, IL1RA, HE4, *2	88.388
2959	ips, *1, EGF, GMCSF, IL1RA, HE4, *2	85.387
2960	mps, dps, CA125, EMILIN, MDK, *1, EGF	97.869
2961	mps, dps, CA125, EMILIN, MDK, *1, GMCSF	97.834
2962	mps, dps, CA125, EMILIN, MDK, *1, IL1RA	98.118
2963	mps, dps, CA125, EMILIN, MDK, *1, HE4	98.118
2964	mps, dps, CA125, EMILIN, MDK, *1, *2	98.153
2965	mps, dps, CA125, EMILIN, MDK, EGF, GMCSF	97.656
2966	mps, dps, CA125, EMILIN, MDK, EGF, IL1RA	98.153
2967	mps, dps, CA125, EMILIN, MDK, EGF, HE4	97.798
2968	mps, dps, CA125, EMILIN, MDK, EGF, *2	97.798
2969	mps, dps, CA125, EMILIN, MDK, GMCSF, IL1RA	97.869
2970	mps, dps, CA125, EMILIN, MDK, GMCSF, HE4	97.834
2971	mps, dps, CA125, EMILIN, MDK, GMCSF, *2	97.798
2972	mps, dps, CA125, EMILIN, MDK, IL1RA, HE4	98.118
2973	mps, dps, CA125, EMILIN, MDK, IL1RA, *2	98.082
2974	mps, dps, CA125, EMILIN, MDK, HE4, *2	97.976
2975	mps, dps, CA125, EMILIN, *1, EGF, GMCSF	97.23
2976	mps, dps, CA125, EMILIN, *1, EGF, IL1RA	97.585
2977	mps, dps, CA125, EMILIN, *1, EGF, *2	97.301

	HE4	
2978	mps, dps, CA125, EMILIN, *1, EGF, *2	97.479
2979	mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA	97.479
2980	mps, dps, CA125, EMILIN, *1, GMCSF, HE4	97.195
2981	mps, dps, CA125, EMILIN, *1, GMCSF, *2	97.301
2982	mps, dps, CA125, EMILIN, *1, IL1RA, HE4	97.408
2983	mps, dps, CA125, EMILIN, *1, IL1RA, *2	97.621
2984	mps, dps, CA125, EMILIN, *1, HE4, *2	97.408
2985	mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA	97.23
2986	mps, dps, CA125, EMILIN, EGF, GMCSF, HE4	97.195
2987	mps, dps, CA125, EMILIN, EGF, GMCSF, *2	97.212
2988	mps, dps, CA125, EMILIN, EGF, IL1RA, HE4	97.55
2989	mps, dps, CA125, EMILIN, EGF, IL1RA, *2	97.656
2990	mps, dps, CA125, EMILIN, EGF, HE4, *2	97.408
2991	mps, dps, CA125, EMILIN, GMCSF, IL1RA, HE4	97.514
2992	mps, dps, CA125, EMILIN, GMCSF, IL1RA, *2	97.55
2993	mps, dps, CA125, EMILIN, GMCSF, HE4, *2	97.337
2994	mps, dps, CA125, EMILIN, IL1RA, HE4, *2	97.727
2995	mps, dps, CA125, MDK, *1, EGF, GMCSF	96.946
2996	mps, dps, CA125, MDK, *1, EGF, IL1RA	97.159
2997	mps, dps, CA125, MDK, *1, EGF, HE4	97.159
2998	mps, dps, CA125, MDK, *1, EGF, *2	97.053
2999	mps, dps, CA125, MDK, *1, GMCSF, IL1RA	96.946
3000	mps, dps, CA125, MDK, *1, GMCSF, HE4	96.911
3001	mps, dps, CA125, MDK, *1, GMCSF, *2	97.053
3002	mps, dps, CA125, MDK, *1, IL1RA, HE4	97.266
3003	mps, dps, CA125, MDK, *1, IL1RA, *2	97.23

3004	mps, dps, CA125, MDK, *1, HE4, *2	97.017
3005	mps, dps, CA125, MDK, EGF, GMCSF, IL1RA	96.982
3006	mps, dps, CA125, MDK, EGF, GMCSF, HE4	96.804
3007	mps, dps, CA125, MDK, EGF, GMCSF, *2	96.662
3008	mps, dps, CA125, MDK, EGF, IL1RA, HE4	97.195
3009	mps, dps, CA125, MDK, EGF, IL1RA, *2	97.053
3010	mps, dps, CA125, MDK, EGF, HE4, *2	96.768
3011	mps, dps, CA125, MDK, GMCSF, IL1RA, HE4	96.911
3012	mps, dps, CA125, MDK, GMCSF, IL1RA, *2	96.875
3013	mps, dps, CA125, MDK, GMCSF, HE4, *2	96.733
3014	mps, dps, CA125, MDK, IL1RA, HE4, *2	97.195
3015	mps, dps, CA125, *1, EGF, GMCSF, IL1RA	95.49
3016	mps, dps, CA125, *1, EGF, GMCSF, HE4	95.526
3017	mps, dps, CA125, *1, EGF, GMCSF, *2	95.348
3018	mps, dps, CA125, *1, EGF, IL1RA, HE4	95.881
3019	mps, dps, CA125, *1, EGF, IL1RA, *2	95.987
3020	mps, dps, CA125, *1, EGF, HE4, *2	95.881
3021	mps, dps, CA125, *1, GMCSF, IL1RA, HE4	95.526
3022	mps, dps, CA125, *1, GMCSF, IL1RA, *2	95.81
3023	mps, dps, CA125, *1, GMCSF, HE4, *2	95.313
3024	mps, dps, CA125, *1, IL1RA, HE4, *2	95.774
3025	mps, dps, CA125, EGF, GMCSF, IL1RA, HE4	95.703
3026	mps, dps, CA125, EGF, GMCSF, IL1RA, *2	95.668
3027	mps, dps, CA125, EGF, GMCSF, HE4, *2	95.455
3028	mps, dps, CA125, EGF, IL1RA, HE4, *2	96.023
3029	mps, dps, CA125, GMCSF, IL1RA, HE4, *2	95.419
3030	mps, dps, EMILIN, MDK, *1, EGF, GMCSF	95.614
3031	mps, dps, EMILIN, MDK, *1, EGF,	96.342

	IL1RA	
3032	mps, dps, EMILIN, MDK, *1, EGF, HE4	95.703
3033	mps, dps, EMILIN, MDK, *1, EGF, *2	95.952
3034	mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA	96.307
3035	mps, dps, EMILIN, MDK, *1, GMCSF, HE4	95.49
3036	mps, dps, EMILIN, MDK, *1, GMCSF, *2	95.916
3037	mps, dps, EMILIN, MDK, *1, IL1RA, HE4	96.307
3038	mps, dps, EMILIN, MDK, *1, IL1RA, *2	96.591
3039	mps, dps, EMILIN, MDK, *1, HE4, *2	96.236
3040	mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA	95.419
3041	mps, dps, EMILIN, MDK, EGF, GMCSF, HE4	94.638
3042	mps, dps, EMILIN, MDK, EGF, GMCSF, *2	94.851
3043	mps, dps, EMILIN, MDK, EGF, IL1RA, HE4	95.597
3044	mps, dps, EMILIN, MDK, EGF, IL1RA, *2	95.739
3045	mps, dps, EMILIN, MDK, EGF, HE4, *2	94.975
3046	mps, dps, EMILIN, MDK, GMCSF, IL1RA, HE4	95.739
3047	mps, dps, EMILIN, MDK, GMCSF, IL1RA, *2	96.058
3048	mps, dps, EMILIN, MDK, GMCSF, HE4, *2	95.099
3049	mps, dps, EMILIN, MDK, IL1RA, HE4, *2	96.449
3050	mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA	95.028
3051	mps, dps, EMILIN, *1, EGF, GMCSF, HE4	93.679
3052	mps, dps, EMILIN, *1, EGF, GMCSF, *2	94.709
3053	mps, dps, EMILIN, *1, EGF, IL1RA, HE4	95.597
3054	mps, dps, EMILIN, *1, EGF, IL1RA, *2	95.739
3055	mps, dps, EMILIN, *1, EGF, HE4, *2	94.602
3056	mps, dps, EMILIN, *1, GMCSF, IL1RA, HE4	95.597
3057	mps, dps, EMILIN, *1, GMCSF, IL1RA, *2	95.685

3058	mps, dps, EMILIN, *1, GMCSF, HE4, *2	94.638
3059	mps, dps, EMILIN, *1, IL1RA, HE4, *2	96.023
3060	mps, dps, EMILIN, EGF, GMCSF, IL1RA, HE4	94.709
3061	mps, dps, EMILIN, EGF, GMCSF, IL1RA, *2	94.744
3062	mps, dps, EMILIN, EGF, GMCSF, HE4, *2	93.253
3063	mps, dps, EMILIN, EGF, IL1RA, HE4, *2	95.277
3064	mps, dps, EMILIN, GMCSF, IL1RA, HE4, *2	95.277
3065	mps, dps, MDK, *1, EGF, GMCSF, IL1RA	94.567
3066	mps, dps, MDK, *1, EGF, GMCSF, HE4	93.714
3067	mps, dps, MDK, *1, EGF, GMCSF, *2	94.638
3068	mps, dps, MDK, *1, EGF, IL1RA, HE4	94.673
3069	mps, dps, MDK, *1, EGF, IL1RA, *2	95.064
3070	mps, dps, MDK, *1, EGF, HE4, *2	94.46
3071	mps, dps, MDK, *1, GMCSF, IL1RA, HE4	94.744
3072	mps, dps, MDK, *1, GMCSF, IL1RA, *2	95.17
3073	mps, dps, MDK, *1, GMCSF, HE4, *2	94.371
3074	mps, dps, MDK, *1, IL1RA, HE4, *2	95.099
3075	mps, dps, MDK, EGF, GMCSF, IL1RA, HE4	93.182
3076	mps, dps, MDK, EGF, GMCSF, IL1RA, *2	93.555
3077	mps, dps, MDK, EGF, GMCSF, HE4, *2	92.489
3078	mps, dps, MDK, EGF, IL1RA, HE4, *2	94.212
3079	mps, dps, MDK, GMCSF, IL1RA, HE4, *2	93.999
3080	mps, dps, *1, EGF, GMCSF, IL1RA, HE4	91.193
3081	mps, dps, *1, EGF, GMCSF, IL1RA, *2	91.69
3082	mps, dps, *1, EGF, GMCSF, HE4, *2	90.661
3083	mps, dps, *1, EGF, IL1RA, HE4, *2	92.045
3084	mps, dps, *1, GMCSF, IL1RA, HE4, *2	90.856
3085	mps, dps, EGF, GMCSF, IL1RA, HE4, *2	90.181
3086	mps, CA125, EMILIN, MDK, *1,	97.727

	EGF, GMCSF	
3087	mps, CA125, EMILIN, MDK, *1, EGF, IL1RA	97.976
3088	mps, CA125, EMILIN, MDK, *1, EGF, HE4	97.674
3089	mps, CA125, EMILIN, MDK, *1, EGF, *2	97.798
3090	mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA	97.94
3091	mps, CA125, EMILIN, MDK, *1, GMCSF, HE4	97.905
3092	mps, CA125, EMILIN, MDK, *1, GMCSF, *2	97.834
3093	mps, CA125, EMILIN, MDK, *1, IL1RA, HE4	98.047
3094	mps, CA125, EMILIN, MDK, *1, IL1RA, *2	98.082
3095	mps, CA125, EMILIN, MDK, *1, HE4, *2	98.082
3096	mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	97.301
3097	mps, CA125, EMILIN, MDK, EGF, GMCSF, HE4	97.638
3098	mps, CA125, EMILIN, MDK, EGF, GMCSF, *2	97.621
3099	mps, CA125, EMILIN, MDK, EGF, IL1RA, HE4	97.763
3100	mps, CA125, EMILIN, MDK, EGF, IL1RA, *2	97.55
3101	mps, CA125, EMILIN, MDK, EGF, HE4, *2	97.816
3102	mps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	97.798
3103	mps, CA125, EMILIN, MDK, GMCSF, IL1RA, *2	97.727
3104	mps, CA125, EMILIN, MDK, GMCSF, HE4, *2	97.834
3105	mps, CA125, EMILIN, MDK, IL1RA, HE4, *2	98.082
3106	mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA	97.088
3107	mps, CA125, EMILIN, *1, EGF, GMCSF, HE4	96.733
3108	mps, CA125, EMILIN, *1, EGF, GMCSF, *2	96.982
3109	mps, CA125, EMILIN, *1, EGF, IL1RA, HE4	97.124
3110	mps, CA125, EMILIN, *1, EGF, IL1RA, *2	97.23
3111	mps, CA125, EMILIN, *1, EGF, HE4, *2	97.017
3112	mps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4	97.283

3113	mps, CA125, EMILIN, *1, GMCSF, IL1RA, *2	97.514
3114	mps, CA125, EMILIN, *1, GMCSF, HE4, *2	97.07
3115	mps, CA125, EMILIN, *1, IL1RA, HE4, *2	97.372
3116	mps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	96.768
3117	mps, CA125, EMILIN, EGF, GMCSF, IL1RA, *2	97.017
3118	mps, CA125, EMILIN, EGF, GMCSF, HE4, *2	96.626
3119	mps, CA125, EMILIN, EGF, IL1RA, HE4, *2	97.017
3120	mps, CA125, EMILIN, GMCSF, IL1RA, HE4, *2	97.195
3121	mps, CA125, MDK, *1, EGF, GMCSF, IL1RA	96.697
3122	mps, CA125, MDK, *1, EGF, GMCSF, HE4	96.52
3123	mps, CA125, MDK, *1, EGF, GMCSF, *2	96.449
3124	mps, CA125, MDK, *1, EGF, IL1RA, HE4	96.662
3125	mps, CA125, MDK, *1, EGF, IL1RA, *2	96.591
3126	mps, CA125, MDK, *1, EGF, HE4, *2	96.555
3127	mps, CA125, MDK, *1, GMCSF, IL1RA, HE4	96.911
3128	mps, CA125, MDK, *1, GMCSF, IL1RA, *2	96.768
3129	mps, CA125, MDK, *1, GMCSF, HE4, *2	96.733
3130	mps, CA125, MDK, *1, IL1RA, HE4, *2	97.017
3131	mps, CA125, MDK, EGF, GMCSF, IL1RA, HE4	96.431
3132	mps, CA125, MDK, EGF, GMCSF, IL1RA, *2	96.165
3133	mps, CA125, MDK, EGF, GMCSF, HE4, *2	96.2
3134	mps, CA125, MDK, EGF, IL1RA, HE4, *2	96.538
3135	mps, CA125, MDK, GMCSF, IL1RA, HE4, *2	96.484
3136	mps, CA125, *1, EGF, GMCSF, IL1RA, HE4	94.602
3137	mps, CA125, *1, EGF, GMCSF, IL1RA, *2	94.744
3138	mps, CA125, *1, EGF, GMCSF, HE4, *2	94.531
3139	mps, CA125, *1, EGF, IL1RA, HE4, *2	94.709

	*2	
3140	mps, CA125, *1, GMCSF, IL1RA, HE4, *2	94.638
3141	mps, CA125, EGF, GMCSF, IL1RA, HE4, *2	94.531
3142	mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	95.277
3143	mps, EMILIN, MDK, *1, EGF, GMCSF, HE4	94.78
3144	mps, EMILIN, MDK, *1, EGF, GMCSF, *2	95.384
3145	mps, EMILIN, MDK, *1, EGF, IL1RA, HE4	95.703
3146	mps, EMILIN, MDK, *1, EGF, IL1RA, *2	95.561
3147	mps, EMILIN, MDK, *1, EGF, HE4, *2	95.614
3148	mps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	95.241
3149	mps, EMILIN, MDK, *1, GMCSF, IL1RA, *2	95.561
3150	mps, EMILIN, MDK, *1, GMCSF, HE4, *2	95.668
3151	mps, EMILIN, MDK, *1, IL1RA, HE4, *2	95.916
3152	mps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	94.034
3153	mps, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	94.318
3154	mps, EMILIN, MDK, EGF, GMCSF, HE4, *2	93.839
3155	mps, EMILIN, MDK, EGF, IL1RA, HE4, *2	94.567
3156	mps, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	94.531
3157	mps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	93.697
3158	mps, EMILIN, *1, EGF, GMCSF, IL1RA, *2	94.212
3159	mps, EMILIN, *1, EGF, GMCSF, HE4, *2	93.111
3160	mps, EMILIN, *1, EGF, IL1RA, HE4, *2	94.389
3161	mps, EMILIN, *1, GMCSF, IL1RA, HE4, *2	94.567
3162	mps, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	92.862
3163	mps, MDK, *1, EGF, GMCSF, IL1RA, HE4	93.572
3164	mps, MDK, *1, EGF, GMCSF, IL1RA, *2	93.963
3165	mps, MDK, *1, EGF, GMCSF, HE4, *2	93.537

3166	mps, MDK, *1, EGF, IL1RA, HE4, *2	94.034
3167	mps, MDK, *1, GMCSF, IL1RA, HE4, *2	93.999
3168	mps, MDK, EGF, GMCSF, IL1RA, HE4, *2	92.365
3169	mps, *1, EGF, GMCSF, IL1RA, HE4, *2	89.862
3170	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF	94.141
3171	dps, CA125, EMILIN, MDK, *1, EGF, IL1RA	94.638
3172	dps, CA125, EMILIN, MDK, *1, EGF, HE4	94.744
3173	dps, CA125, EMILIN, MDK, *1, EGF, *2	94.78
3174	dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA	94.691
3175	dps, CA125, EMILIN, MDK, *1, GMCSF, HE4	94.709
3176	dps, CA125, EMILIN, MDK, *1, GMCSF, *2	94.957
3177	dps, CA125, EMILIN, MDK, *1, IL1RA, HE4	94.815
3178	dps, CA125, EMILIN, MDK, *1, IL1RA, *2	95.099
3179	dps, CA125, EMILIN, MDK, *1, HE4, *2	95.206
3180	dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	93.857
3181	dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4	93.892
3182	dps, CA125, EMILIN, MDK, EGF, GMCSF, *2	94.389
3183	dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4	94.07
3184	dps, CA125, EMILIN, MDK, EGF, IL1RA, *2	94.638
3185	dps, CA125, EMILIN, MDK, EGF, HE4, *2	94.567
3186	dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	94.247
3187	dps, CA125, EMILIN, MDK, GMCSF, IL1RA, *2	94.531
3188	dps, CA125, EMILIN, MDK, GMCSF, HE4, *2	94.407
3189	dps, CA125, EMILIN, MDK, IL1RA, HE4, *2	94.709
3190	dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA	93.395
3191	dps, CA125, EMILIN, *1, EGF, GMCSF, HE4	92.756
3192	dps, CA125, EMILIN, *1, EGF,	93.466

	GMCSF, *2	
3193	dps, CA125, EMILIN, *1, EGF, IL1RA, HE4	93.501
3194	dps, CA125, EMILIN, *1, EGF, IL1RA, *2	93.821
3195	dps, CA125, EMILIN, *1, EGF, HE4, *2	93.537
3196	dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4	93.608
3197	dps, CA125, EMILIN, *1, GMCSF, IL1RA, *2	94.105
3198	dps, CA125, EMILIN, *1, GMCSF, HE4, *2	93.501
3199	dps, CA125, EMILIN, *1, IL1RA, HE4, *2	94.212
3200	dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	92.951
3201	dps, CA125, EMILIN, EGF, GMCSF, IL1RA, *2	93.395
3202	dps, CA125, EMILIN, EGF, GMCSF, HE4, *2	92.791
3203	dps, CA125, EMILIN, EGF, IL1RA, HE4, *2	93.608
3204	dps, CA125, EMILIN, GMCSF, IL1RA, HE4, *2	93.59
3205	dps, CA125, MDK, *1, EGF, GMCSF, IL1RA	94.744
3206	dps, CA125, MDK, *1, EGF, GMCSF, HE4	94.318
3207	dps, CA125, MDK, *1, EGF, GMCSF, *2	94.957
3208	dps, CA125, MDK, *1, EGF, IL1RA, HE4	94.602
3209	dps, CA125, MDK, *1, EGF, IL1RA, *2	95.028
3210	dps, CA125, MDK, *1, EGF, HE4, *2	94.638
3211	dps, CA125, MDK, *1, GMCSF, IL1RA, HE4	94.425
3212	dps, CA125, MDK, *1, GMCSF, IL1RA, *2	94.815
3213	dps, CA125, MDK, *1, GMCSF, HE4, *2	94.709
3214	dps, CA125, MDK, *1, IL1RA, HE4, *2	94.78
3215	dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4	93.75
3216	dps, CA125, MDK, EGF, GMCSF, IL1RA, *2	94.496
3217	dps, CA125, MDK, EGF, GMCSF, HE4, *2	93.75
3218	dps, CA125, MDK, EGF, IL1RA, HE4, *2	94.496

3219	dps, CA125, MDK, GMCSF, IL1RA, HE4, *2	93.768
3220	dps, CA125, *1, EGF, GMCSF, IL1RA, HE4	92.045
3221	dps, CA125, *1, EGF, GMCSF, IL1RA, *2	92.294
3222	dps, CA125, *1, EGF, GMCSF, HE4, *2	91.584
3223	dps, CA125, *1, EGF, IL1RA, HE4, *2	92.401
3224	dps, CA125, *1, GMCSF, IL1RA, HE4, *2	91.335
3225	dps, CA125, EGF, GMCSF, IL1RA, HE4, *2	91.797
3226	dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	90.572
3227	dps, EMILIN, MDK, *1, EGF, GMCSF, HE4	90.199
3228	dps, EMILIN, MDK, *1, EGF, GMCSF, *2	91.335
3229	dps, EMILIN, MDK, *1, EGF, IL1RA, HE4	90.643
3230	dps, EMILIN, MDK, *1, EGF, IL1RA, *2	91.797
3231	dps, EMILIN, MDK, *1, EGF, HE4, *2	91.655
3232	dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	91.016
3233	dps, EMILIN, MDK, *1, GMCSF, IL1RA, *2	91.726
3234	dps, EMILIN, MDK, *1, GMCSF, HE4, *2	92.081
3235	dps, EMILIN, MDK, *1, IL1RA, HE4, *2	92.223
3236	dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	87.145
3237	dps, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	89.276
3238	dps, EMILIN, MDK, EGF, GMCSF, HE4, *2	88.228
3239	dps, EMILIN, MDK, EGF, IL1RA, HE4, *2	89.222
3240	dps, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	89.915
3241	dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	87.109
3242	dps, EMILIN, *1, EGF, GMCSF, IL1RA, *2	88.068
3243	dps, EMILIN, *1, EGF, GMCSF, HE4, *2	86.506
3244	dps, EMILIN, *1, EGF, IL1RA, HE4, *2	88.849
3245	dps, EMILIN, *1, GMCSF, IL1RA,	89.205

	HE4, *2	
3246	dps, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	85.636
3247	dps, MDK, *1, EGF, GMCSF, IL1RA, HE4	89.915
3248	dps, MDK, *1, EGF, GMCSF, IL1RA, *2	90.909
3249	dps, MDK, *1, EGF, GMCSF, HE4, *2	90.092
3250	dps, MDK, *1, EGF, IL1RA, HE4, *2	90.483
3251	dps, MDK, *1, GMCSF, IL1RA, HE4, *2	90.767
3252	dps, MDK, EGF, GMCSF, IL1RA, HE4, *2	87.251
3253	dps, *1, EGF, GMCSF, IL1RA, HE4, *2	84.677
3254	CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	91.442
3255	CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	91.158
3256	CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	91.317
3257	CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4	91.548
3258	CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	91.903
3259	CA125, EMILIN, MDK, *1, EGF, HE4, *2	91.548
3260	CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	91.726
3261	CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	91.903
3262	CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	91.974
3263	CA125, EMILIN, MDK, *1, IL1RA, HE4, *2	92.081
3264	CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	90.554
3265	CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	90.447
3266	CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	90.128
3267	CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	91.193
3268	CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	91.264
3269	CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	88.53
3270	CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	89.24
3271	CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	88.548
3272	CA125, EMILIN, *1, EGF, IL1RA,	88.672

	HE4, *2	
3273	CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	89.702
3274	CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	87.536
3275	CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	90.092
3276	CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	89.95
3277	CA125, MDK, *1, EGF, GMCSF, HE4, *2	89.968
3278	CA125, MDK, *1, EGF, IL1RA, HE4, *2	90.27
3279	CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	90.447
3280	CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	87.962
3281	CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	83.097
3282	EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	83.203
3283	EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	83.736
3284	EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	83.896
3285	EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	83.736
3286	EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	84.268
3287	EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	79.936
3288	EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	76.385
3289	MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	79.048
3290	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF	98.011
3291	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF	98.082
3292	ips, mps, dps, CA125, EMILIN, MDK, *1, IL1RA	98.153
3293	ips, mps, dps, CA125, EMILIN, MDK, *1, HE4	98.047
3294	ips, mps, dps, CA125, EMILIN, MDK, *1, *2	98.047
3295	ips, mps, dps, CA125, EMILIN, MDK, EGF, GMCSF	98.153
3296	ips, mps, dps, CA125, EMILIN, MDK, EGF, IL1RA	98.295
3297	ips, mps, dps, CA125, EMILIN, MDK, EGF, HE4	98.082
3298	ips, mps, dps, CA125, EMILIN, MDK, EGF, *2	98.082

3299	ips, mps, dps, CA125, EMILIN, MDK, GMCSF, IL1RA	98.331
3300	ips, mps, dps, CA125, EMILIN, MDK, GMCSF, HE4	98.082
3301	ips, mps, dps, CA125, EMILIN, MDK, GMCSF, *2	97.976
3302	ips, mps, dps, CA125, EMILIN, MDK, IL1RA, HE4	98.295
3303	ips, mps, dps, CA125, EMILIN, MDK, IL1RA, *2	98.295
3304	ips, mps, dps, CA125, EMILIN, MDK, HE4, *2	98.047
3305	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF	97.905
3306	ips, mps, dps, CA125, EMILIN, *1, EGF, IL1RA	98.153
3307	ips, mps, dps, CA125, EMILIN, *1, EGF, HE4	98.047
3308	ips, mps, dps, CA125, EMILIN, *1, EGF, *2	98.118
3309	ips, mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA	98.082
3310	ips, mps, dps, CA125, EMILIN, *1, GMCSF, HE4	98.082
3311	ips, mps, dps, CA125, EMILIN, *1, GMCSF, *2	98.082
3312	ips, mps, dps, CA125, EMILIN, *1, IL1RA, HE4	98.26
3313	ips, mps, dps, CA125, EMILIN, *1, IL1RA, *2	98.189
3314	ips, mps, dps, CA125, EMILIN, *1, HE4, *2	98.224
3315	ips, mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA	98.082
3316	ips, mps, dps, CA125, EMILIN, EGF, GMCSF, HE4	97.905
3317	ips, mps, dps, CA125, EMILIN, EGF, GMCSF, *2	97.976
3318	ips, mps, dps, CA125, EMILIN, EGF, IL1RA, HE4	98.26
3319	ips, mps, dps, CA125, EMILIN, EGF, IL1RA, *2	98.224
3320	ips, mps, dps, CA125, EMILIN, EGF, HE4, *2	98.082
3321	ips, mps, dps, CA125, EMILIN, GMCSF, IL1RA, HE4	98.224
3322	ips, mps, dps, CA125, EMILIN, GMCSF, IL1RA, *2	98.082
3323	ips, mps, dps, CA125, EMILIN, GMCSF, HE4, *2	98.118
3324	ips, mps, dps, CA125, EMILIN, IL1RA, HE4, *2	98.295
3325	ips, mps, dps, CA125, MDK, *1,	97.763

	EGF, GMCSF	
3326	ips, mps, dps, CA125, MDK, *1, EGF, IL1RA	97.834
3327	ips, mps, dps, CA125, MDK, *1, EGF, HE4	98.047
3328	ips, mps, dps, CA125, MDK, *1, EGF, *2	97.905
3329	ips, mps, dps, CA125, MDK, *1, GMCSF, IL1RA	97.869
3330	ips, mps, dps, CA125, MDK, *1, GMCSF, HE4	97.798
3331	ips, mps, dps, CA125, MDK, *1, GMCSF, *2	97.674
3332	ips, mps, dps, CA125, MDK, *1, IL1RA, HE4	97.905
3333	ips, mps, dps, CA125, MDK, *1, IL1RA, *2	97.869
3334	ips, mps, dps, CA125, MDK, *1, HE4, *2	97.798
3335	ips, mps, dps, CA125, MDK, EGF, GMCSF, IL1RA	97.692
3336	ips, mps, dps, CA125, MDK, EGF, GMCSF, HE4	97.798
3337	ips, mps, dps, CA125, MDK, EGF, GMCSF, *2	97.692
3338	ips, mps, dps, CA125, MDK, EGF, IL1RA, HE4	97.834
3339	ips, mps, dps, CA125, MDK, EGF, IL1RA, *2	97.727
3340	ips, mps, dps, CA125, MDK, EGF, HE4, *2	97.834
3341	ips, mps, dps, CA125, MDK, GMCSF, IL1RA, HE4	97.656
3342	ips, mps, dps, CA125, MDK, GMCSF, IL1RA, *2	97.656
3343	ips, mps, dps, CA125, MDK, GMCSF, HE4, *2	97.692
3344	ips, mps, dps, CA125, MDK, IL1RA, HE4, *2	97.798
3345	ips, mps, dps, CA125, *1, EGF, GMCSF, IL1RA	96.911
3346	ips, mps, dps, CA125, *1, EGF, GMCSF, HE4	97.124
3347	ips, mps, dps, CA125, *1, EGF, GMCSF, *2	96.822
3348	ips, mps, dps, CA125, *1, EGF, IL1RA, HE4	97.195
3349	ips, mps, dps, CA125, *1, EGF, IL1RA, *2	97.017
3350	ips, mps, dps, CA125, *1, EGF, HE4, *2	97.23
3351	ips, mps, dps, CA125, *1, GMCSF, IL1RA, HE4	96.875

3352	ips, mps, dps, CA125, *1, GMCSF, IL1RA, *2	96.733
3353	ips, mps, dps, CA125, *1, GMCSF, HE4, *2	96.946
3354	ips, mps, dps, CA125, *1, IL1RA, HE4, *2	96.911
3355	ips, mps, dps, CA125, EGF, GMCSF, IL1RA, HE4	97.088
3356	ips, mps, dps, CA125, EGF, GMCSF, IL1RA, *2	96.946
3357	ips, mps, dps, CA125, EGF, GMCSF, HE4, *2	97.088
3358	ips, mps, dps, CA125, EGF, IL1RA, HE4, *2	97.23
3359	ips, mps, dps, CA125, GMCSF, IL1RA, HE4, *2	96.911
3360	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF	95.881
3361	ips, mps, dps, EMILIN, MDK, *1, EGF, IL1RA	96.697
3362	ips, mps, dps, EMILIN, MDK, *1, EGF, HE4	95.81
3363	ips, mps, dps, EMILIN, MDK, *1, EGF, *2	95.916
3364	ips, mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA	96.413
3365	ips, mps, dps, EMILIN, MDK, *1, GMCSF, HE4	95.774
3366	ips, mps, dps, EMILIN, MDK, *1, GMCSF, *2	95.987
3367	ips, mps, dps, EMILIN, MDK, *1, IL1RA, HE4	96.768
3368	ips, mps, dps, EMILIN, MDK, *1, IL1RA, *2	96.431
3369	ips, mps, dps, EMILIN, MDK, *1, HE4, *2	95.703
3370	ips, mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA	96.449
3371	ips, mps, dps, EMILIN, MDK, EGF, GMCSF, HE4	95.632
3372	ips, mps, dps, EMILIN, MDK, EGF, GMCSF, *2	95.668
3373	ips, mps, dps, EMILIN, MDK, EGF, IL1RA, HE4	96.342
3374	ips, mps, dps, EMILIN, MDK, EGF, IL1RA, *2	96.52
3375	ips, mps, dps, EMILIN, MDK, EGF, HE4, *2	95.526
3376	ips, mps, dps, EMILIN, MDK, GMCSF, IL1RA, HE4	96.697
3377	ips, mps, dps, EMILIN, MDK, GMCSF, IL1RA, *2	96.342
3378	ips, mps, dps, EMILIN, MDK,	95.526

	GMCSF, HE4, *2	
3379	ips, mps, dps, EMILIN, MDK, IL1RA, HE4, *2	96.449
3380	ips, mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA	95.969
3381	ips, mps, dps, EMILIN, *1, EGF, GMCSF, HE4	94.886
3382	ips, mps, dps, EMILIN, *1, EGF, GMCSF, *2	94.993
3383	ips, mps, dps, EMILIN, *1, EGF, IL1RA, HE4	96.271
3384	ips, mps, dps, EMILIN, *1, EGF, IL1RA, *2	96.165
3385	ips, mps, dps, EMILIN, *1, EGF, HE4, *2	95.099
3386	ips, mps, dps, EMILIN, *1, GMCSF, IL1RA, HE4	96.165
3387	ips, mps, dps, EMILIN, *1, GMCSF, IL1RA, *2	96.342
3388	ips, mps, dps, EMILIN, *1, GMCSF, HE4, *2	95.153
3389	ips, mps, dps, EMILIN, *1, IL1RA, HE4, *2	96.2
3390	ips, mps, dps, EMILIN, EGF, GMCSF, IL1RA, HE4	96.307
3391	ips, mps, dps, EMILIN, EGF, GMCSF, IL1RA, *2	95.756
3392	ips, mps, dps, EMILIN, EGF, GMCSF, HE4, *2	94.886
3393	ips, mps, dps, EMILIN, EGF, IL1RA, HE4, *2	96.2
3394	ips, mps, dps, EMILIN, GMCSF, IL1RA, HE4, *2	96.129
3395	ips, mps, dps, MDK, *1, EGF, GMCSF, IL1RA	95.135
3396	ips, mps, dps, MDK, *1, EGF, GMCSF, HE4	94.957
3397	ips, mps, dps, MDK, *1, EGF, GMCSF, *2	95.028
3398	ips, mps, dps, MDK, *1, EGF, IL1RA, HE4	95.295
3399	ips, mps, dps, MDK, *1, EGF, IL1RA, *2	95.437
3400	ips, mps, dps, MDK, *1, EGF, HE4, *2	94.869
3401	ips, mps, dps, MDK, *1, GMCSF, IL1RA, HE4	95.348
3402	ips, mps, dps, MDK, *1, GMCSF, IL1RA, *2	95.206
3403	ips, mps, dps, MDK, *1, GMCSF, HE4, *2	95.028
3404	ips, mps, dps, MDK, *1, IL1RA, HE4, *2	95.241

3405	ips, mps, dps, MDK, EGF, GMCSF, IL1RA, HE4	95.277
3406	ips, mps, dps, MDK, EGF, GMCSF, IL1RA, *2	94.886
3407	ips, mps, dps, MDK, EGF, GMCSF, HE4, *2	94.638
3408	ips, mps, dps, MDK, EGF, IL1RA, HE4, *2	94.922
3409	ips, mps, dps, MDK, GMCSF, IL1RA, HE4, *2	95.011
3410	ips, mps, dps, *1, EGF, GMCSF, IL1RA, HE4	93.288
3411	ips, mps, dps, *1, EGF, GMCSF, IL1RA, *2	93.537
3412	ips, mps, dps, *1, EGF, GMCSF, HE4, *2	92.898
3413	ips, mps, dps, *1, EGF, IL1RA, HE4, *2	93.466
3414	ips, mps, dps, *1, GMCSF, IL1RA, HE4, *2	93.359
3415	ips, mps, dps, EGF, GMCSF, IL1RA, HE4, *2	93.288
3416	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF	98.26
3417	ips, mps, CA125, EMILIN, MDK, *1, EGF, IL1RA	98.438
3418	ips, mps, CA125, EMILIN, MDK, *1, EGF, HE4	98.26
3419	ips, mps, CA125, EMILIN, MDK, *1, EGF, *2	98.295
3420	ips, mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA	98.58
3421	ips, mps, CA125, EMILIN, MDK, *1, GMCSF, HE4	98.26
3422	ips, mps, CA125, EMILIN, MDK, *1, GMCSF, *2	98.366
3423	ips, mps, CA125, EMILIN, MDK, *1, IL1RA, HE4	98.544
3424	ips, mps, CA125, EMILIN, MDK, *1, IL1RA, *2	98.58
3425	ips, mps, CA125, EMILIN, MDK, *1, HE4, *2	98.295
3426	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	98.651
3427	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF, HE4	98.473
3428	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF, *2	98.509
3429	ips, mps, CA125, EMILIN, MDK, EGF, IL1RA, HE4	98.651
3430	ips, mps, CA125, EMILIN, MDK, EGF, IL1RA, *2	98.615
3431	ips, mps, CA125, EMILIN, MDK,	98.402

	EGF, HE4, *2	
3432	ips, mps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	98.615
3433	ips, mps, CA125, EMILIN, MDK, GMCSF, IL1RA, *2	98.651
3434	ips, mps, CA125, EMILIN, MDK, GMCSF, HE4, *2	98.491
3435	ips, mps, CA125, EMILIN, MDK, IL1RA, HE4, *2	98.651
3436	ips, mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA	98.295
3437	ips, mps, CA125, EMILIN, *1, EGF, GMCSF, HE4	98.136
3438	ips, mps, CA125, EMILIN, *1, EGF, GMCSF, *2	98.153
3439	ips, mps, CA125, EMILIN, *1, EGF, IL1RA, HE4	98.402
3440	ips, mps, CA125, EMILIN, *1, EGF, IL1RA, *2	98.331
3441	ips, mps, CA125, EMILIN, *1, EGF, HE4, *2	98.224
3442	ips, mps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4	98.331
3443	ips, mps, CA125, EMILIN, *1, GMCSF, IL1RA, *2	98.295
3444	ips, mps, CA125, EMILIN, *1, GMCSF, HE4, *2	98.26
3445	ips, mps, CA125, EMILIN, *1, IL1RA, HE4, *2	98.473
3446	ips, mps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	98.438
3447	ips, mps, CA125, EMILIN, EGF, GMCSF, IL1RA, *2	98.366
3448	ips, mps, CA125, EMILIN, EGF, GMCSF, HE4, *2	98.1
3449	ips, mps, CA125, EMILIN, EGF, IL1RA, HE4, *2	98.366
3450	ips, mps, CA125, EMILIN, GMCSF, IL1RA, HE4, *2	98.438
3451	ips, mps, CA125, MDK, *1, EGF, GMCSF, IL1RA	98.011
3452	ips, mps, CA125, MDK, *1, EGF, GMCSF, HE4	98.047
3453	ips, mps, CA125, MDK, *1, EGF, GMCSF, *2	97.905
3454	ips, mps, CA125, MDK, *1, EGF, IL1RA, HE4	98.118
3455	ips, mps, CA125, MDK, *1, EGF, IL1RA, *2	97.976
3456	ips, mps, CA125, MDK, *1, EGF, HE4, *2	97.976
3457	ips, mps, CA125, MDK, *1, GMCSF, IL1RA, HE4	98.047

3458	ips, mps, CA125, MDK, *1, GMCSF, IL1RA, *2	97.976
3459	ips, mps, CA125, MDK, *1, GMCSF, HE4, *2	97.976
3460	ips, mps, CA125, MDK, *1, IL1RA, HE4, *2	98.047
3461	ips, mps, CA125, MDK, EGF, GMCSF, IL1RA, HE4	98.082
3462	ips, mps, CA125, MDK, EGF, GMCSF, IL1RA, *2	97.834
3463	ips, mps, CA125, MDK, EGF, GMCSF, HE4, *2	98.011
3464	ips, mps, CA125, MDK, EGF, IL1RA, HE4, *2	97.905
3465	ips, mps, CA125, MDK, GMCSF, IL1RA, HE4, *2	98.047
3466	ips, mps, CA125, *1, EGF, GMCSF, IL1RA, HE4	97.124
3467	ips, mps, CA125, *1, EGF, GMCSF, IL1RA, *2	97.017
3468	ips, mps, CA125, *1, EGF, GMCSF, HE4, *2	96.946
3469	ips, mps, CA125, *1, EGF, IL1RA, HE4, *2	97.159
3470	ips, mps, CA125, *1, GMCSF, IL1RA, HE4, *2	96.839
3471	ips, mps, CA125, EGF, GMCSF, IL1RA, HE4, *2	97.017
3472	ips, mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	96.342
3473	ips, mps, EMILIN, MDK, *1, EGF, GMCSF, HE4	95.916
3474	ips, mps, EMILIN, MDK, *1, EGF, GMCSF, *2	96.094
3475	ips, mps, EMILIN, MDK, *1, EGF, IL1RA, HE4	96.662
3476	ips, mps, EMILIN, MDK, *1, EGF, IL1RA, *2	96.733
3477	ips, mps, EMILIN, MDK, *1, EGF, HE4, *2	96.165
3478	ips, mps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	96.555
3479	ips, mps, EMILIN, MDK, *1, GMCSF, IL1RA, *2	96.449
3480	ips, mps, EMILIN, MDK, *1, GMCSF, HE4, *2	95.774
3481	ips, mps, EMILIN, MDK, *1, IL1RA, HE4, *2	96.733
3482	ips, mps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	96.662
3483	ips, mps, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	96.52
3484	ips, mps, EMILIN, MDK, EGF,	95.668

	GMCSF, HE4, *2	
3485	ips, mps, EMILIN, MDK, EGF, IL1RA, HE4, *2	96.697
3486	ips, mps, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	96.626
3487	ips, mps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	95.916
3488	ips, mps, EMILIN, *1, EGF, GMCSF, IL1RA, *2	95.739
3489	ips, mps, EMILIN, *1, EGF, GMCSF, HE4, *2	94.851
3490	ips, mps, EMILIN, *1, EGF, IL1RA, HE4, *2	96.165
3491	ips, mps, EMILIN, *1, GMCSF, IL1RA, HE4, *2	96.058
3492	ips, mps, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	96.023
3493	ips, mps, MDK, *1, EGF, GMCSF, IL1RA, HE4	94.957
3494	ips, mps, MDK, *1, EGF, GMCSF, IL1RA, *2	95.099
3495	ips, mps, MDK, *1, EGF, GMCSF, HE4, *2	94.833
3496	ips, mps, MDK, *1, EGF, IL1RA, HE4, *2	95.206
3497	ips, mps, MDK, *1, GMCSF, IL1RA, HE4, *2	95.135
3498	ips, mps, MDK, EGF, GMCSF, IL1RA, HE4, *2	94.851
3499	ips, mps, *1, EGF, GMCSF, IL1RA, HE4, *2	92.862
3500	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF	97.124
3501	ips, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA	97.461
3502	ips, dps, CA125, EMILIN, MDK, *1, EGF, HE4	97.159
3503	ips, dps, CA125, EMILIN, MDK, *1, EGF, *2	97.514
3504	ips, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA	97.195
3505	ips, dps, CA125, EMILIN, MDK, *1, GMCSF, HE4	97.088
3506	ips, dps, CA125, EMILIN, MDK, *1, GMCSF, *2	97.088
3507	ips, dps, CA125, EMILIN, MDK, *1, IL1RA, HE4	97.408
3508	ips, dps, CA125, EMILIN, MDK, *1, IL1RA, *2	97.479
3509	ips, dps, CA125, EMILIN, MDK, *1, HE4, *2	97.248
3510	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	97.053

3511	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4	96.804
3512	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF, *2	97.195
3513	ips, dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4	97.088
3514	ips, dps, CA125, EMILIN, MDK, EGF, IL1RA, *2	97.443
3515	ips, dps, CA125, EMILIN, MDK, EGF, HE4, *2	96.804
3516	ips, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	97.088
3517	ips, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, *2	97.301
3518	ips, dps, CA125, EMILIN, MDK, GMCSF, HE4, *2	97.124
3519	ips, dps, CA125, EMILIN, MDK, IL1RA, HE4, *2	97.443
3520	ips, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA	96.413
3521	ips, dps, CA125, EMILIN, *1, EGF, GMCSF, HE4	96.165
3522	ips, dps, CA125, EMILIN, *1, EGF, GMCSF, *2	96.2
3523	ips, dps, CA125, EMILIN, *1, EGF, IL1RA, HE4	96.484
3524	ips, dps, CA125, EMILIN, *1, EGF, IL1RA, *2	96.52
3525	ips, dps, CA125, EMILIN, *1, EGF, HE4, *2	96.413
3526	ips, dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4	96.378
3527	ips, dps, CA125, EMILIN, *1, GMCSF, IL1RA, *2	96.342
3528	ips, dps, CA125, EMILIN, *1, GMCSF, HE4, *2	96.129
3529	ips, dps, CA125, EMILIN, *1, IL1RA, HE4, *2	96.591
3530	ips, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	96.307
3531	ips, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, *2	96.378
3532	ips, dps, CA125, EMILIN, EGF, GMCSF, HE4, *2	96.342
3533	ips, dps, CA125, EMILIN, EGF, IL1RA, HE4, *2	96.804
3534	ips, dps, CA125, EMILIN, GMCSF, IL1RA, HE4, *2	96.484
3535	ips, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA	97.337
3536	ips, dps, CA125, MDK, *1, EGF, GMCSF, HE4	97.088
3537	ips, dps, CA125, MDK, *1, EGF, *2	97.159

	GMCSF, *2	
3538	ips, dps, CA125, MDK, *1, EGF, IL1RA, HE4	96.911
3539	ips, dps, CA125, MDK, *1, EGF, IL1RA, *2	96.982
3540	ips, dps, CA125, MDK, *1, EGF, HE4, *2	96.733
3541	ips, dps, CA125, MDK, *1, GMCSF, IL1RA, HE4	97.053
3542	ips, dps, CA125, MDK, *1, GMCSF, IL1RA, *2	97.017
3543	ips, dps, CA125, MDK, *1, GMCSF, HE4, *2	96.804
3544	ips, dps, CA125, MDK, *1, IL1RA, HE4, *2	96.573
3545	ips, dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4	96.839
3546	ips, dps, CA125, MDK, EGF, GMCSF, IL1RA, *2	96.911
3547	ips, dps, CA125, MDK, EGF, GMCSF, HE4, *2	96.911
3548	ips, dps, CA125, MDK, EGF, IL1RA, HE4, *2	96.52
3549	ips, dps, CA125, MDK, GMCSF, IL1RA, HE4, *2	96.591
3550	ips, dps, CA125, *1, EGF, GMCSF, IL1RA, HE4	95.987
3551	ips, dps, CA125, *1, EGF, GMCSF, IL1RA, *2	95.703
3552	ips, dps, CA125, *1, EGF, GMCSF, HE4, *2	95.987
3553	ips, dps, CA125, *1, EGF, IL1RA, HE4, *2	95.987
3554	ips, dps, CA125, *1, GMCSF, IL1RA, HE4, *2	95.348
3555	ips, dps, CA125, EGF, GMCSF, IL1RA, HE4, *2	95.81
3556	ips, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	93.413
3557	ips, dps, EMILIN, MDK, *1, EGF, GMCSF, HE4	92.862
3558	ips, dps, EMILIN, MDK, *1, EGF, GMCSF, *2	93.324
3559	ips, dps, EMILIN, MDK, *1, EGF, IL1RA, HE4	93.004
3560	ips, dps, EMILIN, MDK, *1, EGF, IL1RA, *2	93.928
3561	ips, dps, EMILIN, MDK, *1, EGF, HE4, *2	93.501
3562	ips, dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	93.377
3563	ips, dps, EMILIN, MDK, *1, GMCSF, IL1RA, *2	94.016

3564	ips, dps, EMILIN, MDK, *1, GMCSF, HE4, *2	93.768
3565	ips, dps, EMILIN, MDK, *1, IL1RA, HE4, *2	93.643
3566	ips, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	92.259
3567	ips, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	93.004
3568	ips, dps, EMILIN, MDK, EGF, GMCSF, HE4, *2	92.152
3569	ips, dps, EMILIN, MDK, EGF, IL1RA, HE4, *2	92.756
3570	ips, dps, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	92.951
3571	ips, dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	92.116
3572	ips, dps, EMILIN, *1, EGF, GMCSF, IL1RA, *2	92.134
3573	ips, dps, EMILIN, *1, EGF, GMCSF, HE4, *2	91.903
3574	ips, dps, EMILIN, *1, EGF, IL1RA, HE4, *2	92.436
3575	ips, dps, EMILIN, *1, GMCSF, IL1RA, HE4, *2	92.631
3576	ips, dps, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	91.016
3577	ips, dps, MDK, *1, EGF, GMCSF, IL1RA, HE4	93.892
3578	ips, dps, MDK, *1, EGF, GMCSF, IL1RA, *2	94.141
3579	ips, dps, MDK, *1, EGF, GMCSF, HE4, *2	93.572
3580	ips, dps, MDK, *1, EGF, IL1RA, HE4, *2	93.04
3581	ips, dps, MDK, *1, GMCSF, IL1RA, HE4, *2	93.892
3582	ips, dps, MDK, EGF, GMCSF, IL1RA, HE4, *2	92.347
3583	ips, dps, *1, EGF, GMCSF, IL1RA, HE4, *2	91.122
3584	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	96.52
3585	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	96.449
3586	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	96.413
3587	ips, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4	96.555
3588	ips, CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	96.768
3589	ips, CA125, EMILIN, MDK, *1, EGF, HE4, *2	96.484
3590	ips, CA125, EMILIN, MDK, *1,	96.449

	GMCSF, IL1RA, HE4	
3591	ips, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	96.555
3592	ips, CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	96.591
3593	ips, CA125, EMILIN, MDK, *1, IL1RA, HE4, *2	96.697
3594	ips, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	96.236
3595	ips, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	96.662
3596	ips, CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	96.289
3597	ips, CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	96.591
3598	ips, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	96.697
3599	ips, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	95.028
3600	ips, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	95.419
3601	ips, CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	95.064
3602	ips, CA125, EMILIN, *1, EGF, IL1RA, HE4, *2	95.455
3603	ips, CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	95.561
3604	ips, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	95.295
3605	ips, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	96.768
3606	ips, CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	96.555
3607	ips, CA125, MDK, *1, EGF, GMCSF, HE4, *2	96.733
3608	ips, CA125, MDK, *1, EGF, IL1RA, HE4, *2	96.307
3609	ips, CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	96.697
3610	ips, CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	96.236
3611	ips, CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	94.354
3612	ips, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	91.388
3613	ips, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	91.548
3614	ips, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	90.874
3615	ips, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	91.371
3616	ips, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	91.584

3617	ips, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	90.341
3618	ips, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	88.281
3619	ips, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	90.856
3620	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF	97.443
3621	mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA	97.674
3622	mps, dps, CA125, EMILIN, MDK, *1, EGF, HE4	97.479
3623	mps, dps, CA125, EMILIN, MDK, *1, EGF, *2	97.55
3624	mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA	97.656
3625	mps, dps, CA125, EMILIN, MDK, *1, GMCSF, HE4	97.55
3626	mps, dps, CA125, EMILIN, MDK, *1, GMCSF, *2	97.585
3627	mps, dps, CA125, EMILIN, MDK, *1, IL1RA, HE4	97.656
3628	mps, dps, CA125, EMILIN, MDK, *1, IL1RA, *2	97.656
3629	mps, dps, CA125, EMILIN, MDK, *1, HE4, *2	97.621
3630	mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	97.55
3631	mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4	97.39
3632	mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, *2	97.514
3633	mps, dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4	97.585
3634	mps, dps, CA125, EMILIN, MDK, EGF, IL1RA, *2	97.621
3635	mps, dps, CA125, EMILIN, MDK, EGF, HE4, *2	97.479
3636	mps, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	97.763
3637	mps, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, *2	97.621
3638	mps, dps, CA125, EMILIN, MDK, GMCSF, HE4, *2	97.585
3639	mps, dps, CA125, EMILIN, MDK, IL1RA, HE4, *2	97.869
3640	mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA	97.159
3641	mps, dps, CA125, EMILIN, *1, EGF, GMCSF, HE4	96.982
3642	mps, dps, CA125, EMILIN, *1, EGF, GMCSF, *2	97.23
3643	mps, dps, CA125, EMILIN, *1, EGF, *2	97.23

	IL1RA, HE4	
3644	mps, dps, CA125, EMILIN, *1, EGF, IL1RA, *2	97.266
3645	mps, dps, CA125, EMILIN, *1, EGF, HE4, *2	97.159
3646	mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4	97.124
3647	mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA, *2	97.195
3648	mps, dps, CA125, EMILIN, *1, GMCSF, HE4, *2	97.017
3649	mps, dps, CA125, EMILIN, *1, IL1RA, HE4, *2	97.159
3650	mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	97.159
3651	mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, *2	97.124
3652	mps, dps, CA125, EMILIN, EGF, GMCSF, HE4, *2	97.195
3653	mps, dps, CA125, EMILIN, EGF, IL1RA, HE4, *2	97.39
3654	mps, dps, CA125, EMILIN, GMCSF, IL1RA, HE4, *2	97.23
3655	mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA	96.68
3656	mps, dps, CA125, MDK, *1, EGF, GMCSF, HE4	96.52
3657	mps, dps, CA125, MDK, *1, EGF, GMCSF, *2	96.52
3658	mps, dps, CA125, MDK, *1, EGF, IL1RA, HE4	96.484
3659	mps, dps, CA125, MDK, *1, EGF, IL1RA, *2	96.591
3660	mps, dps, CA125, MDK, *1, EGF, HE4, *2	96.555
3661	mps, dps, CA125, MDK, *1, GMCSF, IL1RA, HE4	96.733
3662	mps, dps, CA125, MDK, *1, GMCSF, IL1RA, *2	96.768
3663	mps, dps, CA125, MDK, *1, GMCSF, HE4, *2	96.449
3664	mps, dps, CA125, MDK, *1, IL1RA, HE4, *2	96.733
3665	mps, dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4	96.449
3666	mps, dps, CA125, MDK, EGF, GMCSF, IL1RA, *2	96.52
3667	mps, dps, CA125, MDK, EGF, GMCSF, HE4, *2	96.378
3668	mps, dps, CA125, MDK, EGF, IL1RA, HE4, *2	96.502
3669	mps, dps, CA125, MDK, GMCSF, IL1RA, HE4, *2	96.52

3670	mps, dps, CA125, *1, EGF, GMCSF, IL1RA, HE4	95.49
3671	mps, dps, CA125, *1, EGF, GMCSF, IL1RA, *2	95.49
3672	mps, dps, CA125, *1, EGF, GMCSF, HE4, *2	95.455
3673	mps, dps, CA125, *1, EGF, IL1RA, HE4, *2	95.49
3674	mps, dps, CA125, *1, GMCSF, IL1RA, HE4, *2	95.313
3675	mps, dps, CA125, EGF, GMCSF, IL1RA, HE4, *2	95.526
3676	mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	95.561
3677	mps, dps, EMILIN, MDK, *1, EGF, GMCSF, HE4	94.709
3678	mps, dps, EMILIN, MDK, *1, EGF, GMCSF, *2	95.17
3679	mps, dps, EMILIN, MDK, *1, EGF, IL1RA, HE4	95.739
3680	mps, dps, EMILIN, MDK, *1, EGF, IL1RA, *2	95.845
3681	mps, dps, EMILIN, MDK, *1, EGF, HE4, *2	95.455
3682	mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	95.739
3683	mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA, *2	95.774
3684	mps, dps, EMILIN, MDK, *1, GMCSF, HE4, *2	95.135
3685	mps, dps, EMILIN, MDK, *1, IL1RA, HE4, *2	95.881
3686	mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	94.922
3687	mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	95.241
3688	mps, dps, EMILIN, MDK, EGF, GMCSF, HE4, *2	94.141
3689	mps, dps, EMILIN, MDK, EGF, IL1RA, HE4, *2	95.348
3690	mps, dps, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	95.561
3691	mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	94.709
3692	mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA, *2	95.064
3693	mps, dps, EMILIN, *1, EGF, GMCSF, HE4, *2	93.75
3694	mps, dps, EMILIN, *1, EGF, IL1RA, HE4, *2	95.241
3695	mps, dps, EMILIN, *1, GMCSF, IL1RA, HE4, *2	95.241
3696	mps, dps, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	94.709

	IL1RA, HE4, *2	
3697	mps, dps, MDK, *1, EGF, GMCSF, IL1RA, HE4	93.75
3698	mps, dps, MDK, *1, EGF, GMCSF, IL1RA, *2	94.318
3699	mps, dps, MDK, *1, EGF, GMCSF, HE4, *2	93.999
3700	mps, dps, MDK, *1, EGF, IL1RA, HE4, *2	94.247
3701	mps, dps, MDK, *1, GMCSF, IL1RA, HE4, *2	94.176
3702	mps, dps, MDK, EGF, GMCSF, IL1RA, HE4, *2	93.146
3703	mps, dps, *1, EGF, GMCSF, IL1RA, HE4, *2	90.838
3704	mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	97.408
3705	mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	97.266
3706	mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	97.372
3707	mps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4	97.585
3708	mps, CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	97.408
3709	mps, CA125, EMILIN, MDK, *1, EGF, HE4, *2	97.159
3710	mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	97.55
3711	mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	97.656
3712	mps, CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	97.408
3713	mps, CA125, EMILIN, MDK, *1, IL1RA, HE4, *2	97.585
3714	mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	97.195
3715	mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	97.266
3716	mps, CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	97.266
3717	mps, CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	97.337
3718	mps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	97.479
3719	mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	96.697
3720	mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	96.839
3721	mps, CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	96.733
3722	mps, CA125, EMILIN, *1, EGF, IL1RA, HE4, *2	96.964

3723	mps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	96.857
3724	mps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	96.733
3725	mps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	96.165
3726	mps, CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	96.058
3727	mps, CA125, MDK, *1, EGF, GMCSF, HE4, *2	95.881
3728	mps, CA125, MDK, *1, EGF, IL1RA, HE4, *2	96.271
3729	mps, CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	96.52
3730	mps, CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	96.129
3731	mps, CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	94.318
3732	mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	94.531
3733	mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	94.993
3734	mps, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	94.815
3735	mps, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	95.348
3736	mps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	95.17
3737	mps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	93.892
3738	mps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	93.661
3739	mps, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	93.217
3740	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	94.105
3741	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	93.874
3742	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	94.247
3743	dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4	94.176
3744	dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	94.673
3745	dps, CA125, EMILIN, MDK, *1, EGF, HE4, *2	94.425
3746	dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	94.212
3747	dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	94.691
3748	dps, CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	94.389
3749	dps, CA125, EMILIN, MDK, *1,	94.567

	IL1RA, HE4, *2	
3750	dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	93.466
3751	dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	94.176
3752	dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	93.928
3753	dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	94.123
3754	dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	94.212
3755	dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	92.685
3756	dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	92.898
3757	dps, CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	92.614
3758	dps, CA125, EMILIN, *1, EGF, IL1RA, HE4, *2	93.2
3759	dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	92.969
3760	dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	92.969
3761	dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	94.318
3762	dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	94.283
3763	dps, CA125, MDK, *1, EGF, GMCSF, HE4, *2	94.247
3764	dps, CA125, MDK, *1, EGF, IL1RA, HE4, *2	94.318
3765	dps, CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	94.176
3766	dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	93.857
3767	dps, CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	91.726
3768	dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	89.844
3769	dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	90.518
3770	dps, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	90.341
3771	dps, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	90.661
3772	dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	91.016
3773	dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	88.352
3774	dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	87.464
3775	dps, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	90.057

3776	CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	91.193
3777	CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	91.264
3778	CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	90.838
3779	CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	91.104
3780	CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	91.797
3781	CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	90.092
3782	CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	88.406
3783	CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	89.471
3784	EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	83.31
3785	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF	98.189
3786	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA	98.153
3787	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, HE4	98.189
3788	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, *2	98.118
3789	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA	98.26
3790	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF, HE4	98.118
3791	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF, *2	98.224
3792	ips, mps, dps, CA125, EMILIN, MDK, *1, IL1RA, HE4	98.189
3793	ips, mps, dps, CA125, EMILIN, MDK, *1, IL1RA, *2	98.224
3794	ips, mps, dps, CA125, EMILIN, MDK, *1, HE4, *2	98.082
3795	ips, mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA	98.224
3796	ips, mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4	98.153
3797	ips, mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, *2	98.082
3798	ips, mps, dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4	98.438
3799	ips, mps, dps, CA125, EMILIN, MDK, EGF, IL1RA, *2	98.331
3800	ips, mps, dps, CA125, EMILIN, MDK, EGF, HE4, *2	98.224
3801	ips, mps, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4	98.331
3802	ips, mps, dps, CA125, EMILIN,	98.331

	MDK, GMCSF, IL1RA, *2	
3803	ips, mps, dps, CA125, EMILIN, MDK, GMCSF, HE4, *2	98.118
3804	ips, mps, dps, CA125, EMILIN, MDK, IL1RA, HE4, *2	98.26
3805	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA	98.047
3806	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF, HE4	97.94
3807	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF, *2	97.976
3808	ips, mps, dps, CA125, EMILIN, *1, EGF, IL1RA, HE4	98.26
3809	ips, mps, dps, CA125, EMILIN, *1, EGF, IL1RA, *2	98.224
3810	ips, mps, dps, CA125, EMILIN, *1, EGF, HE4, *2	98.047
3811	ips, mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4	98.189
3812	ips, mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA, *2	98.189
3813	ips, mps, dps, CA125, EMILIN, *1, GMCSF, HE4, *2	98.118
3814	ips, mps, dps, CA125, EMILIN, *1, IL1RA, HE4, *2	98.26
3815	ips, mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4	98.118
3816	ips, mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, *2	98.1
3817	ips, mps, dps, CA125, EMILIN, EGF, GMCSF, HE4, *2	97.94
3818	ips, mps, dps, CA125, EMILIN, EGF, IL1RA, HE4, *2	98.224
3819	ips, mps, dps, CA125, EMILIN, GMCSF, IL1RA, HE4, *2	98.118
3820	ips, mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA	97.798
3821	ips, mps, dps, CA125, MDK, *1, EGF, GMCSF, HE4	97.834
3822	ips, mps, dps, CA125, MDK, *1, EGF, GMCSF, *2	97.621
3823	ips, mps, dps, CA125, MDK, *1, EGF, IL1RA, HE4	98.118
3824	ips, mps, dps, CA125, MDK, *1, EGF, IL1RA, *2	97.834
3825	ips, mps, dps, CA125, MDK, *1, EGF, HE4, *2	98.011
3826	ips, mps, dps, CA125, MDK, *1, GMCSF, IL1RA, HE4	97.905
3827	ips, mps, dps, CA125, MDK, *1, GMCSF, IL1RA, *2	97.834
3828	ips, mps, dps, CA125, MDK, *1, GMCSF, HE4, *2	97.834

3829	ips, mps, dps, CA125, MDK, *1, IL1RA, HE4, *2	97.976
3830	ips, mps, dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4	97.798
3831	ips, mps, dps, CA125, MDK, EGF, GMCSF, IL1RA, *2	97.656
3832	ips, mps, dps, CA125, MDK, EGF, GMCSF, HE4, *2	97.834
3833	ips, mps, dps, CA125, MDK, EGF, IL1RA, HE4, *2	97.834
3834	ips, mps, dps, CA125, MDK, GMCSF, IL1RA, HE4, *2	97.727
3835	ips, mps, dps, CA125, *1, EGF, GMCSF, IL1RA, HE4	97.159
3836	ips, mps, dps, CA125, *1, EGF, GMCSF, IL1RA, *2	96.875
3837	ips, mps, dps, CA125, *1, EGF, GMCSF, HE4, *2	96.946
3838	ips, mps, dps, CA125, *1, EGF, IL1RA, HE4, *2	97.053
3839	ips, mps, dps, CA125, *1, GMCSF, IL1RA, HE4, *2	96.875
3840	ips, mps, dps, CA125, EGF, GMCSF, IL1RA, HE4, *2	96.946
3841	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	96.484
3842	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF, HE4	95.845
3843	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF, *2	95.952
3844	ips, mps, dps, EMILIN, MDK, *1, EGF, IL1RA, HE4	96.697
3845	ips, mps, dps, EMILIN, MDK, *1, EGF, IL1RA, *2	96.733
3846	ips, mps, dps, EMILIN, MDK, *1, EGF, HE4, *2	95.845
3847	ips, mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	96.68
3848	ips, mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA, *2	96.413
3849	ips, mps, dps, EMILIN, MDK, *1, GMCSF, HE4, *2	95.756
3850	ips, mps, dps, EMILIN, MDK, *1, IL1RA, HE4, *2	96.697
3851	ips, mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	96.413
3852	ips, mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	96.484
3853	ips, mps, dps, EMILIN, MDK, EGF, GMCSF, HE4, *2	95.632
3854	ips, mps, dps, EMILIN, MDK, EGF, IL1RA, HE4, *2	96.378
3855	ips, mps, dps, EMILIN, MDK,	96.52

	GMCSF, IL1RA, HE4, *2	
3856	ips, mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	96.058
3857	ips, mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA, *2	95.969
3858	ips, mps, dps, EMILIN, *1, EGF, GMCSF, HE4, *2	94.957
3859	ips, mps, dps, EMILIN, *1, EGF, IL1RA, HE4, *2	96.236
3860	ips, mps, dps, EMILIN, *1, GMCSF, IL1RA, HE4, *2	96.271
3861	ips, mps, dps, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	95.987
3862	ips, mps, dps, MDK, *1, EGF, GMCSF, IL1RA, HE4	95.419
3863	ips, mps, dps, MDK, *1, EGF, GMCSF, IL1RA, *2	95.33
3864	ips, mps, dps, MDK, *1, EGF, GMCSF, HE4, *2	95.011
3865	ips, mps, dps, MDK, *1, EGF, IL1RA, HE4, *2	95.313
3866	ips, mps, dps, MDK, *1, GMCSF, IL1RA, HE4, *2	95.419
3867	ips, mps, dps, MDK, EGF, GMCSF, IL1RA, HE4, *2	95.135
3868	ips, mps, dps, *1, EGF, GMCSF, IL1RA, HE4, *2	93.43
3869	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	98.509
3870	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	98.295
3871	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	98.384
3872	ips, mps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4	98.544
3873	ips, mps, CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	98.58
3874	ips, mps, CA125, EMILIN, MDK, *1, EGF, HE4, *2	98.438
3875	ips, mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	98.615
3876	ips, mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	98.615
3877	ips, mps, CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	98.402
3878	ips, mps, CA125, EMILIN, MDK, *1, IL1RA, HE4, *2	98.544
3879	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	98.793
3880	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	98.686
3881	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	98.509

3882	ips, mps, CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	98.757
3883	ips, mps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	98.686
3884	ips, mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	98.366
3885	ips, mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	98.366
3886	ips, mps, CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	98.224
3887	ips, mps, CA125, EMILIN, *1, EGF, IL1RA, HE4, *2	98.473
3888	ips, mps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	98.295
3889	ips, mps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	98.402
3890	ips, mps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	98.189
3891	ips, mps, CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	98.047
3892	ips, mps, CA125, MDK, *1, EGF, GMCSF, HE4, *2	98.118
3893	ips, mps, CA125, MDK, *1, EGF, IL1RA, HE4, *2	98.047
3894	ips, mps, CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	98.082
3895	ips, mps, CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	97.976
3896	ips, mps, CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	97.088
3897	ips, mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	96.626
3898	ips, mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	96.733
3899	ips, mps, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	96.058
3900	ips, mps, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	96.626
3901	ips, mps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	96.555
3902	ips, mps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	96.52
3903	ips, mps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	95.81
3904	ips, mps, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	95.099
3905	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	97.088
3906	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	96.911
3907	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	96.982
3908	ips, dps, CA125, EMILIN, MDK, *1,	97.23

	EGF, IL1RA, HE4	
3909	ips, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	97.514
3910	ips, dps, CA125, EMILIN, MDK, *1, EGF, HE4, *2	97.124
3911	ips, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	97.124
3912	ips, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	97.301
3913	ips, dps, CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	97.159
3914	ips, dps, CA125, EMILIN, MDK, *1, IL1RA, HE4, *2	97.266
3915	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	96.839
3916	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	97.266
3917	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	96.768
3918	ips, dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	97.408
3919	ips, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	97.195
3920	ips, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	96.342
3921	ips, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	96.342
3922	ips, dps, CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	96.129
3923	ips, dps, CA125, EMILIN, *1, EGF, IL1RA, HE4, *2	96.52
3924	ips, dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	96.484
3925	ips, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	96.307
3926	ips, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	97.088
3927	ips, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	97.124
3928	ips, dps, CA125, MDK, *1, EGF, GMCSF, HE4, *2	96.839
3929	ips, dps, CA125, MDK, *1, EGF, IL1RA, HE4, *2	96.946
3930	ips, dps, CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	96.839
3931	ips, dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	96.804
3932	ips, dps, CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	95.739
3933	ips, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	93.058
3934	ips, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	93.537

3935	ips, dps, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	93.2
3936	ips, dps, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	93.501
3937	ips, dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	93.732
3938	ips, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	92.56
3939	ips, dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	92.152
3940	ips, dps, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	93.857
3941	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	96.378
3942	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	96.52
3943	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	96.271
3944	ips, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	96.733
3945	ips, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	96.555
3946	ips, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	96.378
3947	ips, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	94.922
3948	ips, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	96.697
3949	ips, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	91.051
3950	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	97.656
3951	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	97.585
3952	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	97.656
3953	mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4	97.763
3954	mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	97.887
3955	mps, dps, CA125, EMILIN, MDK, *1, EGF, HE4, *2	97.514
3956	mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	97.621
3957	mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	97.692
3958	mps, dps, CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	97.763
3959	mps, dps, CA125, EMILIN, MDK, *1, IL1RA, HE4, *2	97.869
3960	mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	97.585
3961	mps, dps, CA125, EMILIN, MDK,	97.479

	EGF, GMCSF, IL1RA, *2	
3962	mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	97.479
3963	mps, dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	97.763
3964	mps, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	97.834
3965	mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	97.088
3966	mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	97.23
3967	mps, dps, CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	97.053
3968	mps, dps, CA125, EMILIN, *1, EGF, IL1RA, HE4, *2	97.283
3969	mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	97.159
3970	mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	97.195
3971	mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	96.697
3972	mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	96.768
3973	mps, dps, CA125, MDK, *1, EGF, GMCSF, HE4, *2	96.573
3974	mps, dps, CA125, MDK, *1, EGF, IL1RA, HE4, *2	96.839
3975	mps, dps, CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	96.839
3976	mps, dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	96.591
3977	mps, dps, CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	95.49
3978	mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	95.526
3979	mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	95.668
3980	mps, dps, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	94.886
3981	mps, dps, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	95.792
3982	mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	95.668
3983	mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	95.17
3984	mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	95.064
3985	mps, dps, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	94.176
3986	mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	97.621
3987	mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	97.55

3988	mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	97.372
3989	mps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	97.727
3990	mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	97.692
3991	mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	97.266
3992	mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	96.626
3993	mps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	96.236
3994	mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	94.709
3995	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	93.803
3996	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	94.176
3997	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	94.105
3998	dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	94.212
3999	dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	94.318
4000	dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	93.857
4001	dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	92.685
4002	dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	94.247
4003	dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	90.057
4004	CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	90.945
4005	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA	98.295
4006	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4	98.224
4007	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, *2	98.153
4008	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4	98.295
4009	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, *2	98.295
4010	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, HE4, *2	98.189
4011	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4	98.295
4012	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, *2	98.224
4013	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF, HE4, *2	98.224
4014	ips, mps, dps, CA125, EMILIN,	98.402

	MDK, *1, IL1RA, HE4, *2	
4015	ips, mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4	98.295
4016	ips, mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, *2	98.242
4017	ips, mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, HE4, *2	98.153
4018	ips, mps, dps, CA125, EMILIN, MDK, EGF, IL1RA, HE4, *2	98.438
4019	ips, mps, dps, CA125, EMILIN, MDK, GMCSF, IL1RA, HE4, *2	98.295
4020	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4	98.047
4021	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, *2	98.224
4022	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF, HE4, *2	97.94
4023	ips, mps, dps, CA125, EMILIN, *1, EGF, IL1RA, HE4, *2	98.153
4024	ips, mps, dps, CA125, EMILIN, *1, GMCSF, IL1RA, HE4, *2	98.047
4025	ips, mps, dps, CA125, EMILIN, EGF, GMCSF, IL1RA, HE4, *2	98.011
4026	ips, mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4	97.834
4027	ips, mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, *2	97.834
4028	ips, mps, dps, CA125, MDK, *1, EGF, GMCSF, HE4, *2	97.94
4029	ips, mps, dps, CA125, MDK, *1, EGF, IL1RA, HE4, *2	98.011
4030	ips, mps, dps, CA125, MDK, *1, GMCSF, IL1RA, HE4, *2	97.905
4031	ips, mps, dps, CA125, MDK, EGF, GMCSF, IL1RA, HE4, *2	97.798
4032	ips, mps, dps, CA125, *1, EGF, GMCSF, IL1RA, HE4, *2	96.928
4033	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	96.449
4034	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	96.52
4035	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	95.739
4036	ips, mps, dps, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	96.697
4037	ips, mps, dps, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	96.555
4038	ips, mps, dps, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	96.378
4039	ips, mps, dps, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	95.934
4040	ips, mps, dps, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	95.455

4041	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	98.58
4042	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	98.58
4043	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	98.438
4044	ips, mps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	98.651
4045	ips, mps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	98.722
4046	ips, mps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	98.828
4047	ips, mps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	98.331
4048	ips, mps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	98.189
4049	ips, mps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	96.662
4050	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	96.875
4051	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	97.195
4052	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	96.946
4053	ips, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	97.23
4054	ips, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	97.195
4055	ips, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	97.053
4056	ips, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	95.916
4057	ips, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	97.017
4058	ips, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	93.217
4059	ips, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	96.307
4060	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	97.727
4061	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	97.834
4062	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	97.585
4063	mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	97.905
4064	mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	97.763
4065	mps, dps, CA125, EMILIN, MDK, EGF, GMCSF, IL1RA, HE4, *2	97.585
4066	mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	97.195
4067	mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	96.697

	GMCSF, IL1RA, HE4, *2	
4068	mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	95.419
4069	mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	97.585
4070	dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	93.892
4071	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4	98.366
4072	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, *2	98.295
4073	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, HE4, *2	98.26
4074	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, IL1RA, HE4, *2	98.402
4075	ips, mps, dps, CA125, EMILIN, MDK, *1, GMCSF, IL1RA, HE4, *2	98.438
4076	ips, mps, dps, CA125, EMILIN,	98.366

	MDK, EGF, GMCSF, IL1RA, HE4, *2	
4077	ips, mps, dps, CA125, EMILIN, *1, EGF, GMCSF, IL1RA, HE4, *2	98.082
4078	ips, mps, dps, CA125, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	97.798
4079	ips, mps, dps, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	96.325
4080	ips, mps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	98.615
4081	ips, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	97.088
4082	mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	97.621
4083	ips, mps, dps, CA125, EMILIN, MDK, *1, EGF, GMCSF, IL1RA, HE4, *2	98.402

Reference documents

- 5 1. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics*. 2007; 8:118–127
2. Everitt, B. *The Cambridge Dictionary of Statistics*. Cambridge, UK New York: 1998; Cambridge Universit Press.
3. Kohavi R, and John GH. Wrappers for feature subset selection. *Artificial Intelligence* 1997; 97(1-2):273-324.
- 10 4. Breiman L. Random forests. *Machine Learning*, 2001; 45(1):5-32.
5. Liaw A. Documentation for R package randomForest (PDF). <http://cran.r-project.org/web/packages/randomForest/randomForest.pdf>, 16 October 2012, Retrieved: 7 April 2015.
- 15 Golland P, Liang F, Mukherjee S, and Panchenko D. Permutation tests for classification. In *Annual Conference on Learning Theory*, 2005; pages 501–515

CLAIMS

1. A computer-implemented in vitro method of determining a subject's diagnostic state, the method comprising:

in a machine-learning phase:

- 5 – preparing a set of decision trees, each decision tree comprising at least a root node and a plurality of leaf nodes;
- wherein each node which is not a leaf node is associated with a feature and at least one threshold value for the feature;
- and wherein each feature indicates a level of a biomarker and/or clinical variable;
- 10 – and wherein each leaf node indicates a likelihood for the subject to have a disease;

in a diagnostic phase:

- 15 – processing levels of biomarkers and/or clinical variables obtained from the subject, wherein said processing comprises:
 - traversing each of a subset of the set of decision trees from the root node to one of its leaf nodes;
 - while traversing, at each node which is not a leaf node, comparing the threshold of the feature of the node with the level of the biomarker and/or clinical variable obtained from the subject and continuing traversing towards one of the leaf nodes based on said comparison;
 - 20 – when said traversing ends at a leaf node, obtaining a likelihood value for the subject to have the disease from the leaf node at which said traversing ends;
- 25 – after traversing all decision trees in the subset, combining the likelihood values obtained from the leaf nodes.

2. The method of claim 1, wherein said preparing the set of decision trees comprises executing a computer-executed process, which comprises:

- preparing a search space of multiple candidate feature subsets;
- 30 – using a machine-learning search process, wherein a heuristic function guides the search to find feature subsets with highest-scoring evaluator functions; and wherein an accuracy estimate is used as both the heuristic function and the evaluator function.

3. The method of claim 2, wherein repeated cross-validation is used as the evaluator function.
4. The method of any one of the preceding claims, further comprising using
5 bootstrap aggregation with random subsets of features to fit the decision trees to training data, to thereby reduce overfitting with training data.
5. The method of any one of the preceding claims, wherein at least some decision trees of the subset comprise one or more intermediate nodes between the
10 root node and the leaf nodes.
6. The method of any one of the preceding claims, wherein at least some of the features indicate clinical variables selected from a group which consists of the subject's general information, surgical information, medical history, obstetric history, and symptoms of one or more pains.
- 15 7. The method of any one of the preceding claims, wherein at least some of the features indicate clinical variables, which comprise qualitative assessment(s) of one or more pains, wherein the pains are selected from a group consisting of intercourse pain, menstrual pain and defecation pain.
8. The method of any one of the preceding claims, wherein at least some of
20 the features indicate levels of biomarkers, wherein the biomarkers comprise one or more biomarkers selected from a group consisting of CA125, MDK, EMILIN1, GM-CSF, PC ae C38:1, PC ae C38:2, EGF, IL-1Ra, IL-17, and HE4.
9. The method of any one of the preceding claims, wherein said disease is a disease associated with lower abdominal pain.
- 25 10. The method according to claim 9, wherein said disease is selected from a group consisting of endometriosis, endometrial cancer, ovarian cancer, colon cancer, ulcerative colitis, irritable bowel disease, irritable bowel syndrome and Crohn's disease.
11. A processor comprising:
30 – memory for storing program code instructions and data;
– one or more processing units for executing the program code instructions;

- means for accessing clinical variables and biomarkers with respect to one or more subjects;
- wherein executing the program code instructions on the one or more processing units causes the processor to carry out the steps of the method of claim 1.

5

12. A tangible non-transitory memory, comprising the program code instructions as defined in claim 11.

13. A method of determining a subject's endometriosis state, said method comprising:

- 10 a) assessing levels of biomarkers comprising CA125,MDK, and EMILIN1 in a sample obtained from said subject,
 - b) comparing the determined biomarker levels and corresponding control levels, and
 - c) responsive to the comparison, determining the subject's endometriosis state,
- 15 wherein increased levels of CA125 and MDK, and decreased level of EMILIN1 in said sample are indicative of endometriosis.

14. The method according to claim 13, wherein the biomarkers further comprise at least one biomarker selected from the group consisting of GM-CSF, PC ae C38:1, PC ae C38:2, and any combination thereof.

20

15. The method according to claim 14, wherein the biomarkers further comprise at least one biomarker selected from the group consisting of EGF, IL-1Ra, IL-17, and any combination thereof.

16. The method according to any one of claims 13-15, wherein the biomarkers further comprise HE4.

25

17. The method according to any one of claims 13-16, wherein the method further comprises assessing at least one clinical variable selected from the group consisting of the subject's general information, surgical information, medical history, obstetric history, and pain symptoms.

30 18. The method according to claim 17, wherein said pain symptom comprises at least one pain symptom selected from the group consisting of menstrual pain, intercourse pain, and defecation pain.19. The method according to any

one of claims 13-18, wherein determining the endometriosis state comprises diagnosing, testing for, prognosing or monitoring endometriosis state, risk of endometriosis, response to treatment of endometriosis, recurrence or relapse of endometriosis, or risk of recurrence or relapse of endometriosis.

- 5 20. The method according to any one of claims 13-18, wherein the method is used for excluding the presence or risk of a lower abdominal pain-associated disease other than endometriosis.

21. The method according to claim 20, wherein said lower abdominal pain-associated disease is selected from the group consisting of endometrial cancer, ovarian cancer, colon cancer, ulcerative colitis, irritable bowel disease,
10 irritable bowel syndrome and Crohn's disease.

22. The method according to any one of claims 13-21, wherein said sample is selected from the group consisting of urine, blood, serum, plasma, biopsy and tissue samples.

- 15 23. The method according to any one of claims 12-22, wherein said comparison of biomarker levels and determination of the endometriosis state are performed by a processor of a computing device.

24. An *in vitro* screening kit comprising reagents for determining a biological sample for the level of biomarkers comprising CA125, MDK, and EMILIN1.

- 20 25. The kit according to claim 24, further comprising reagents for determining the level of at least one biomarker selected from the group consisting of GM-CSF, PC ae C38:1, PC ae C38:2, and any combination thereof.

26. The kit according to claim 24 or 25, further comprising reagents for determining the level of at least one biomarker selected from the group consisting of
25 EGF, IL-1Ra, IL-17, and any combination thereof.

27. The kit according to any one of claims 24-26, further comprising reagents for determining the level of HE4.

28. Use of a biomarker combination comprising CA125, MDK, and EMILIN1 for determining a subject's endometriosis state.

- 30 29. The use according to claim 28, wherein said combination further comprises

at least one biomarker selected from the group consisting of, GM-CSF, PC ae C38:1, PC ae C38:2, and any combination thereof.

30. The use according to claim 28 or 29, wherein said combination further comprises at least one biomarker selected from the group consisting of EGF,
5 IL-1Ra, IL-17, and any combination thereof.

31. The use according to any one of claims 28-30, wherein said combination further comprises HE4.

1/9

Fig. 1






Fig. 2



2/9

Fig. 3



3/9

Fig. 4A

Endometriosis Symptom-based questionnaire
This questionnaire is designed to assess the risk of endometriosis in women

Step 1/9

Age (in years)

Height (in centimeters)

Weight (in kilograms)

Are you menopausal? (No spontaneous bleeding in the last six months)
☐ Yes ☒ No

Start date of the last menstrual period:

Menstrual bleeding days

The length of the menstrual cycle in days
(from the first day of bleeding to the next first day bleeding)

Fig. 4B

Endometriosis Symptom-based questionnaire
This questionnaire is designed to assess the risk of endometriosis in women

Step 9/9

Biomarker Data

Do you wish to have Biomarker Data?
☒ Yes ☐ No

Add Biomarker Data

CA125	▼	13	▲▼
HE4	▼	10	▲▼
IL1RA	▼	25	▲▼

Endometriosis Symptom-based questionnaire


This questionnaire is designed to assess the risk of endometriosis in women

Risk Assessment**Risk: High**

Your symptoms are highly suggestive of endometriosis and you should have a consultation with a specialist gynecologist who is experienced in the different available treatments for endometriosis

Recommendations:

If the typical hormonal treatments (continuous contraceptive pill, progestin, pain medication) do not give you sufficient alleviation for your symptoms, the option of surgical treatment should be evaluated. Surgical treatment should be performed by a skilled gynecological surgeon with experience in the treatment of endometriosis. All efforts should be exhausted in order to avoid repeat surgery. Post-surgery treatment is of high importance and should not be discontinued except for a wish for pregnancy. After the first months of breast-feeding the treatment should always be started again, before the symptoms return.



5/9

Fig. 5

Fig. 5A

Fig. 5B

Fig. 5A







Fig. 5B



7/9

Fig. 6A


Importance of Features in Endometriosis Diagnosis




8/9

Fig. 6B

Clinical Data and Biomarker Data in Endometriosis Diagnosis





INTERNATIONAL SEARCH REPORT

International application No

PCT/FI2016/050417

A. CLASSIFICATION OF SUBJECT MATTER

INV. G06F19/00 G06F19/24 G01N33/68
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G06F G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/113747 A2 (PREDICTION SCIENCES LLC [US]) 26 October 2006 (2006-10-26)	1-7,11,12
Y	abstract; paragraphs 3, 118-122; Figures 1 and 3	8-10
Y	----- US 2014/220580 A1 (BROWN KIRK [US] ET AL) 7 August 2014 (2014-08-07) paragraph [0882]	8-10
X	----- US 2011/236903 A1 (MCCLELLAND MICHAEL [US] ET AL) 29 September 2011 (2011-09-29) paragraph [0224]; claims; tables 7A,20,36,39	24
	----- -/-	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 November 2016

Date of mailing of the international search report

22/11/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Vogt, Titus

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI2016/050417

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No

PCT/FI2016/050417

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NEZIRI ALBAN Y ET AL: "Correlation Between Altered Central Pain Processing and Concentration of Peritoneal Fluid Inflammatory Cytokines in Endometriosis Patients With Chronic Pelvic Pain", REGIONAL ANESTHESIA AND PAIN MEDICINE, vol. 39, no. 3, May 2014 (2014-05), pages 181-184, XP002763808, Discussion; table 2	13-31
Y	PIETRO SANTULLI ET AL: "Increased Serum Cancer Antigen-125 Is a Marker for Severity of Deep Endometriosis", JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, vol. 22, no. 2, 19 October 2014 (2014-10-19), pages 275-284, XP55314871, NL ISSN: 1553-4650, DOI: 10.1016/j.jmig.2014.10.013 abstract; tables 2,3	13-31
Y	HYE WON CHUNG ET AL.: "Pleiotrophin (PTN) and midkine(MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis", MOLECULAR HUMAN REPRODUCTION, OXFORD UNIVERSITY PRESS, GB - BE, vol. 8, no. 4, 1 January 2002 (2002-01-01), pages 350-355, XP002991729, ISSN: 1360-9947, DOI: 10.1093/MOLEHR/8.4.350 Abstract; Conclusions	13-31
Y	ANNI P. VEHMAS ET AL: "Ovarian Endometriosis Signatures Established through Discovery and Directed Mass Spectrometry Analysis", JOURNAL OF PROTEOME RESEARCH., vol. 13, no. 11, 7 November 2014 (2014-11-07), pages 4983-4994, XP55314882, US ISSN: 1535-3893, DOI: 10.1021/pr500384n abstract; table 2	13-31
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No
PCT/FI2016/050417

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHANG LI-HUI ET AL: "Differential proteomic analysis of endometriosis", CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, BEIJING, CN, vol. 26, no. 1, 1 January 2010 (2010-01-01), pages 70-74, XP009192336, ISSN: 1005-9040 abstract	13-31
Y	----- K HUHTINEN ET AL: "Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts", BRITISH JOURNAL OF CANCER, vol. 100, no. 8, 31 March 2009 (2009-03-31), pages 1315-1319, XP55316614, GB ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6605011 the whole document	13-31
Y	----- Beate E Seeber ET AL: "Diagnosis of Endometriosis: Biomarkers" In: "Endometriosis", 25 January 2012 (2012-01-25), WILEY, XP55316622, pages 309-323, DOI: 10.1002/9781444398519.ch30, the whole document -----	13-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/FI2016/050417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006113747	A2	26-10-2006	EP 1872124 A2 02-01-2008
			EP 2386854 A1 16-11-2011
			US 2006275844 A1 07-12-2006
			WO 2006113747 A2 26-10-2006

US 2014220580	A1	07-08-2014	AU 2012271516 A1 23-01-2014
			BR 112013032232 A2 20-09-2016
			CA 2839530 A1 20-12-2012
			CN 103797131 A 14-05-2014
			EP 2721179 A2 23-04-2014
			JP 2014519340 A 14-08-2014
			KR 20140072014 A 12-06-2014
			US 2014220580 A1 07-08-2014
			WO 2012174282 A2 20-12-2012

US 2011236903	A1	29-09-2011	CA 2745961 A1 10-06-2010
			CN 102308212 A 04-01-2012
			EP 2370813 A1 05-10-2011
			US 2011236903 A1 29-09-2011
			US 2014011861 A1 09-01-2014
			WO 2010065940 A1 10-06-2010

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-12

a computer-implemented in vitro method for determining a subject's diagnostic state, using decision trees based on levels biomarkers

2. claims: 13-31

a method for determining a subject's endometriosis state by assessing levels of biomarkers comprising CA125, MDK and EMIL-IN1 and an in vitro screening kit for determining levels of these biomarkers
